Pyrimidines and variants thereof, and uses therefor

ABSTRACT

The present disclosure provides pyrimidine compounds of Formula 1 and uses thereof for example, for the potential treatment of diseases associated with P2X purinergic receptors. In certain aspects, the present disclosure provides P2X3 and/or P2X2/3 antagonists which are useful, for example, for the potential treatment of visceral organ, cardiovascular and pain-related diseases, conditions and disorders.

FIELD OF THE INVENTION

The present disclosure pertains to pyrimidine compounds and variantsthereof, as well as the use thereof, for example, for the potentialtreatment of diseases associated with P2X purinergic receptors, and moreparticularly to P2X3 and/or P2X2/3 antagonists usable for the potentialtreatment of visceral, cardiovascular and pain-related diseases,conditions and disorders.

BACKGROUND OF THE INVENTION

The information provided herein and references cited are provided solelyto assist the understanding of the reader, and does not constitute anadmission that any of the references or information is prior art to thepresent invention.

Purines, acting via cell surface purinoceptors, have been implicated ashaving a variety of physiological and pathological roles. ATP, and to alesser extent, adenosine, can stimulate sensory nerve endings resultingin intense pain and irritation and a pronounced increase in sensorynerve discharge. ATP receptors have been classified into two majorfamilies, the P2Y- and P2X-purinoreceptors, on the basis of molecularstructure, transduction mechanisms, and pharmacologicalcharacterization. The P2Y-purinoceptors are G-protein coupled receptors,while the P2X-purinoceptors are a family of ATP-gated cation channels.Purinergic receptors, in particular, P2X receptors, are known to formhomomultimers or heteromultimers. To date, cDNAs for seven P2X subunitshave been cloned, (P2X1, P2X2, P2X3, P2X4, P2X5, P2X6 and P2X7), eachable to produce homotrimeric channels and some able to formheterotrimeric receptors (e.g. P2X2/3, P2X4/6 and P2X1/5). The structureand chromosomal mapping of mouse and human genomic P2X3 receptorsubunits have also been described. In vitro, co-expression of P2X2 andP2X3 receptor subunits is necessary to produce ATP-gated currents withthe properties seen in some sensory neurons.

P2X3 receptor subunits are found on primary sensory afferentsinnervating rodent and human organs and tissues. Data exist suggestingthat ATP may be released from epithelial/endothelial cells of the holloworgans or from muscle beds as a result of distention, movement, injuryinfection and inflammation. ATP released in this manner may serve a rolein conveying information to nearby sensory neurons located. P2Xreceptors have been studied in a number of neurons, including sensory,sympathetic, parasympathetic, mesenteric, and central neurons. Somestudies indicate that P2X purinergic receptors play a role in afferentneurotransmission from the many organ systems and tissues, and thatmodulators of P2X receptors are potentially useful in the treatment offunctional organ or tissue disorders and attenuate common chronicsymptoms and signs of important diseases or conditions.

Evidence also suggests a role of endogenous ATP and purinergic receptorsin nociceptive responses in mice. ATP-induced activation of P2X3receptors on dorsal root ganglion nerve terminals in the dorsal horn ofthe spinal cord has been shown to stimulate release of glutamate, a keyneurotransmitter involved in nociceptive signalling. P2X3 receptors havebeen identified on nociceptive neurons in the tooth pulp. ATP releasedfrom distressed or damaged cells in many tissue systems may thus lead topain by activating P2X3 containing receptors on nociceptive sensorynerve endings. This is consistent with observations of the induction ofpain and discomfort by intradermally applied ATP in the humanblister-base model or following its infusion into a muscle bed. P2Xantagonists have been shown to be analgesic in many animal models. Thisevidence suggests that P2X3 containing channels are involved in thesensitization of nerves that drives and maintains heightened nociceptionsignalling, and that modulators of P2X receptors are potentially usefulas inhibitors of sensitization and may have applicability as analgesics,anti-pruritics, antitussives and treatments for autonomichyperresponsiveness.

The use of antagonists of P2X2 and P2X2/3 for the treatment of pain wasdiscussed by Carter, et al., (Bioorganic and Medical Chemistry Letters,2009, 19(6), 1628-1635; doi:10.1016/j.bmcl.2009.02.003). Thestructure-activity relationship of a series of diaminopyrimidines wasstudied. The selectivity of these compounds for P2X3 and P2X2/3 vs.other P2X purinoceptors was also discussed.

Vandenbeuch et al. (J. Physiol, 2015, 593(5), 1113-1125; doi:10/1113/jphysiol.2014.281014) discuss the role of both P2X3 and P2X2/3channels in taste transduction.

SUMMARY OF THE INVENTION

Described herein are compounds of Formula 1 or their pharmaceuticallyacceptable salts which are inhibitors of P2X3 and/or P2X2/3 receptors.Also described herein are uses of these compounds in the potentialtreatment or prevention of a P2X3- and/or P2X2/3-associated disease ordisorder. Also disclosed herein are compositions comprising one or moreof these compounds. Further disclosed herein are uses of thesecompositions in the potential treatment or prevention of a P2X3- and/orP2X2/3-associated disease or disorder.

DETAILED DESCRIPTION OF THE INVENTION

In a first aspect of the present disclosure, there are providedcompounds of Formula 1:

or a pharmaceutically acceptable salt thereof, wherein:

-   -   W is selected from CH₂, O, S and NR, wherein R is H, or C₁₋₃        alkyl;    -   X₁ is N or CR²;    -   X₂ is N or CR³;    -   X₃ is N or CR⁴;    -   X₄ is N or CR⁵, provided, however not more than two of X₁, X₂,        X₃, or X₄ are N at the same time;    -   X₅ is N or CR⁶, provided, however, when X₁ is CR², X₂ is CR³, X₃        is CR⁴ and X₄ is CR⁵, W is not O or —CH₂—;    -   Y is selected from hydrogen and —NHR^(d), wherein R^(d) is        selected from: hydrogen; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl;        C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy;        C₁₋₁₂-hydroxyalkyl; C₂₋₁₂-alkoxyalkyl; acetyl;        C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;        C₂₋₁₂-aminocarbonyloxyalkyl; C₁₋₁₂-hydroxycarbonylalkyl;        C₂₋₁₂-hydroxylalkyloxycarbonylalkyl; C₅₋₁₂-aryl;        C₆₋₁₂-arylalkyl; C₅₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl;        C₆₋₁₂-heteroarylalkyl; C₅₋₁₂-heteroarylsulfonyl;        C₃₋₁₂-heterocyclyl; and C₄₋₁₂-heterocyclylalkyl;    -   D is an optional oxygen;    -   R¹ is selected from C₁₋₁₂-alkyl; C₂₋₁₂-alkenyl; C₂₋₁₂-alkynyl;        C₃₋₁₂-cycloalkyl; C₃₋₁₂-cycloalkenyl; halo; C₁₋₁₂-haloalkyl; and        C₁₋₁₂-hydroxyalkyl;    -   R², R³, R⁴ and R⁵ are each independently selected from hydrogen;        C₁₋₁₂-alkyl; C₂₋₁₂-alkenyl; C₂₋₁₂-alkynyl; amino; halo; amido;        C₁₋₁₂-haloalkyl; C₁₋₁₂-alkoxy; hydroxy; C₁₋₁₂-haloalkoxy; nitro;        C₁₋₁₂-hydroxyalkyl; C₂₋₁₂-alkoxyalkyl; C₁₋₁₂-hydroxyalkoxy;        C₃₋₁₂-alkynylalkoxy; C₁₋₁₂-alkylsulfonyl; C₅₋₁₂-arylsulfonyl;        cyano; C₆₋₁₂-aryl; C₅₋₁₂-heteroaryl; C₃₋₁₂-heterocyclyl;        C₄₋₁₂-heterocyclylalkoxy; C₆₋₁₂-aryloxy; C₅₋₁₂-heteroaryloxy;        C₇₋₁₂-arylalkyloxy; C₆₋₁₂-heteroaralkyloxy; optionally        substituted phenoxy; —(CH₂)_(m)—(Z)_(n)—(CO)—R^(f) and        —(CH₂)_(m)—(Z)_(n)—SO₂—(NR^(g))_(n′)—R^(f), where m, n and n′        are each independently 0 or 1,    -   Z is O or NR^(g),    -   R^(f) is selected from hydrogen, C₁₋₁₂-alkyl, hydroxy,        C₁₋₁₂-alkoxy, amino, C₁₋₁₂-hydroxyalkyl and C₂₋₁₂-alkoxyalkyl        and    -   each R^(g) is independently hydrogen or C₁₋₁₂-alkyl;    -   or R³ and R⁴ together with the atoms to which they are attached        may form a five or six-membered ring that optionally includes        one or two heteroatoms selected from O, S and N;    -   or R² and R³ may together form an alkylene dioxy; or R² and R³        together with the atoms to which they are attached may form a        five or six-membered ring that optionally includes one or two        heteroatoms selected from O, S and N;    -   R⁶ is selected from hydrogen and C₁₋₁₂-alkyl; and    -   R⁷ is selected from hydrogen; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl;        C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy;        C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; acetyl;        C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;        C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;        C₃₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;        C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl;        C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; and        C₄₋₁₂-heterocyclylalkyl.

In certain aspects of the present disclosure, compounds of Formula 1have greater than ten-fold (10×) selectivity for the P2X3 homotrimericreceptor compared to the P2X2/3 heterotrimeric receptor. In anotheraspect, compounds of Formula 1 have greater than 20× selectivity forP2X3 receptor compared to P2X2/3 receptor. In another aspect, compoundsof Formula 1 have greater than 30× selectivity for P2X3 receptorcompared to P2X2/3 receptor. In another aspect, compounds of Formula 1have greater than 40× selectivity for P2X3 receptor compared to P2X2/3receptor. In another aspect, compounds of Formula 1 have greater than50× selectivity for P2X3 receptor compared to P2X2/3 receptor. Inanother aspect, compounds of Formula 1 have greater than 1×, but lessthan 10× selectivity for P2X3 receptor compared to P2X2/3 receptor.

In a second aspect, the present disclosure provides methods for treatinga disease mediated by a P2X3 receptor antagonist, a P2X2/3 receptorantagonist, or both, said method comprising administering to a subjectin need thereof an effective amount of a compound of Formula 1:

or a pharmaceutically acceptable salt thereof, wherein:

-   -   W is CH₂, NR (where R is H, or C₁₋₃ alkyl), O or S;    -   X₁ is N or CR²;    -   X₂ is N or CR³;    -   X₃ is N or CR⁴;    -   X₄ is N or CR⁵, provided, however not more than two of X₁, X₂,        X₃, or X₄ are N at the same time;    -   X₅ is N or CR⁶, provided, however, when X₁ is C—R², X₂ is C—R³,        X₃ is C—R⁴ and X₄ is C—R⁵, W is not O or —CH₂—;    -   Y is selected from hydrogen and —NHR^(d), wherein R^(d) is        selected from; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl;        C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy;        C₁₋₁₂-hydroxyalkyl; C₂₋₁₂-alkoxyalkyl; acetyl;        C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;        C₂₋₁₂-aminocarbonyloxyalkyl; C₁₋₁₂-hydroxycarbonylalkyl;        C₂₋₁₂-hydroxylalkyloxycarbonylalkyl; C₅₋₁₂-aryl;        C₆₋₁₂-arylalkyl; C₅₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl;        C₆₋₁₂-heteroarylalkyl; C₅₋₁₂-heteroarylsulfonyl;        C₃₋₁₂-heterocyclyl; and C₄₋₁₂-heterocyclylalkyl;    -   D is an optional oxygen;    -   R¹ is selected from C₁₋₁₂-alkyl; C₂₋₁₂-alkenyl; C₂₋₁₂-alkynyl;        C₃₋₁₂-cycloalkyl; C₃₋₁₂-cycloalkenyl; halo; C₁₋₁₂-haloalkyl; and        C₁₋₁₂-hydroxyalkyl;    -   R², R³, R⁴ and R⁵ are each independently selected from hydrogen;        C₁₋₁₂-alkyl; C₂₋₁₂-alkenyl; C₂₋₁₂-alkynyl; amino; halo; amido;        C₁₋₁₂-haloalkyl; C₁₋₁₂-alkoxy; hydroxy; C₁₋₁₂-haloalkoxy; nitro;        C₁₋₁₂-hydroxyalkyl; C₂₋₁₂-alkoxyalkyl; C₁₋₁₂-hydroxyalkoxy;        C₃₋₁₂-alkynylalkoxy; C₁₋₁₂-alkylsulfonyl; C₅₋₁₂-arylsulfonyl;        cyano; C₆₋₁₂-aryl; C₅₋₁₂-heteroaryl; C₃₋₁₂-heterocyclyl;        C₄₋₁₂-heterocyclylalkoxy; C₆₋₁₂-aryloxy; C₅₋₁₂-heteroaryloxy;        C₇₋₁₂-arylalkyloxy; C₆₋₁₂-heteroaralkyloxy; optionally        substituted phenoxy; —(CH₂)_(m)—(Z)_(n)—(CO)—R^(f) and        —(CH₂)_(m)—(Z)_(n)—SO₂—(NR^(g))_(n′)—R^(f), where m, n and n′        are each independently 0 or 1,    -   Z is O or NR^(g),    -   R^(f) is selected from hydrogen, C₁₋₁₂-alkyl, hydroxy,        C₁₋₁₂-alkoxy, amino, C₁₋₁₂-hydroxyalkyl and C₂₋₁₂-alkoxyalkyl        and    -   each R^(g) is independently hydrogen or C₁₋₁₂-alkyl;    -   or R³ and R⁴ together with the atoms to which they are attached        may form a five or six-membered ring that optionally includes        one or two heteroatoms selected from O, S and N;    -   or R² and R³ may together form an alkylene dioxy; or R² and R³        together with the atoms to which they are attached may form a        five or six-membered ring that optionally includes one or two        heteroatoms selected from O, S and N;    -   R⁶ is selected from hydrogen and C₁₋₁₂-alkyl; and    -   R⁷ is selected from hydrogen; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl;        C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy;        C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; acetyl;        C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;        C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;        C₃₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;        C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl;        C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl and        C₄₋₁₂-heterocyclylalkyl.

Exemplary diseases and conditions that are rationally treated by a P2X3receptor antagonist, or a P2X2/3 receptor antagonist, or antagonist atboth channels, contemplated herein include disorders of the urinarytract (aka uropathy), disease states associated with the urinary tract(aka urinary tract disease states), overactive bladder (aka detrusorhyperactivity or urge incontinence), outlet obstruction (aka benignprostatic hypertrophy), outlet insufficiency, pelvic hypersensitivity,bladder pain syndrome, endometriosis, respiratory symptoms, cough orurge to cough associated with a respiratory disease, asthma,hypertension, heart failure, dyspnea (aka shortness of breath), sleepapnea, signs and symptoms of carotid body hypertonicity andhyperreflexia (such as breathlessness and fatigue), sympatheticoveractivity in a subject, and the like. Additionally, signs andsymptoms of upper respiratory tract infection, including the cold andflu symptoms of pharyngitis, rhinitis, nasal congestion, hypertussivity,rhinorrhea and sneezing targeted conditions for treatment with anantagonist for P2X3 containing receptors.

In other instances the disease may be a disease associated with pain.The disease associated with pain may be: inflammatory pain; surgicalpain; visceral pain; dental pain; premenstrual pain; central pain; paindue to burns; migraine or cluster headaches; nerve injury; neuropathy;neuritis; neuralgias; poisoning; ischemic injury; interstitial cystitis;cancer pain; pain of viral, parasitic or bacterial infection;post-traumatic injury pain; or pain associated with irritable bowelsyndrome and inflammatory bowel diseases.

In additional instances the disorders or disease states may includehepatocellular carcinoma, tinnitus, migraine, itch (pruritus), diabetesmellitus, endometriosis and dysmenorrhea, peripheral artery occlusivedisease (PAOD), intermittent claudication, acute and chronic heartfailure, metabolic syndrome, chronic obstructive pulmonary disease(COPD), atopic dermatitis and other forms of eczema or dermatitis,prurigo nodularis, bursitis, tendonitis, fibromyalgia, gout, jointreplacement, lichen sclerosus, psoriasis and psoriatic arthritis, coldsores, kidney stones, gall stones, smell disorders, taste disordersincluding dysgeusia or burning mouth syndrome, binge eating disorders,hyperphagia, obesity, gastro esophageal reflux disease (GERD), or painfrom sickle cell anemia and ischemia.

The present disclosure also provides pharmaceutical compositionscomprising the compounds, methods of using the compounds, and methods ofpreparing the compounds.

Unless otherwise stated, the following terms used in this Application,including the specification and claims, have the definitions givenherein.

It must be noted that, as used in the specification and the appendedclaims, the singular forms “a”, “an”, and “the” include plural referentsunless the context clearly dictates otherwise.

“Agonist” refers to a compound that enhances the activity of anothercompound or receptor site.

“Antagonist” refers to a compound that diminishes or prevents the actionof another compound or receptor site. Antagonist selectivity for P2X3subunit containing trimeric channel types, for example, is of increasinginterest in the search for therapeutically preferred medicines. This isdue to increased understanding, driven by clinical experience with firstgeneration antagonists, of the potential contribution of blockade ofdistinct trimers with desirable (e.g., efficacy as antitussive,antihypertensive and antihyperalgesic) and less desirable (e.g.,tolerability events such as hypogeusia, oropharyngeal dysesthesia)outcomes in treated patients.

Improved clinical effectiveness (efficacy vs. tolerability profile) isexpected based on findings suggesting that channels formed solely fromP2X3 subunits (homomeric P2X3 or P2X3.3.3) are found in nociceptivesensory fibers responsible for mediating irritative, painful andbothersome (“targeted”) pathological symptoms such as cough, emanatingmostly from neural crest derived sensory neurons of DRG and certaincranial (trigeminal, jugular) ganglia. In contrast, P2X channelsinvolved in ATP mediation of the sense of taste, innervating thegustatory papillae of the tongue and oropharynx, are formed inplacodally derived sensory neurons, notably from geniculate, petrosaland nodose cranial ganglia, as the heterotrimeric P2X2/3 (i.e., P2X2.3.3and P2X2.2.3) channels found to be expressed in these cells.

Accordingly, antagonists with increased potency (pIC₅₀) at P2X3homotrimers relative to P2X2/3 heterotrimers achieve greater attenuationof nociceptor sensitization and symptoms of pain, urgency, irritation,dyspnea, fatigue and autonomic hyperreflexia, before exposures arereached that introduce gustatory disturbance and raise issues oftolerability and patient compliance.

“Alkyl” means the monovalent linear or branched saturated hydrocarbonmoiety, consisting solely of carbon and hydrogen atoms, having from oneto twelve carbon atoms.

“Lower alkyl” refers to an alkyl group of one to six carbon atoms, i.e.C₁₋₆ alkyl. Examples of alkyl groups include, but are not limited to,methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl,pentyl, n-hexyl, octyl, dodecyl, and the like.

“Alkylene” means a linear or branched saturated divalent hydrocarbonradical of one to twelve carbon atoms or a branched saturated divalenthydrocarbon radical of three to six carbon atoms, e.g., methylene,ethylene, 2,2-dimethylethylene, propylene, 2-methylpropylene, butyleneand pentylene.

“Alkenyl” means a linear monovalent hydrocarbon radical of two to twelvecarbon atoms or a branched monovalent hydrocarbon radical of three totwelve carbon atoms, containing at least one double bond. Examples ofalkenyl groups include, but are not limited to, ethenyl (vinyl,—CH═CH₂), 1-propenyl (—CH═CH—CH₃), 2-propenyl (allyl, —CH—CH═CH₂) andisopropenyl (1-methylvinyl, —C(CH₃)═CH₂).

“Alkynyl” means a linear monovalent hydrocarbon radical of two to twelvecarbon atoms or a branched monovalent hydrocarbon radical of three totwelve carbon atoms, containing at least one triple bond. Examples ofalkynyl groups include, but are not limited to, ethynyl (—C≡CH) and2-propynyl (propargyl, —CH₂C≡CH).

“Alkoxy” means a moiety of the formula —OR, wherein R is an alkyl moietyas defined herein. Examples of alkoxy moieties include, but are notlimited to, methoxy, ethoxy, and iso-propoxy.

“Alkoxyalkyl” means a moiety of the formula R^(a)—O—R^(b)—, where R^(a)is alkyl and R^(b) is alkylene as defined herein. Exemplary alkoxyalkylgroups include, by way of example, 2-methoxyethyl, 3-methoxypropyl,1-methyl-2-methoxyethyl, 1-(2-methoxyethyl)-3-methoxy-propyl, and1-(2-methoxyethyl)-3-methoxypropyl.

“Alkoxyalkoxyalkl” means a group of the formula —R—O—R′—O—R″ wherein Rand R′ each are alkylene and R″ is alkyl as defined herein.

“Alkylcarbonyloxyalkyl” means a group of the formula —R—O—C(O)—R′wherein R is alkylene and R′ is alkyl as defined herein.

“Alkylcarbonyl” means a moiety of the formula —R′—R″, where R′ is—C(═O)— and R″ is alkyl as defined herein.

“Alkylsulfonyl” means a moiety of the formula —R′—R″, where R′ is —SO₂—and R″ is alkyl as defined herein.

“Alkylsulfonylalkyl” means a moiety of the formula —R′—R″—R′″ where R′is alkyl, R″ is —SO₂— and R′″ is alkyl as defined herein.

“Alkylamino” means a moiety of the formula —NR—R′ wherein R is hydrogenor alkyl and R′ is alkyl as defined herein.

“Alkoxyamino” means a moiety of the formula —NR—OR′ wherein R ishydrogen or alkyl and R′ is alkyl as defined herein.

“Alkylsulfanyl” means a moiety of the formula —SR wherein R is alkyl asdefined herein.

“Alkali metal ion” means a monovalent ion of a group I metal such aslithium, sodium, potassium, rubidium or cesium, preferably sodium orpotassium.

“Alkaline earth metal ion” means a divalent ion of a group II metal suchas berylium, magnesium, calcium, strontium or barium, preferablymagnesium or calcium.

“Amino” means a group —NR′R″ wherein R′ and R″ each independently ishydrogen or alkyl. “Amino” as used herein thus encompasses “alkylamino”and “dialkylamino”.

“Alkylaminoalkyl” means a group —R—NHR′ wherein R is alkylene and R′ isalkyl. Alkylaminoalkyl includes methylaminomethyl, methylaminoethyl,methylaminopropyl, and ethylaminoethyl.

“Dialkylaminoalkyl” means a group —R—NR′R″ wherein R is alkylene and R′and R″ are alkyl as defined herein. Dialkylaminoalkyl includesdimethylaminomethyl, dimethylaminoethyl, dimethylaminopropyl andN-methyl-N-ethylaminoethyl.

“Aminoalkyl” means a group —R—R′ wherein R′ is amino and R is alkyleneas defined herein. “Aminoalkyl” includes aminomethyl, aminoethyl,1-aminopropyl, and 2-aminopropyl.

“Aminoalkoxy” means a group —OR—R′ wherein R′ is amino and R is alkyleneas defined herein.

“Alkylsulfonylamido” means a moiety of the formula —NR′SO₂—R wherein Ris alkyl and R′ is hydrogen or alkyl.

“Aminocarbonyloxyalkyl” or “carbamylalkyl” means a groups —R—O—C(═O)—R′wherein R′ is amino and R is alkylene as defined herein.

“Aminosulfonyl” means a group —SO₂—NR′R″ wherein R′ and R″ eachindependently is hydrogen or alkyl. “Aminosulfonyl” as used herein thusencompasses “alkylaminosulfonyl” and “dialkylaminosulfonyl”.

“Alkynylalkoxy” means a group of the formula —O—R—R′ wherein R isalkylene and R′ is alkynyl as defined herein.

“Aryl” means a monovalent cyclic aromatic hydrocarbon moiety consistingof a mono-, bi- or tricyclic aromatic ring. The aryl group can beoptionally substituted as defined herein. Examples of aryl moietiesinclude, but are not limited to, optionally substituted phenyl,naphthyl, phenanthryl, fluorenyl, indenyl, pentalenyl, azulenyl,oxydiphenyl, biphenyl, methylenediphenyl, aminodiphenyl,diphenylsulfidyl, diphenylsulfonyl, diphenylisopropylidenyl,benzodioxanyl, benzofuranyl, benzodioxylyl, benzopyranyl, benzoxazinyl,benzoxazinonyl, benzopiperadinyl, benzopiperazinyl, benzopyrrolidinyl,benzomorpholinyl, methylenedioxyphenyl and ethylenedioxyphenyl,including partially hydrogenated derivatives thereof.

“Arylalkyl” and “Aralkyl”, which may be used interchangeably, mean aradical —R^(a)R^(b) where R^(a) is an alkylene group and R^(b) is anaryl group as defined herein; e.g., phenylalkyls such as benzyl,phenylethyl, 3-(3-chlorophenyl)-2-methylpentyl, and the like areexamples of arylalkyl.

“Arylsulfonyl means a group of the formula —SO₂—R wherein R is aryl asdefined herein.

“Aryloxy” means a group of the formula —O—R wherein R is aryl as definedherein.

“Aralkyloxy” or “Arylalkyloxy” means a group of the formula —O—R—R″wherein R is alkylene and R′ is aryl as defined herein.

“Cyanoalkyl” “means a moiety of the formula —R′—R″, where R′ is alkyleneas defined here-in and R″ is cyano or nitrile.

“Cycloalkyl” means a monovalent saturated carbocyclic moiety consistingof mono- or bicyclic rings. Cycloalkyl can optionally be substitutedwith one or more substituents, wherein each substituent is independentlyhydroxy, alkyl, alkoxy, halo, haloalkyl, amino, monoalkylamino, ordialkylamino, unless otherwise specifically indicated. Examples ofcycloalkyl moieties include, but are not limited to, cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, including partiallyunsaturated derivatives thereof.

“Cycloalkenyl” means a monovalent unsaturated carbocyclic moietyconsisting of mono- or bicyclic rings containing at least one doublebond. Cycloalkenyl can optionally be substituted with one or moresubstituents, wherein each substituent is independently hydroxy, alkyl,alkoxy, halo, haloalkyl, amino, monoalkylamino, or dialkylamino, unlessotherwise specifically indicated. Examples of cycloalkenyl moietiesinclude, but are not limited to, cyclopropenyl, cyclobutenyl,cyclopentenyl, cyclohexenyl, cycloheptenyl.

“Cycloalkylalkyl” means a moiety of the formula —R′—R″, where R′ isalkylene and R″ is cycloalkyl as defined herein.

“Cycloalkylene” means a divalent saturated carbocyclic radicalconsisting of mono- or bi-cyclic rings. Cycloalkylene can optionally besubstituted with one or more substituents, wherein each substituent isindependently hydroxy, alkyl, alkoxy, halo, haloalkyl, amino,monoalkylamino, or dialkylamino, unless otherwise specificallyindicated.

“Cycloalkylalkylene” means a moiety of the formula —R′—R″—, where R′ isalkylene and R″ is cycloalkylene as defined herein.

“Heteroalkyl” means an alkyl radical as defined herein wherein one, twoor three hydrogen atoms have been replaced with a substituentindependently selected from the group consisting of —OR^(a),—NR^(b)R^(c), and —S(O)_(n)R^(d) (where n is an integer from 0 to 2),with the understanding that the point of attachment of the heteroalkylradical is through a carbon atom, wherein R^(a) is hydrogen, acyl,alkyl, cycloalkyl, or cycloalkylalkyl; R^(b) and R^(c) are independentlyof each other hydrogen, acyl, alkyl, cycloalkyl, or cycloalkylalkyl; andwhen n is 0, R^(d) is hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl,and when n is 1 or 2, R^(d) is alkyl, cycloalkyl, cycloalkylalkyl,amino, acylamino, monoalkylamino, or dialkylamino. Representativeexamples include, but are not limited to, 2-hydroxyethyl,3-hydroxypropyl, 2-hydroxy-1-hydroxymethylethyl, 2,3-dihydroxypropyl,1-hydroxymethylethyl, 3-hydroxybutyl, 2,3-dihydroxybutyl,2-hydroxy-1-methylpropyl, 2-aminoethyl, 3-aminopropyl,2-methylsulfonylethyl, aminosulfonylmethyl, aminosulfonylethyl,aminosulfonylpropyl, methylaminosulfonylmethyl, methylaminosulfonylethyland methylaminosulfonylpropyl.

“Heteroaryl” means a monocyclic or bicyclic radical of 5 to 12 ringatoms having at least one aromatic ring containing one, two, or threering heteroatoms selected from N, O, or S, the remaining ring atomsbeing C, with the understanding that the attachment point of theheteroaryl radical will be on an aromatic ring. The heteroaryl ring maybe optionally substituted as defined herein. Examples of heteroarylmoieties include, but are not limited to, optionally substitutedimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl,thiadiazolyl, pyrazinyl, thienyl, benzothienyl, thiophenyl, furanyl,pyranyl, pyridyl, pyrrolyl, pyrazolyl, pyrimidyl, quinolinyl,isoquinolinyl, benzofuryl, benzothiophenyl, benzothiopyranyl,benzimidazolyl, benzooxazolyl, benzooxadiazolyl, benzothiazolyl,benzothiadiazolyl, benzopyranyl, indolyl, isoindolyl, triazolyl,triazinyl, quinoxalinyl, purinyl, quinazolinyl, quinolizinyl,naphthyridinyl, pteridinyl, carbazolyl, azepinyl, diazepinyl andacridinyl, including partially hydrogenated derivatives thereof.

Heteroarylalkyl” or “heteroaralkyl” means a group of the formula —R—R′wherein R is alkylene and R′ is heteroaryl as defined herein.

“Heteroarylsulfonyl” means a group of the formula —SO₂—R wherein R isheteroaryl as defined herein.

“Heteroaryloxy” means a group of the formula —O—R wherein R isheteroaryl as defined herein.

“Heteroaralkyloxy” means a group of the formula —O—R—R″ wherein R isalkylene and R′ is heteroaryl as defined herein.

“Heterocyclylalkoxy means a group of the formula —O—R—R′ wherein R isalkylene and R′ is heterocyclyl as defined herein.

The terms “halo”, “halogen” and “halide”, which may be usedinterchangeably, refer to a substituent fluoro, chloro, bromo, or iodo.In some embodiments, halo refers to a fluoro substituent.

“Haloalkyl” means alkyl as defined herein in which one or more hydrogenhas been replaced with same or different halogen. In some embodiments,haloalkyl is a fluoroalkyl; in some embodiments, the haloalkyl is aperfluoroalkyl. Exemplary haloalkyls include, but are not limited to,—CH₂Cl, —CH₂CF₃, —CH₂CCl₃ and perfluoroalkyl (e.g., —CF₃).

“Haloalkoxy” means a moiety of the formula —OR, wherein R is a haloalkylmoiety as defined herein. In some embodiments, haloalkoxy is afluoroalkoxy; in some embodiments, the haloalkoxyl is a perfluoroalkoxy.An exemplary haloalkoxy is difluoromethoxy.

“Heterocycloamino” means a saturated ring wherein at least one ring atomis N, NH or N-alkyl and the remaining ring atoms form an alkylene group.

“Heterocyclyl” means a monovalent saturated moiety, consisting of one tothree rings, incorporating one, two, or three or four heteroatoms(chosen from nitrogen, oxygen or sulfur). The heterocyclyl ring may beoptionally substituted as defined herein. Examples of heterocyclylmoieties include, but are not limited to, optionally substitutedpiperidinyl, piperazinyl, homopiperazinyl, azepinyl, pyrrolidinyl,pyrazolidinyl, imidazolinyl, imidazolidinyl, pyridinyl, pyridazinyl,pyrimidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl,isothiazolidinyl, quinuclidinyl, quinolinyl, isoquinolinyl,benzimidazolyl, thiadiazolylidinyl, benzothiazolidinyl,benzoazolylidinyl, dihydrofuryl, tetrahydrofuryl, dihydropyranyl,tetrahydropyranyl, thiamorpholinyl, thiamorpholinylsulfoxide,thiamorpholinylsulfone, dihydroquinolinyl, dihydrisoquinolinyl,tetrahydroquinolinyl and tetrahydroisoquinolinyl.

“Heterocyclylalkyl” means a moiety of the formula —R—R′ wherein R isalkylene and R′ is heterocyclyl as defined herein.

“Heterocyclyloxy” means a moiety of the formula —OR wherein R isheterocyclyl as defined herein.

“Heterocyclylalkoxy” means a moiety of the formula —OR—R′ wherein R isalkylene and R′ is heterocyclyl as defined herein.

“Hydroxyalkoxy” means a moiety of the formula —OR wherein R ishydroxyalkyl as defined herein.

“Hydroxyalkylamino” means a moiety of the formula —NR—R′ wherein R ishydrogen or alkyl and R′ is hydroxyalkyl as defined herein.

“Hydroxyalkylaminoalkyl” means a moiety of the formula —R—NR′—R″ whereinR is alkylene, R′ is hydrogen or alkyl, and R″ is hydroxyalkyl asdefined herein.

“Hydroxyalkyl” means an alkyl moiety as defined herein, substituted withone or more, preferably one, two or three hydroxy groups, provided thatthe same carbon atom does not carry more than one hydroxy group.Representative examples include, but are not limited to, hydroxymethyl,2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl,1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl,4-hydroxybutyl, 2,3-dihydroxy-propyl, 2-hydroxy-1-hydroxymethylethyl,2,3-dihydroxybutyl, 3,4-dihydroxybutyl and2-(hydroxymethyl)-3-hydroxypropyl.

“Hydroxycarbonylalkyl” or “carboxyalkyl” means a group of the formula—R—(CO)—OH where R is alkylene as defined herein.

“Hydroxyalkyloxycarbonylalkyl” or “hydroxyalkoxycarbonylalkyl” means agroup of the formula —R—C(O)—O—R—OH wherein each R is alkylene and maybe the same or different.

“Hydroxyalkyl” means an alkyl moiety as defined herein, substituted withone or more, preferably one, two or three hydroxy groups, provided thatthe same carbon atom does not carry more than one hydroxy group.Representative examples include, but are not limited to, hydroxymethyl,2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl,1-(hydroxyl-5-methyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl,4-hydroxybutyl, 2,3-dihydroxypropyl, 2-hydroxy-1-hydroxymethylethyl,2,3-dihydroxybutyl, 3,4-dihydroxybutyl and2-(hydroxymethyl)-3-hydroxypropyl.

“Hydroxycycloalkyl” means a cycloalkyl moiety as defined herein whereinone, two or three hydrogen atoms in the cycloalkyl radical have beenreplaced with a hydroxy substituent. Representative examples include,but are not limited to, 2-, 3-, or 4-hydroxy-cyclohexyl.

“Urea” or “ureido” means a group of the formula —NR′—C(O)—NR″R′″ whereinR, R″ and R′″ each independently is hydrogen or alkyl.

“Carbamate” means a group of the formula —O—C(O)—NR′R″ wherein R′ and R″each independently is hydrogen or alkyl.

“Carboxy” means a group of the formula —C(O)OH.

“Sulfonamido” means a group of the formula —SO₂—NR′R″ wherein R′, R″ andR″ each independently is hydrogen or alkyl.

“Nitro” means —NO₂.

“Cyano” mean —CN.

“Phenoxy” means a phenyl ring that is substituted with at least one —OHgroup.

“Acetyl” means —C(═O)—CH₃.

“C_(n-m)—” is used as a prefix before a functional group wherein ‘n’ and‘m’ are recited as integer values (i.e. 0, 1, 2, 12), for exampleC₁₋₁₂-alkyl or C₅₋₁₂-heteroaryl. The prefix denotes the number, or rangeof numbers, of carbons atoms present in the functional group. In thecase of ring systems the prefix denotes the number of ring atoms, orrange of the number of ring atoms, whether the ring atoms are carbonatoms or heteroatoms. In the case of functional groups made up a ringportion and a non-ring portion (i.e. “arylalkyl” is made up of an arylportion and an alkyl portion) the prefix is used to denote how manycarbon atoms and ring atoms are present in total. For example, witharylalkyl, “C₇-arylalkyl” may be used to denote “phenyl-CH₂—”. In thecase of some functional groups zero carbon atoms may be present, forexample C₀-aminosulfonyl (i.e. —SO₂—NH₂, with both potential R groups ashydrogen) the ‘0’ indicates that no carbon atoms are present.

“Peptide” means an amide derived from two or more amino acids bycombination of the amino group of one acid with the carboxyl group.“Monopeptide” means a single amino acid, “dipeptide” means an amidecompound comprising two amino acids, “tripeptide” means an amidecompound comprising three amino acids, and so on. The C-terminus of a“peptide” may be joined to another moiety via an ester functionality.

“Optionally substituted”, when used in association with “aryl”, phenyl”,“heteroaryl” “cyclo-hexyl” or “heterocyclyl”, means an aryl, phenyl,heteroaryl, cyclohexyl or heterocyclyl which is optionally substitutedindependently with one to four substituents, preferably one or twosubstituents selected from alkyl, cycloalkyl, cycloalkylalkyl,heteroalkyl, hydroxyalkyl, halo, nitro, cyano, hydroxy, alkoxy, amino,acylamino, monoalkylamino, dialkylamino, haloalkyl, haloalkoxy,heteroalkyl, —COR (where R is hydrogen, alkyl, phenyl or phenylalkyl),—(CR′R″)_(n)˜COOR (where n is an integer from 0 to 5, R′ and R″ areindependently hydrogen or alkyl, and R is hydrogen, alkyl, cycloalkyl,cycloalkylalkyl, phenyl or phenylalkyl), or —(CR′R″)_(n)—CONR^(a)R^(b)(where n is an integer from 0 to 5, R′ and R″ are independently hydrogenor alkyl, and R^(a) and R are, independently of each other, hydrogen,alkyl, cycloalkyl, cycloalkylalkyl, phenyl or phenylalkyl).

“Leaving group” means the group with the meaning conventionallyassociated with it in synthetic organic chemistry, i.e., an atom orgroup displaceable under substitution reaction conditions. Examples ofleaving groups include, but are not limited to, halogen, alkane- orarylenesulfonyloxy, such as methanesulfonyloxy, ethanesulfonyloxy,thiomethyl, benzenesulfonyloxy, tosyloxy, and thienyloxy,dihalophosphinoyloxy, optionally substituted benzyloxy, isopropyloxy andacyloxy.

“Modulator” means a molecule that interacts with a target. Theinteractions include, but are not limited to, agonist and antagonist, asdefined herein.

“Optional” or “optionally” means that the subsequently described eventor circumstance may but need not occur, and that the descriptionincludes instances where the event or circumstance occurs and instancesin which it does not.

“Disease” and “disease state” means any disease, condition, symptom,disorder or indication.

“Inert organic solvent” or “inert solvent” means the solvent is inertunder the conditions of the reaction being described in conjunctiontherewith, including, e.g., benzene, toluene, acetonitrile,tetrahydrofuran, N,N-dimethylformamide, chloroform, methylene chlorideor dichloromethane, dichloroethane, diethyl ether, ethyl acetate,acetone, methyl ethyl ketone, methanol, ethanol, propanol, isopropanol,tert-butanol, dioxane, pyridine, and the like. Unless specified to thecontrary, the solvents used in the reactions of the present disclosureare inert solvents.

“Pharmaceutically acceptable” means that which is useful in preparing apharmaceutical composition that is generally safe, non-toxic, andneither biologically nor otherwise un-desirable and includes that whichis acceptable for veterinary as well as human pharmaceutical use.

“Pharmaceutically acceptable salts” of a compound means salts that arepharmaceutically acceptable, as defined herein, and that possess thedesired pharmacological activity of the parent compound. Such saltsinclude: acid addition salts formed with inorganic acids such ashydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,phosphoric acid, and the like; or formed with organic acids such asacetic acid, benzenesulfonic acid, benzoic, camphorsulfonic acid, citricacid, ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconicacid, glutamic acid, glycolic acid, hydroxynaphtoic acid,2-hydroxyethanesulfonic acid, lactic acid, maleic acid, malic acid,malonic acid, mandelic acid, methanesulfonic acid, muconic acid,2-naphthalene-sulfonic acid, propionic acid, salicylic acid, succinicacid, tartaric acid, p-toluenesulfonic acid and trimethylacetic acid; orsalts formed when an acidic proton present in the parent compound eitheris replaced by a metal ion, e.g., an alkali metal ion, an alkaline earthion, or an aluminum ion; or coordi-nates with an organic or inorganicbase. Acceptable organic bases include diethanolamine, ethanolamine,N-methylglucamine, triethanolamine, trimethylamine and tromethamine.Acceptable inorganic bases include aluminum hydroxide, calciumhydroxide, potassium hydroxide, sodium carbonate and sodium hydroxide.

The preferred pharmaceutically acceptable salts are the salts formedfrom acetic acid, hydrochloric acid, sulphuric acid, methanesulfonicacid, maleic acid, phosphoric acid, tartaric acid, citric acid, sodium,potassium, calcium, zinc, and magnesium.

It should be understood that all references to pharmaceuticallyacceptable salts include solvent addition forms (solvates) or crystalforms (polymorphs) as defined herein, of the same acid addition salt.

The terms “pro-drug” and “prodrug”, which may be used interchangeablyherein, refer to any compound which releases an active parent drugaccording to Formula I in vivo when such prodrug is administered to amammalian subject. Prodrugs of a compound of Formula I are prepared bymodifying one or more functional group(s) present in the compound ofFormula I in such a way that the modification(s) may be cleaved in vivoto release the parent compound. Prodrugs include compounds of Formula Iwherein a hydroxy, amino, or sulfhydryl group in a compound of Formula Iis bonded to any group that may be cleaved in vivo to regenerate thefree hydroxyl, amino, or sulfhydryl group, respectively. Examples ofprodrugs include, but are not limited to, esters (e.g., acetate,formate, and benzoate derivatives), carbamates (e.g.,N,N-dimethylaminocarbonyl) of hydroxy functional groups in compounds ofFormula I, N-acyl derivatives (e.g. N-acetyl) N-Mannich bases, Schiffbases and enaminones of amino functional groups, oximes, acetals, ketalsand enol esters of ketone and aldehyde functional groups in compounds ofFormula I, see Bundegaard, “Design of Prodrugs” p 1-92, Elsevier, NewYork-Oxford (1985).

“Protective group” or “protecting group” means the group whichselectively blocks one reactive site in a multifunctional compound suchthat a chemical reaction can be carried out selectively at anotherunprotected reactive site in the meaning conventionally associated withit in synthetic chemistry. Certain processes of the present disclosurerely upon the protective groups to block reactive nitrogen and/or oxygenatoms present in the reactants. For example, the terms “amino-protectinggroup” and “nitrogen protecting group” are used interchangeably hereinand refer to those organic groups intended to protect the nitrogen atomagainst undesirable reactions during synthetic procedures. Exemplarynitrogen protecting groups include, but are not limited to,trifluoroacetyl, acetamido, benzyl (Bn), benzyloxycarbonyl(carbobenzyloxy, CBZ), p-methoxybenzyloxycarbonyl,p-nitrobenzyloxycarbonyl, and tert-butoxycarbonyl (BOC). The personskilled in the art will know how to choose a group for the ease ofremoval and for the ability to withstand the following reactions.

“Solvates” means solvent additions forms that contain eitherstoichiometric or non-stoichiometric amounts of solvent. Some compoundshave a tendency to trap a fixed molar ratio of solvent molecules in thecrystalline solid state, thus forming a solvate. If the solvent is waterthe solvate formed is a hydrate, when the solvent is alcohol, thesolvate formed is an alcoholate. Hydrates are formed by the combinationof one or more molecules of water with one of the substances in whichthe water retains its molecular state as H₂O, such com-bination beingable to form one or more hydrate.

“Subject” means mammals and non-mammals. Mammals means any member of themammalia class including, but not limited to, humans; non-human primatessuch as chimpanzees and other apes and monkey species; farm animals suchas cows, horses, sheep, goats, and swine; domestic animals such asrabbits, dogs, and cats; laboratory animals in-eluding rodents, such asrats, mice, and guinea pigs; and the like. Examples of non-mammalsinclude, but are not limited to, birds. The term “subject” does notdenote a particular age or sex.

“Disorders of the urinary tract” or “uropathy” used interchangeably with“symptoms of the urinary tract” means the pathologic changes in theurinary tract. Examples of urinary tract disorders include, but are notlimited to, incontinence, benign prostatic hypertrophy (BPH),prostatitis, detrusor hyperreflexia, outlet obstruction, urinaryfrequency, nocturia, urinary urgency, overactive bladder, pelvichypersensitivity, urge incontinence, urethritis, prostatodynia, cystitisand idiophatic bladder hypersensitivity.

“Disease states associated with the urinary tract” or “urinary tractdisease states” or “uropathy” used interchangeably with “symptoms of theurinary tract” mean the pathologic changes in the urinary tract, ordysfunction of urinary bladder smooth muscle or its innervation causingdisordered urinary storage or voiding. Symptoms of the urinary tractinclude, but are not limited to, overactive bladder (also known asdetrusor hyperactivity), outlet obstruction, outlet insufficiency, andpelvic hypersensitivity.

“Overactive bladder” or “detrusor hyperactivity” includes, but is notlimited to, the changes symptomatically manifested as urgency,frequency, altered bladder capacity, incontinence, low micturitionthreshold, unstable bladder contractions, sphincteric spasticity,detrusor hyperreflexia (neurogenic bladder; dyssynergia) and detrusorinstability.

“Outlet obstruction” includes, but is not limited to, benign prostatichypertrophy (BPH), urethral stricture disease, tumors, low flow rates,difficulty in initiating urination, urgency and suprapubic pain.

“Outlet insufficiency” includes, but is not limited to, urethralhypermobility, intrinsic sphincteric deficiency, mixed incontinence andstress incontinence.

“Pelvic Hypersensitivity” includes, but is not limited to, pelvic pain,interstitial (cell) cystitis, prostatodynia, prostatitis, vulvadynia,urethritis, orchidalgia and overactive bladder.

“Cough” includes acute, sub-acute and chronic cough, treatment-resistantcough, idiopathic chronic cough, post-viral cough, iatrogenic cough,cough associated with post-nasal drip, cough associated with upperrespiratory infection, asthma and/or COPD, cough associated withinterstitial disease, cough associated with gastroesophageal refjuxdisease (GERD), cough associated with smoking or a form of bronchitis,and neuronal hypeersensitivity underlying acute, sub-acute or chroniccough.

The term “hypertension” as used herein refers to a condition or diseasewell known in the art in which the blood pressure in a mammal ischronically elevated. In certain embodiments hypertension may refer to acondition in which a subject's resting systolic blood pressure is aboveabout 120 mmHg and/or diastolic pressure is above about 80 mmHg. Incertain embodiments hypertension may refer to a condition in which asubject's resting systolic blood pressure is above about 115 mmHg; orabove about 120 mmHg; or above about 125 mmHg; or above about 130 mmHg;or above about 135 mmHg; or above about 140 mmHg; or above about 145mmHg; or above about 150 mmHg; or above about 155; or above about 160;or above about 165; or above about 170 and/or resting diastolic pressureis above about 75 mmHg; or above about 80 mmHg; or above about 85 mmHg;or above about 90 mmHg; or above about 95 mmHg; or above about 100 mmHg;or above about 105 mmHg; or above about 110 mmHg. In some embodimentshypertension may be primary or secondary hypertension. In someembodiments hypertension may be chronic treatment resistanthypertension, defined as persistent hypertension (resting office bloodpressure >140/90 [SBP/DBP]) despite use of 2 or 3 antihypertensivemedications including a diuretic, as well as hypertension in patientsunable to tolerate currently preferred antihypertensive medications, orin whom approved medications cannot achieve recommended levels of BPcontrol. Diagnosis of hypertension in a subject may in variousembodiments be performed by an individual qualified to make suchdiagnosis in a particular jurisdiction.

The term “heart failure” as used herein refers to a condition or diseasewell known in the art which is associated with the heart being unable tomaintain blood flow sufficient to maintain the needs of the body.Diagnosis of heart failure may in certain embodiments be based onechocardiography results characteristic of heart failure. In someembodiments, heart failure may refer to a condition often referred to ascongestive heart failure. In some embodiments, heart failure may referto systolic heart failure, also called heart failure due to reducedejection fraction (HFREF) or heart failure due to left ventricularsystolic dysfunction. In some embodiments, heart failure may refer toheart failure with preserved ejection fraction (HFPEF) also known asdiastolic heart failure or heart failure with normal ejection fraction(HFNEF). In some embodiments, heart failure may be chronic heart failureand in other embodiments the heart failure may be acute heart failure.Diagnosis of heart failure in a subject may in various embodiments beperformed by an individual qualified to make such diagnosis in aparticular jurisdiction.

The term “dyspnea” as used herein refers to a condition or disease wellknown in the art in which a subject experiences feelings or sensationsassociated with impaired breathing. In some embodiments dyspnea mayrefer to a condition consistent with the America Thoracic Societydefinition of dyspnea, i.e., “a subjective experience of breathingdiscomfort that consists of qualitatively distinct sensations that varyin intensity”. In some embodiments dyspnea may refer to sensations ofinadequate breathing, uncomfortable awareness of breathing and/orbreathlessness. Diagnosis of dyspnea in a subject may in variousembodiments be performed by an individual qualified to make suchdiagnosis in a particular jurisdiction.

The term “sleep apnea” as used herein refers to a condition or diseasewell known in the art characterized by disruptions in breathing (e.g.,pauses in breathing or instances of shallow or infrequent breathing,accompanied by ischemia/hypoxemia) during sleep. In some aspects sleepapnea is central sleep apnea, obstructive sleep apnea, or mixed sleepapnea. In some embodiments, sleep apnea may be characterized by morethan about 5 apneic events per hour of sleep; or more than about 10apneic events per hour of sleep; or more than about 15 apneic events perhour sleep; or more than about 20 apneic events per hour of sleep, ormore than about 25 apneic events per hour of sleep, or more than about30 apneic sleep events per hour sleep; or more than about 35 apneicsleep events per hour sleep. Diagnosis of dyspnea in a subject may invarious embodiments be performed by an individual qualified to make suchdiagnosis in a particular jurisdiction.

The term “carotid body” as used herein refers to a small cluster ofchemoreceptors and supporting cells located near the fork (bifurcation)of the carotid artery. The carotid body is also referred in the art ascarotid glomus or glomus caroticum. The term “altering carotid bodytonicity” or activity as used herein means modifying the level ofexcitation of carotid sinus nerve chemoreceptor afferents that aredischarging excessively in response to dysregulated levels of arterialchemicals (hyperreflexia), as well as attenuating the aberrant,spontaneous discharge of such nerve fibers that can occur in the absenceof chemical dysregulation (hypertonoicity).

“Therapeutically effective amount” means an amount of a compound that,when administered to a subject for treating a disease state, issufficient to effect such treatment for the disease state. The“therapeutically effective amount” will vary depending on the compound,disease state being treated, the severity or the disease treated, theage and relative health of the subject, the route and form ofadministration, the judgment of the attending medical or veterinarypractitioner, and other factors.

The terms “those defined above” and “those defined herein” whenreferring to a variable incorporates by reference the broad definitionof the variable as well as preferred, more preferred and most preferreddefinitions, if any.

“Treating” or “treatment” of a disease state includes:

-   -   (i) preventing the disease state, i.e. causing the clinical        symptoms of the disease state not to develop in a subject that        may be exposed to or predisposed to the disease state, but does        not yet experience or display symptoms of the disease state.    -   (ii) inhibiting the disease state, ie., arresting the        development of the disease state or its clinical symptoms, or    -   (iii) relieving the disease state, ie., causing temporary or        permanent regression of the disease state or its clinical        symptoms.

The terms “treating”, “contacting” and “reacting” when referring to achemical reaction means adding or mixing two or more reagents underappropriate conditions to produce the indicated and/or the desiredproduct. It should be appreciated that the reaction which produces theindicated and/or the desired product may not necessarily result directlyfrom the combination of two reagents which were initially added, i.e.,there may be one or more intermediates which are produced in the mixturewhich ultimately leads to the formation of the indicated and/or thedesired product.

Any open valency appearing on a carbon, oxygen, sulfur or nitrogen atomin the structures herein indicates the presence of a hydrogen atom.

All patents and publications identified herein are incorporated hereinby reference in their entirety.

In certain embodiments, X₁ in Formula 1 is C—R² and W is S, providingcompounds of Formula 1a as follows:

In certain embodiments, X₁ in Formula 1 is N, providing compounds of theFormula 1b, as follows:

In some embodiments of Formula 1b, W is O. In some embodiments ofFormula 1b, W is S. In some embodiments of Formula 1b, W is CH₂. In someembodiments of Formula 1b, W is NR.

In certain embodiments, X₁ in Formula 1 is C—R² and X₂ is N, providingcompounds of Formula 1c, as follows:

In some embodiments of Formula 1c, W is O. In some embodiments ofFormula 1c, W is S. In some embodiments of Formula 1c, W is CH₂. In someembodiments of Formula 1c, W is NR.

In certain embodiments, X₁ in Formula 1 is C—R² and X₃ is N, providingcompounds of Formula 1d, as follows:

In some embodiments of Formula 1d, W is O. In some embodiments ofFormula 1d, W is S. In some embodiments of Formula 1d, W is CH₂. In someembodiments of Formula 1d, W is NR.

In certain embodiments, X₁ in Formula 1 is C—R² and X₄ is N, providingcompounds of Formula 1e, as follows:

In some embodiments of Formula 1e, W is O. In some embodiments ofFormula 1e, W is S. In some embodiments of Formula 1e, W is CH₂. In someembodiments of Formula 1e, W is NR.

In certain embodiments, X₁ in Formula 1 is C—R² and both X₂ and X₃ areN, providing compounds of Formula 1f, as follows:

In some embodiments of Formula 1f, W is O. In some embodiments ofFormula 1f, W is S. In some embodiments of Formula 1f, W is CH₂. In someembodiments of Formula 1f, W is NR.

In certain embodiments, X₁ in Formula 1 is C—R² and both X₂ and X₄ areN, providing compounds of Formula 1g, as follows:

In some embodiments of Formula 1g, W is O. In some embodiments ofFormula 1g, W is S. In some embodiments of Formula 1g, W is CH₂. In someembodiments of Formula 1g, W is NR.

In certain embodiments, X₁ in Formula 1 is C—R² and both X₃ and X₄ areN, providing compounds of Formula 1h, as follows:

In some embodiments of Formula 1h, W is O. In some embodiments ofFormula 1h, W is S. In some embodiments of Formula 1h, W is CH₂. In someembodiments of Formula 1h, W is NR.

In certain embodiments, both X₁ and X₂ of Formula 1 are N, providingcompounds of Formula 1i as follows:

In some embodiments of Formula 1i, W is O. In some embodiments ofFormula 1i, W is S. In some embodiments of Formula 1i, W is CH₂. In someembodiments of Formula 1i, W is NR.

In certain embodiments, both X₁ and X₃ of Formula 1 are N, providing thecompounds of Formula 1j, as follows:

In some embodiments of Formula 1j, W is O. In some embodiments ofFormula 1j, W is S. In some embodiments of Formula 1j, W is CH₂. In someembodiments of Formula 1j, W is NR.

In certain embodiments, both X₁ and X₄ of Formula 1 are N, providingcompounds of Formula 1k, as follows:

In some embodiments of Formula 1k, W is O. In some embodiments ofFormula 1k, W is S. In some embodiments of Formula 1k, W is CH₂. In someembodiments of Formula 1k, W is NR.

In certain embodiments, X₅ of Formula 1 is N, providing compounds ofFormula 1l, as follows:

In some embodiments of Formula 1l, W is O. In some embodiments ofFormula 1l, W is S. In some embodiments of Formula 1l, W is CH₂. In someembodiments of Formula 1l, W is NR.

In certain embodiments, X₅ of Formula 1 is C—R⁶, providing compounds ofFormula 1m, as follows:

In some embodiments of Formula 1m, W is O. In some embodiments ofFormula 1m, W is S. In some embodiments of Formula m, W is CH₂. In someembodiments of Formula 1m, W is NR. In certain embodiments of Formula1m, when X₁ is C—R², X₂ is C—R³, X₃ is C—R⁴ and X₄ is C—R⁵, W is not Oor —CH₂—.

In certain embodiments of any one of Formulae 1-1m, R⁵ and R⁶ arehydrogen.

In certain embodiments of any one of Formulae 1-1m, R⁶ is hydrogen ormethyl.

In certain embodiments of any one of Formulae 1-1m, R² is hydrogen.

In certain embodiments of any one of Formulae 1-1m, D is absent.

In certain embodiments of any one of Formulae 1-1m, R¹ is selected fromC₁₋₁₂-alkyl, C₂₋₁₂-alkenyl and C₃₋₁₂-cycloalkyl. In some of theseembodiments, R¹ is selected from ethyl, cyclopropyl, isopropenyl andisopropyl. In particular embodiments, R¹ is isopropyl. In particularembodiments, R¹ is ethyl. In particular embodiments, R¹ is cyclopropyl.

In certain embodiments of any one of Formulae 1-1m, R⁷ is selected from:C₁₋₁₂-alkyl, C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; C₂₋₁₂-alkylsulfonylalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl; C₆₋₁₂-arylsulfonyl;C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl; C₅₋₁₂-heteroarylsulfonyl;C₃₋₁₂-heterocyclyl; and C₄₋₁₂-heterocyclylalkyl.

In certain embodiments of any one of Formulae 1-1m, R⁷ is selected fromC₁₋₁₂-alkyl, C₁₋₁₂-hydroxyalkyl and C₁₋₁₂-haloalkyl.

In certain embodiments of any one of Formulae 1-1m, Y is —NHR^(d). Insome of these embodiments of formula 1, R^(d) is selected from:C₁₋₁₂-alkyl, C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; C₂₋₁₂-alkylsulfonylalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl; C₆₋₁₂-arylsulfonyl;C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl; C₅₋₁₂-heteroarylsulfonyl;C₃₋₁₂-heterocyclyl; and C₄₋₁₂-heterocyclylalkyl. In particularembodiments, R^(d) is selected from C₁₋₁₂-alkyl, C₁₋₁₂-hydroxyalkyl andC₁₋₁₂-haloalkyl.

In certain embodiments of any one of Formulae 1-1m, R³ and R⁴ eachindependently is C₁₋₁₂-alkyl, C₂₋₁₂-alkynyl, cyano, C₀₋₁₂-sulfonamido,—COOH, C₅₋₁₂-heteroaryl, halo, C₁₋₁₂-alkoxy, C₁₋₁₂-halo-alkoxy orC₁₋₁₂-alkylsulfonyl.

In certain embodiments of any one of Formulae 1-1m, R³ is halo,C₁₋₁₂-alkoxy, C₁₋₁₂-haloalkoxy or hydroxy. In further embodiments, R³ ismethoxy, fluoro, or chloro. In particular embodiments, R³ is methoxy. Incertain embodiments R³ is hydroxy.

In certain embodiments of any one of Formulae 1-1m, R⁴ is C₁₋₁₂-alkyl,C₂₋₁₂-alkynyl, cyano, C₀₋₁₂-sulfonamido, —COOH, halo, C₁₋₁₂-alkoxy,C₁₋₁₂-alkylsulfonyl or C₅₋₁₂-heteroaryl. In further embodiments, R⁴ ismethoxy, iodo, methanesulfonyl or C₅₋₁₂-heteroaryl. In particularembodiments, R⁴ is methoxy, methyl, cyano, bromo, chloro, iodo,—C≡C—CH₃, —C≡CH, —COOH, —S(O)₂CH₃, —S(O)₂NH₂ or tetrazolyl. In specificembodiments R⁴ is methoxy, while in other embodiments R⁴ is iodo.

In certain embodiments of any one of Formulae 1-1m, R⁷, R^(d) and R^(e)are hydrogen.

In certain embodiments of any one of Formulae 1-1m, R³ and R⁴ togetherwith the atoms to which they are attached form a five or six-memberedring that optionally includes one or two heteroatoms selected from O, Sand N. In many such embodiments R3 and R4 together with the atoms towhich they are attached form: a five membered aromatic with onenitrogen, i.e. a pyrrol ring; a five membered aromatic with twonitrogens, i.e., a pyrazol or imidazol ring; a five membered aromaticwith one nitrogen and one oxygen, i.e., an ox-azole or isoxazole ring; afive membered aromatic with one nitrogen and one sulfur, i.e., athiazole or isothiazole ring; a five membered aromatic with one oxygen,i.e., a furanyl ring; or a five membered aromatic with one sulfur, i.e.,a thiophenyl ring.

In certain embodiments of any one of Formulae 1-1m, R² and R³ togetherwith the atoms to which they are attached form a five or six-memberedring that optionally includes one or two heteroatoms selected from O, Sand N. In many such embodiments R³ and R⁴ together with the atoms towhich they are attached form: a five membered aromatic with onenitrogen, i.e. a pyrrol ring; a five membered aromatic with twonitrogens, i.e. a pyrazol or imidazole ring; a five membered aromaticwith one nitrogen and one oxygen, i.e., an oxazole or isoxazole ring; afive membered aromatic with one nitrogen and one sulfur, i.e., athiazole or isothiazole ring; a five membered aromatic with one oxygen,i.e., a furanyl ring; or a five membered aromatic with one sulfur, i.e.,a thiophenyl ring.

In some embodiments of the present disclosure, the compounds are ofFormula 2:

wherein:

-   -   R¹ is C₁₋₁₂-alkyl; C₂₋₁₂-alkenyl; C₃₋₁₂-cycloalkyl; or        C₃₋₁₂-cycloalkenyl; or halo;    -   R³ and R⁴ each independently is: hydrogen; C₁₋₁₂-alkyl;        C₂₋₁₂-alkenyl; C₂₋₁₂-alkynyl; amino; halo; amido;        C₁₋₁₂-haloalkyl; C₁₋₁₂-alkoxy; hydroxy; C₁₋₁₂-haloalkoxy; nitro;        C₁₋₁₂-hydroxyalkyl; C₂₋₁₂-alkoxyalkyl; C₁₋₁₂-hydroxyalkoxy;        C₃₋₁₂-alkynylalkoxy; C₂₋₁₂-alkylsulfonyl; C₁₋₁₂-arylsulfonyl;        cyano; C₆₋₁₂-aryl; C₅₋₁₂-heteroaryl; C₃₋₁₂-heterocyclyl;        C₄₋₁₂-heterocyclylalkoxy; C₆₋₁₂-aryloxy; C₅₋₁₂-heteroaryloxy;        C₇₋₁₂-arylalkyloxy; C₆₋₁₂-heteroarylalkyloxy; optionally        substituted phenoxy; —(CH₂)_(m)—(Z)_(n)—(CO)—R^(f) or        —(CH₂)_(m)—(Z)_(n)—SO₂—(NR^(g))_(n′)—R^(f), where m, n and n′        are each independently 0 or 1,    -   Z is O or NR^(g),    -   R^(f) is hydrogen, C₁₋₁₂-alkyl, hydroxy, C₁₋₁₂-alkoxy, amino,        C₁₋₁₂-hydroxyalkyl or C₂₋₁₂-alkoxyalkyl, and each R^(g) is        independently hydrogen or C₁₋₁₂-alkyl; or R³ and R⁴ together        with the atoms to which they are attached may form a five or        six-membered ring that optionally includes one or two        heteroatoms selected from O, S and N;    -   R⁷ is selected from hydrogen; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl;        C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy;        C₁₋₁₂-hydroxyalkyl; C₂₋₁₂-alkoxyalkyl; acetyl;        C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;        C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;        C₂₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;        C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆ 2-heteroarylalkyl;        C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; and        C₄₋₁₂-heterocyclylalkyl; and    -   R^(d) is selected from hydrogen; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl;        C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy;        C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; acetyl;        C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;        C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;        C₂₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;        C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl;        C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; and        C₄₋₁₂-heterocyclylalkyl.

In certain embodiments of Formula 2, R¹ is selected from C₁₋₁₂-alkyl,C₂₋₁₂-alkenyl and C₃₋₁₂-cycloalkyl. In some of these embodiments, R¹ isselected from ethyl, cyclopropyl, isopropenyl and isopropyl. Inparticular embodiments, R¹ is isopropyl. In particular embodiments, R¹is ethyl. In particular embodiments, R¹ is cyclopropyl.

In certain embodiments of Formula 2, R⁷ is selected from: C₁₋₁₂-alkyl,C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; C₂₋₁₂-alkylsulfonylalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl; C₆₋₁₂-arylsulfonyl;C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl; C₅₋₁₂-heteroarylsulfonyl;C₃₋₁₂-heterocyclyl; and C₄₋₁₂-heterocyclylalkyl.

In certain embodiments of Formula 2, R⁷ is selected from C₁₋₁₂-alkyl,C₁₋₁₂-hydroxyalkyl and C₁₋₁₂-haloalkyl.

In certain embodiments of Formula 2, R^(d) is selected from:C₁₋₁₂-alkyl, C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; C₂₋₁₂-alkylsulfonylalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl; C₆₋₁₂-arylsulfonyl;C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl; C₅₋₁₂-heteroarylsulfonyl;C₃₋₁₂-heterocyclyl; and C₄₋₁₂-heterocyclylalkyl. In further embodiments,R^(d) is selected from C₁₋₁₂-alkyl, C₁₋₁₂-hydroxyalkyl andC₁₋₁₂-haloalkyl.

In certain embodiments of Formula 1, R³ and R⁴ each independently isC₁₋₁₂-alkyl, C₂₋₁₂-alkynyl, cyano, C₀₋₁₂-sulfonamido, —COOH,C₅₋₁₂-heteroaryl, halo, C₁₋₁₂-alkoxy, C₁₋₁₂-halo-alkoxy orC₁₋₁₂-alkylsulfonyl.

In certain embodiments of Formula 1, R³ is halo, C₁₋₁₂-alkoxy,C₁₋₁₂-haloalkoxy or hydroxy. In further embodiments, R³ is methoxy,fluoro, or chloro. In particular embodiments, R³ is methoxy. In certainembodiments R³ is hydroxy.

In certain embodiments of Formula 1, R⁴ is C₁₋₁₂-alkyl, C₂₋₁₂-alkynyl,cyano, C₀₋₁₂-sulfonamido, —COOH, halo, C₁₋₁₂-alkoxy, C₁₋₁₂-alkylsulfonylor C₅₋₁₂-heteroaryl. In further embodiments, R⁴ is methoxy, iodo,methanesulfonyl or C₅₋₁₂-heteroaryl. In particular embodiments, R⁴ ismethoxy, methyl, cyano, bromo, chloro, iodo, —C≡C—CH₃, —C≡CH, —COOH,—S(O)₂CH₃, —S(O)₂NH₂ or tetrazolyl. In specific embodiments R⁴ ismethoxy, while in other embodiments R⁴ is iodo.

In certain embodiments of Formula 2, R⁷, R^(d) and R^(e) are hydrogen.

In certain embodiments of Formula 2, R⁴ is C₅₋₁₂-heteroaryl. Theheteroaryl may be, in certain embodiments, tetrazolyl, pyrazolyl,oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl,isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyl, or pyrrolyl. Morespecifically, the heteroaryl may be tetrazol-5-yl, pyrazol-1-yl,3-methylpyrazol-1-yl, oxazol-2-yl, ox-azol-5-yl, imidazol-2-yl,thiazol-2-yl, thiazol-4-yl, thiophen-3-yl, 5-chloro-thiophen-2-yl,1-methyl-imidazol-2-yl, imidazol-1-yl, pyrazol-3-yl,2-methyl-thiazol-4-yl, furan-2-yl, 3,5-dimethyl-pyrazol-1-yl,4,5-dihydrooxazol-2-yl, isoxazol-5-yl, [1,2,4]-oxadiazol-3-yl,benzo[b]thiophen-3-yl, oxazol-4-yl, furan-3-yl, 4-methyl-thiophen-2-yl,thiazol-5-yl, tetrazol-1-yl, [1,2,4] triazol-1-yl,2-methyl-thiazol-5-yl, 1-methyl-pyrazol-4-yl, 2-thiolyl-imidazol-1-yl,pyridin-2-yl, or 2,5-dimethyl-pyrrol-1-yl).

In certain embodiments of Formula 2, R³ and R⁴ together with the atomsto which they are attached form a five or six-membered ring thatoptionally includes one or two heteroatoms selected from O, S and N. Inmany such embodiments R³ and R⁴ together with the atoms to which theyare attached form: a five membered aromatic with one nitrogen, i.e. apyrrol ring; a five membered aromatic with two nitrogens, i.e., apyrazol or imidazol ring; a five membered aromatic with one nitrogen andone oxygen, i.e., an ox-azole or isoxazole ring; a five memberedaromatic with one nitrogen and one sulfur, i.e., a thiazole orisothiazole ring; a five membered aromatic with one oxygen, i.e., afuranyl ring; or a five membered aromatic with one sulfur, i.e., athiophenyl ring.

In a further embodiment of Formula 2, R¹ is C₁₋₁₂-alkyl, C₂₋₁₂-alkenyl,C₃₋₁₂-cycloalkyl, or halo, R³ is C₁₋₁₂-alkoxy, hydroxy or halo, and R⁴is C₁₋₁₂-alkyl, C₂₋₁₂-alkynyl, cyano, C₀₋₁₂-sulfonamido, —COOH, halo,C₁₋₁₂-alkoxy, C₁₋₁₂-alkylsulfonyl or C₅₋₁₂-heteroaryl selected fromtetrazolyl, pyrazolyl, oxazolyl, imidazolyl, thiazolyl, thiophenyl,triazolyl, furanyl, isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyland pyrrolyl.

In another further embodiment of Formula 2, R¹ is C₁₋₁₂-alkyl,C₂₋₁₂-alkenyl, C₃₋₁₂-cycloalkyl, or halo, R³ is C₁₋₁₂-alkoxy, hydroxy orhalo, and R⁴ is C₁₋₁₂-alkyl, C₂₋₁₂-alkynyl, cyano, C₀₋₁₂-sulfonamido,—COOH, halo, C₁₋₁₂-alkoxy or C₁₋₁₂-alkylsulfonyl.

In another further embodiment of Formula 2, R¹ is C₁₋₁₂-alkyl,C₂₋₁₂-alkenyl, C₃₋₁₂-cycloalkyl, or halo, R³ is C₁₋₁₂-alkoxy, hydroxy orhalo, and R⁴ is C₅₋₁₂-heteroaryl selected from tetrazolyl, pyrazolyl,oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl,isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyl and pyrrolyl.

In another further embodiment of Formula 2, R¹ is C₁₋₁₂-alkyl,C₂₋₁₂-alkenyl, C₃₋₁₂-cycloalkyl, or halo, R³ is C₁₋₁₂-alkoxy, hydroxy orhalo, R⁴ is C₁₋₁₂-alkyl, C₂₋₁₂-alkynyl, cyano, C₀₋₁₂-sulfonamido, —COOH,halo, C₁₋₁₂-alkoxy or C₁₋₁₂-alkylsulfonyl, R⁷ is hydrogen, and R^(d) ishydrogen, C₁₋₁₂-alkyl, C₁₋₁₂-hydroxyalkyl or C₁₋₁₂-haloalkyl.

In another further embodiment of Formula 2, R¹ is C₁₋₁₂-alkyl,C₂₋₁₂-alkenyl, C₃₋₁₂-cycloalkyl, or halo, R³ is C₁₋₁₂-alkoxy, hydroxy orhalo, R⁴ is C₅₋₁₂-heteroaryl selected from tetrazolyl, pyrazolyl,oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl,isoxazolyl, oxadiazolyl, benzo-thiophenyl, pyridinyl and pyrrolyl, R⁷ ishydrogen, and R^(d) is hydrogen, C₁₋₁₂-alkyl, acetyl, C₁₋₁₂-hydroxyalkylor C₁₋₁₂-haloalkyl.

In another further embodiment of Formula 2, R¹ is isopropyl,isopropenyl, cyclopropyl or iodo, R³ is C₁₋₁₂-alkoxy, hydroxy or halo,and R⁴ is C₁₋₁₂-alkyl, C₂₋₁₂-alkynyl, cyano, C₀₋₁₂-sulfonamido, —COOH,halo, C₁₋₁₂-alkoxy, C₁₋₁₂-alkylsulfonyl or C₅₋₁₂-heteroaryl.

In another further embodiment of Formula 2, R¹ is isopropyl,isopropenyl, cyclopropyl or iodo, R³ is C₁₋₁₂-alkoxy, hydroxy or halo,R⁴ is C₁₋₁₂-alkyl, C₂₋₁₂-alkynyl, cyano, C₀₋₁₂-sulfonamido, —COOH, halo,C₁₋₁₂-alkoxy, C₁₋₁₂-alkylsulfonyl or C₅₋₁₂-heteroaryl, R⁷ is hydrogen,and R^(d) is hydrogen, C₁₋₁₂-alkyl, C₁₋₁₂-hydroxyalkyl orC₁₋₁₂-haloalkyl.

In another further embodiment of Formula 2, R¹ is isopropyl or iodo, R³is methoxy, hydroxy, chloro, bromo or iodo, and R⁴ is methoxy, methyl,cyano, bromo, chloro, iodo, —C≡C—CH₃, —C≡CH, —COOH, —S(O)₂CH₃, —S(O)₂NH₂or tetrazolyl.

In another further embodiment of Formula 2, R¹ is isopropyl or iodo, R³is methoxy, hydroxy, chloro, bromo or iodo, R⁴ methoxy, methyl, cyano,bromo, chloro, iodo, —C≡C—CH₃, —C≡CH, —COOH, —S(O)₂CH₃, —S(O)₂NH₂ ortetrazolyl, R⁷ is hydrogen, and R^(d) is hydrogen, C₁₋₁₂-alkyl,C₁₋₁₂-hydroxyalkyl or C₁₋₁₂-haloalkyl.

In another further embodiment of Formula 2, R¹ is isopropyl, R³ ismethoxy, hydroxy, chloro, bromo or iodo, and R⁴ is methoxy, methyl,cyano, bromo, chloro, iodo, —C≡C—CH₃, —C≡CH, —COOH, —S(O)₂CH₃, —S(O)₂NH₂or tetrazolyl.

In another further embodiment of Formula 2, R¹ is isopropyl, R³ ismethoxy, hydroxy, chloro, bromo or iodo, R⁴ methoxy, methyl, cyano,bromo, chloro, iodo, —C≡C—CH₃, —C≡CH, —COOH, —S(O)₂CH₃, —S(O)₂NH₂ ortetrazolyl, R⁷ is hydrogen, and R^(d) is hydrogen, C₁₋₁₂-alkyl,C₁₋₁₂-hydroxyalkyl or C₁₋₁₂-haloalkyl.

In other embodiments of the present disclosure, the compounds are ofFormula 3:

wherein:

-   -   R³ and R⁴ each independently is: hydrogen; C₁₋₁₂-alkyl;        C₂₋₁₂-alkenyl; C₂₋₁₂-alkynyl; amino; halo; amido;        C₁₋₁₂-haloalkyl; C₁₋₁₂-alkoxy; hydroxy; C₁₋₁₂-haloalkoxy; nitro;        C₁₋₁₂-hydroxyalkyl; C₂₋₁₂-alkoxyalkyl; C₁₋₁₂-hydroxyalkoxy;        C₃₋₁₂-alkynylalkoxy; C₁₋₁₂-alkylsulfonyl; C₆₋₁₂-arylsulfonyl;        cyano; C₆₋₁₂-aryl; C₅₋₁₂-heteroaryl; C₃₋₁₂-heterocyclyl;        C₄₋₁₂-heterocyclylalkoxy; C₆₋₁₂-aryloxy; C₅₋₁₂-heteroaryloxy;        C₇₋₁₂-arylalkyloxy; C₆₋₁₂-heteroaralkyloxy; optionally        substituted phenoxy; —(CH₂)_(m)—(Z)_(n)—(CO)—R^(f) or        —(CH₂)_(m)—(Z)_(n)—SO₂—(NR^(g))_(n′)—R^(f), where m, n and n′        are each independently 0 or 1,    -   Z is O or NR^(g),    -   R^(f) is hydrogen, C₁₋₁₂-alkyl, hydroxy, C₁₋₁₂-alkoxy, amino,        C₁₋₁₂-hydroxyalkyl or C₂₋₁₂-alkoxyalkyl, and each R^(g) is        independently hydrogen or C₁₋₁₂-alkyl;    -   R³ and R⁴ together with the atoms to which they are attached may        form a five or six-membered ring that optionally includes one or        two heteroatoms selected from O, S and N;    -   R⁷ is selected from: hydrogen; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl;        C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy;        C₁₋₁₂-hydroxyalky; C₁₋₁₂-alkoxyalkyl; acetyl;        C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;        C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;        C₂₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;        C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl;        C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; and        C₄₋₁₂-heterocyclylalkyl; and    -   R^(d) is selected from: hydrogen; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl;        C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy;        C₁₋₁₂-hydroxyalky; C₁₋₁₂-alkoxyalkyl; acetyl        C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;        C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;        C₂₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;        C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl;        C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; and        C₄₋₁₂-heterocyclylalkyl.

In certain embodiments Formula 3, R⁷ is selected from: C₁₋₁₂alkyl,C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; C₂₋₁₂-alkylsulfonylalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl; C₆₋₁₂-arylsulfonyl;C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl; C₅₋₁₂-heteroarylsulfonyl;C₃₋₁₂-heterocyclyl; and C₄₋₁₂-heterocyclylalkyl.

In certain embodiments of Formula 3, R⁷ is selected from C₁₋₁₂-alkyl,C₁₋₁₂-hydroxyalkyl and C₁₋₁₂-haloalkyl.

In certain embodiments of Formula 3, R^(d) is selected from:C₁₋₁₂-alkyl, C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; C₂₋₁₂-alkylsulfonylalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl; C₆₋₁₂-arylsulfonyl;C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl; C₅₋₁₂-heteroarylsulfonyl;C₃₋₁₂-heterocyclyl; and C₄₋₁₂-heterocyclylalkyl.

In certain embodiments of Formula 3, R^(d) is selected from: C₁₋₁₂alkyl,C₁₋₁₂-hydroxyalkyl and C₁₋₁₂-haloalkyl.

In certain embodiments of Formula 3, R³ and R⁴ each independently isC₁₋₁₂-alkyl, C₂₋₁₂-alkynyl, cyano, C₀₋₁₂-sulfonamido, —COOH,C₅₋₁₂-heteroaryl, halo, C₁₋₁₂-alkoxy, C₁₋₁₂-halo-alkoxy orC₁₋₁₂-alkylsulfonyl.

In certain embodiments of Formula 3, R³ is halo, C₁₋₁₂-alkoxy,C₁₋₁₂-haloalkoxy or hydroxy. In further embodiments, R³ is methoxy,fluoro, or chloro. In particular embodiments, R³ is methoxy. In certainembodiments R³ is hydroxy.

In certain embodiments of Formula 3, R⁴ is C₁₋₁₂-alkyl, C₂₋₁₂-alkynyl,cyano, C₀₋₁₂-sulfonamido, —COOH, halo, C₁₋₁₂-alkoxy, C₁₋₁₂-alkylsulfonylor C₅₋₁₂-heteroaryl. In further embodiments, R⁴ is methoxy, iodo,methanesulfonyl or C₅₋₁₂-heteroaryl. In particular embodiments, R⁴ ismethoxy, methyl, cyano, bromo, chloro, iodo, —C≡C—CH₃, —C≡CH, —COOH,—S(O)₂CH₃, —S(O)₂NH₂ or 5-tetrazolyl. In specific embodiments R⁴ may bemethoxy, while in other embodiments R⁴ may be iodo.

In certain embodiments of Formula 3, R⁷ and R^(d) are hydrogen.

In certain embodiments of Formula 3, R⁴ is C₅₋₁₂-heteroaryl. Theheteroaryl may be, in certain embodiments, tetrazolyl, pyrazolyl,oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl,isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyl, or pyrrolyl. Morespecifically, the heteroaryl may be tetrazol-5-yl, pyrazol-1-yl,3-methylpyrazol-1-yl, oxazol-2-yl, oxazol-5-yl, imidazol-2-yl,thiazol-2-yl, thiazol-4-yl, thiophen-3-yl, 5-chloro-thiophen-2-yl,1-methyl-imidazol-2-yl, imidazol-1-yl, pyrazol-3-yl,2-methyl-thiazol-4-yl, furan-2-yl, 3,5-dimethyl-pyrazol-1-yl,4,5-dihydrooxazol-2-yl, isoxazol-5-yl, [1,2,4]-oxa-diazol-3-yl,benzo[b]thiophen-3-yl, oxazol-4-yl, furan-3-yl, 4-methyl-thiophen-2-yl,thi-azol-5-yl, tetrazol-1-yl, [1,2,4] triazol-1-yl,2-methyl-thiazol-5-yl, l-methyl-pyrazol-4-yl, 2-thiolyl-imidazol-1-yl,pyridin-2-yl, or 2,5-dimethyl-pyrrol-1-yl).

In certain embodiments of Formula 3, R³ and R⁴ together with the atomsto which they are attached form a five or six-membered ring thatoptionally includes one or two heteroatoms selected from O, S and N; asshown in Formula 4:

wherein:

-   -   R¹ is C₁₋₁₂-alkyl; C₂₋₁₂-alkenyl; C₃₋₁₂-cycloalkyl; or        C₃₋₁₂-cycloalkenyl; or halo;    -   R² is hydrogen; C₁₋₁₂-alkyl; C₂₋₁₂-alkenyl; C₂₋₁₂-alkynyl;        amino; halo; amido; C₁₋₁₂-haloalkyl; C₁₋₁₂-alkoxy; hydroxy;        C₁₋₁₂-haloalkoxy; nitro; C₁₋₁₂-hydroxyalkyl; C₂₋₁₂-alkoxyalkyl;        C₁₋₁₂-hydroxyalkoxy; C₃₋₁₂-alkynylalkoxy; C₁₋₁₂-alkylsulfonyl;        C₆₋₁₂-arylsulfonyl; cyano; C₆₋₁₂-aryl; C₅₋₁₂-heteroaryl;        C₃₋₁₂-heterocyclyl; C₄₋₁₂-heterocyclylalkoxy; C₆₋₁₂-aryloxy;        C₅₋₁₂-heteroaryloxy; C₇₋₁₂-arylalkyloxy;        C₆₋₁₂-heteroarylalkyloxy; optionally substituted phenoxy; or        —(CH₂)_(m)—(Z)_(n)—(CO)—R^(f) or        —(CH₂)_(m)—(Z)_(n)—SO₂—(NR^(g))_(n′)—R^(f), where m, n and n′        are each independently 0 or 1,    -   Z is O or NR^(g),    -   R^(f) is hydrogen, C₁₋₁₂-alkyl, hydroxy, C₁₋₁₂-alkoxy, amino,        C₁₋₁₂-hydroxyalkyl or C₂₋₁₂-alkoxyalkyl, and each R^(g) is        independently hydrogen or C₁₋₁₂-alkyl;    -   R⁷ is selected from: hydrogen; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl;        C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy;        C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; acetyl;        C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;        C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;        C₂₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;        C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆ 2-heteroarylalkyl;        C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; and        C₄₋₁₂-heterocyclylalkyl;    -   R^(d) is selected from: hydrogen; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl;        C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy;        C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; acetyl;        C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;        C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;        C₂₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;        C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl;        C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; and        C₄₋₁₂-heterocyclylalkyl;    -   Q is (CR⁹)_(x), one of A and E is O, S or NR¹⁰ and the other is        (CR⁹)_(x) or N, wherein each x is independently 1 or 2; or    -   Q is N, one of A and E is NR¹⁰ and the other is (CR⁹)_(x);    -   each R⁹ is independently hydrogen, C₁₋₁₂-alkyl, halo or        C₁₋₁₂-alkoxy; and    -   R¹⁰ is hydrogen, C₁₋₁₂-alkyl, C₁₋₁₂-hydroxyalkyl,        C₂₋₁₂-alkoxyalkyl, —(CH₂)_(m)—(Z)_(n)—(CO)—R^(f), or        —(CH₂)_(m)—(Z)_(n)—SO₂—(NR^(g))_(n′)—R^(f).

In many such embodiments R³ and R⁴ together with the atoms to which theyare attached form: a five membered aromatic with one nitrogen, i.e. apyrrole ring; a five membered aromatic with two nitrogens, i.e. apyrazole or imidazole ring; a five membered aromatic with one nitrogenand one oxygen, i.e., an oxazole or isoxazole ring; a five memberedaromatic with one nitrogen and one sulfur, i.e., a thiazole orisothiazole ring; a five membered aromatic with one oxygen, i.e., afuranyl ring; or a five membered aromatic with one sulfur, i.e., athiophenyl ring.

In additional embodiments, R³ and R⁴ together with the atoms to whichthey are attached form a six membered cycloalkyl, heterocyclic, aromaticor heteroaromatic ring, e.g., a heterocycle or heteroaromatic with onenitrogen (e.g., a tetrahydroquinoline or a quinoline) a six memberedheterocycle or heteroaromatic with two nitrogens, e.g., atetrahydrocinnoline/tetrahydroquinazoline/tetrahydroquinoxaline or acinnoline/quinazoline/quinoxaline ring; a six membered heterocycle withone nitrogen and one oxygen, i.e., a benzoxazine ring; a six memberedheterocycle or with one nitrogen and one sulfur, i.e., a benzothiazinering; a six membered heterocycle with one oxygen, i.e., a chromane ring;or a six membered heterocycle with one sulfur, i.e., a thiochromanering.

In certain embodiments of Formula 4, A is NR¹⁰, Q and E are CR⁹, andx=1; in certain embodiments of Formula 4, A is NR¹⁰, Q and E are CR⁹,and x=2.

In certain embodiments of Formula 4, E is NR¹⁰, A and Q are CR⁹, andx=1; in certain embodiments of Formula 4, E is NR¹⁰, A and Q are CR⁹,and x=2.

In certain embodiments of Formula 4, Q is NR¹⁰, A and E are CR, and x=1;in certain embodiments of Formula 4, Q is NR¹⁰, A and E are CR, and x=2.

In certain embodiments of Formula 4, A is O, E is N, Q is CR⁹, and x=1;in certain embodiments of Formula 4, A is O, E is N, Q is CR⁹, and x=2.

In certain embodiments of Formula 4, A is N, E is O, Q is CR⁹, and x=1;in certain embodiments of Formula 4, A is N, E is O, Q is CR⁹, and x=2.

In certain embodiments of Formula 4, A is S, E is N, Q is CR⁹, and x=1;in certain embodiments of Formula 4, A is S, E is N, Q is CR⁹, and x=2.

In certain embodiments of Formula 4, A is N, E is S, Q is CR⁹, and x=1;in certain embodiments of Formula 4, A is N, E is S, Q is CR⁹, and x=2.

In certain embodiments of Formula 4, E is S, A and Q are CR⁹, and x=1;in certain embodiments of Formula 4, E is S, A and Q are CR⁹, and x=2.

In certain embodiments of Formula 4, E is O, A and Q are CR⁹, and x=1;in certain embodiments of Formula 4, E is O, A and Q are CR⁹, and x=2.

In certain embodiments of Formula 4, A is S, E and Q are CR⁹, and x=1;in certain embodiments of Formula 4, A is S, E and Q are CR⁹, and x=2.

In certain embodiments of Formula 4, A is O, E and Q are CR^(9′) andx=1; in certain embodiments of Formula 4, A is O, E and Q are CR⁹, andx=2.

In certain embodiments of Formula 4, A is NR¹⁰, Q is N, E is CR⁹, andx=1; in certain embodiments of Formula 4, A is NR¹⁰, Q is N, E is CR⁹,and x=2.

In certain embodiments of Formula 4, E is NR¹⁰, Q is N, A is CR⁹, andx=1; in certain embodiments of Formula 4, E is NR¹⁰, Q is N, A is CR⁹,and x=2.

In certain embodiments of Formula 4, R² is hydrogen.

In certain embodiments of Formula 4, R¹ is C₁₋₁₂-alkyl, C₂₋₁₂-alkenyl orC₃₋₁₂-cycloalkyl. In further embodiments, R¹ is ethyl, cyclopropyl,isopropenyl or isopropyl. In particular embodiments, R¹ is isopropyl. Inparticular embodiments, R¹ is ethyl. In particular embodiments, R¹ iscyclopropyl.

In certain embodiments of Formula 4, R⁷ is selected from: C₁₋₁₂-alkyl,C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; C₂₋₁₂-alkylsulfonylalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl; C₆₋₁₂-arylsulfonyl;C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl; C₅₋₁₂-heteroarylsulfonyl;C₃₋₁₂-heterocyclyl; and C₄₋₁₂-heterocyclylalkyl.

In certain embodiments of Formula 4, R⁷ is selected from: C₁₋₁₂-alkyl,C₁₋₁₂-hydroxyalkyl and C₁₋₁₂-haloalkyl.

In certain embodiments of Formula 4, R^(d) is selected from:C₁₋₁₂-alkyl, C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; C₂₋₁₂-alkylsulfonylalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl; C₆₋₁₂-arylsulfonyl;C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl; C₅₋₁₂-heteroarylsulfonyl;C₃₋₁₂-heterocyclyl; and C₄₋₁₂-heterocyclylalkyl.

In certain embodiments of Formula 4, R^(d) is selected from:C₁₋₁₂-alkyl, C₁₋₁₂-hydroxyalkyl and C₁₋₁₂-haloalkyl.

In certain embodiments of Formula 4, R⁷ and R^(d) are hydrogen.

In some embodiments of the present disclosure, the compounds are ofFormula 5:

wherein:

-   -   R¹ is: C₁₋₁₂-alkyl; C₂₋₁₂-alkenyl; C₃₋₁₂-cycloalkyl; or        C₃₋₁₂-cycloalkenyl; or halo;    -   R⁴ is: hydrogen; C₁₋₁₂-alkyl; C₂₋₁₂-alkenyl; C₂₋₁₂-alkynyl;        amino; halo; amido; C₁₋₁₂-haloalkyl; C₁₋₁₂-alkoxy; hydroxy;        C₁₋₁₂-haloalkoxy; nitro; C₁₋₁₂-hydroxyalkyl; C₂₋₁₂-alkoxyalkyl;        C₁₋₁₂-hydroxyalkoxy; C₃₋₁₂-alkynylalkoxy; C₁₋₁₂-alkylsulfonyl;        C₆₋₁₂-arylsulfonyl; cyano; C₆₋₁₂-aryl; C₅₋₁₂-heteroaryl;        C₃₋₁₂-heterocyclyl; C₄₋₁₂-heterocyclylalkoxy; C₁₋₁₂-aryloxy;        C₅₋₁₂-heteroaryloxy; C₇₋₁₂-arylalkyloxy;        C₆₋₁₂-heteroarylalkyloxy; optionally substituted phenoxy; or        —(CH₂)_(m)—(Z)_(n)—(CO)—R^(f) or        —(CH₂)_(m)—(Z)_(n)—SO₂—(NR^(g))_(n′)—R^(f), where m, n and n′        are each independently 0 or 1,    -   Z is O or NR^(g), R^(f) is hydrogen, C₁₋₁₂-alkyl, hydroxy,        C₁₋₁₂-alkoxy, amino, C₁₋₁₂-hydroxyalkyl or C₂₋₁₂-alkoxyalkyl,        and each R⁹ is independently hydrogen or alkyl;    -   R⁷ is selected from hydrogen; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl;        C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy;        C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; acetyl;        C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;        C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;        C₂₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;        C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl;        C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; and        C₄₋₁₂-heterocyclylalkyl;    -   R^(d) is selected from: hydrogen; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl;        C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy;        C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; acetyl;        C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;        C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;        C₂₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;        C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl;        C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; and        C₄₋₁₂-heterocyclylalkyl;    -   Q is (CR⁹)_(x), one of A and E is O, S or NR¹⁰ and the other is        (CR⁹)_(x) or N, wherein each x is independently 1 or 2; or    -   Q is N, one of A and E is NR¹⁰ and the other is (CR⁹)_(x);    -   each R⁹ is independently hydrogen, C₁₋₁₂-alkyl, halo or        C₁₋₁₂-alkoxy; and    -   R¹⁰ is hydrogen, C₁₋₁₂-alkyl, C₁₋₁₂-hydroxyalkyl,        C₂₋₁₂-alkoxyalkyl, —(CH₂)_(m)—(Z)_(n)—(CO)—R^(f), or        —(CH₂)_(m)—(Z)_(n)—SO₂—(NR^(g))_(n′)—R^(f).

In certain embodiments of Formula 5, A is NR¹⁰, Q and E are CR⁹ and x=1;in certain embodiments of Formula 5, A is NR¹⁰, Q and E are CR⁹ and x=2.

In certain embodiments of Formula 5, E is NR¹⁰, A and Q are CR⁹, andx=1; in certain embodiments of Formula 5, E is NR¹⁰, A and Q are CR⁹,and x=2.

In certain embodiments of Formula 5, Q is NR¹⁰, A and E are CR⁹, andx=1; in certain embodiments of Formula 5, Q is NR¹⁰, A and E are CR⁹,and x=2.

In certain embodiments of Formula 5, A is O, E is N, Q is CR⁹, and x=1;in certain embodiments of Formula 5, A is O, E is N, Q is CR⁹, and x=2.

In certain embodiments of Formula 5, A is N, E is O, Q is CR⁹, and x=1;in certain embodiments of Formula 5, A is N, E is O, Q is CR⁹, and x=2.

In certain embodiments of Formula 5, A is S, E is N, Q is CR⁹, and x=1;in certain embodiments of Formula 5, A is N, E is O, Q is CR⁹, and x=2.

In certain embodiments of Formula 5, A is N, E is S, Q is CR⁹, and x=1;in certain embodiments of Formula 5, A is N, E is S, Q is CR⁹, and x=2.

In certain embodiments of Formula 5, E is S, A and Q are CR⁹, and x=1;in certain embodiments of Formula 5, E is S, A and Q are CR⁹, and x=2.

In certain embodiments of Formula 5, E is O, A and Q are CR⁹ and x=1; incertain embodiments of Formula 5, E is O, A and Q are CR⁹, and x=2.

In certain embodiments of Formula 5, A is S, E and Q are CR⁹, and x=1;in certain embodiments of Formula 5, A is S, E and Q are CR⁹, and x=2.

In certain embodiments of Formula 5, A is O, E and Q are CR⁹, and x=1;in certain embodiments of Formula 5, A is O, E and Q are CR⁹, and x=2.

In certain embodiments of Formula 5, A is NR¹⁰, Q is N, E is CR⁹, andx=1; in certain embodiments of Formula 5, A is NR¹⁰, Q is N, E is CR⁹,and x=2.

In certain embodiments of Formula 5, E is NR¹⁰, Q is N, A is CR⁹, andx=1; in certain embodiments of Formula 5, E is NR¹⁰, Q is N, A is CR⁹,and x=2.

In certain embodiments of Formula 5, R¹ is C₁₋₁₂-alkyl, C₂₋₁₂-alkenyl orC₃₋₁₂-cycloalkyl. Preferably, R¹ is ethyl, cyclopropyl, isopropenyl orisopropyl. In certain embodiments, R¹ is isopropyl. In particularembodiments, R¹ is ethyl. In particular embodiments, R¹ is cyclopropyl.

In certain embodiments of Formula 5, R⁷ is selected from: C₁₋₁₂-alkyl,C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; C₂₋₁₂-alkylsulfonylalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl; C₆₋₁₂-arylsulfonyl;C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl; C₅₋₁₂-heteroarylsulfonyl;C₃₋₁₂-heterocyclyl; and C₄₋₁₂-heterocyclylalkyl.

In certain embodiments of Formula 5, R⁷ is selected from C₁₋₁₂-alkyl,C₁₋₁₂-hydroxyalkyl and C₁₋₁₂-haloalkyl.

In certain embodiments of Formula 5, R^(d) is selected from:C₁₋₁₂-alkyl, C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; C₂₋₁₂-alkylsulfonylalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl; C₆₋₁₂-arylsulfonyl;C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl; C₅₋₁₂-heteroarylsulfonyl;C₃₋₁₂-heterocyclyl; and C₄₋₁₂-heterocyclylalkyl.

In certain embodiments of Formula 5, R^(d) is selected from C₁₋₁₂-alkyl,C₁₋₁₂-hydroxyalkyl and C₁₋₁₂-haloalkyl.

In certain embodiments of Formula 5, R⁷ and R^(d) are hydrogen.

In certain embodiments of Formula 1, R⁴ is C₁₋₁₂-alkyl, C₂₋₁₂-alkynyl,cyano, C₀₋₁₂-sulfonamido, —COOH, halo, C₁₋₁₂-alkoxy, C₁₋₁₂-alkylsulfonylor C₅₋₁₂-heteroaryl. In further embodiments, R⁴ is methoxy, iodo,methanesulfonyl or C₅₋₁₂-heteroaryl. In particular embodiments, R⁴ ismethoxy, methyl, cyano, bromo, chloro, iodo, —C≡C—CH₃, —C≡CH, —COOH,—S(O)₂CH₃, —S(O)₂NH₂ or tetrazolyl. In specific embodiments R⁴ ismethoxy, while in other embodiments R⁴ is iodo.

In certain embodiments of Formula 5, R⁴ is C₅₋₁₂-heteroaryl. TheC₅₋₁₂-heteroaryl may be, in certain embodiments, tetrazolyl, pyrazolyl,oxazolyl, imidazolyl, thiazolyl, thiophenyl, triazolyl, furanyl,isoxazolyl, oxadiazolyl, benzothiophenyl, pyridinyl, or pyrrolyl.

More specifically, the heteroaryl may be tetrazol-5-yl, pyrazol-1-yl,3-methylpyrazol-1-yl, oxazol-2-yl, oxazol-5-yl, imidazol-2-yl,thiazol-2-yl, thiazol-4-yl, thiophen-3-yl, 5-chloro-thio-phen-2-yl,l-methyl-imidazol-2-yl, imidazol-1-yl, pyrazol-3-yl,2-methyl-thiazol-4-yl, furan-2-yl, 3,5-dimethyl-pyrazol-1-yl,4,5-dihydrooxazol-2-yl, isoxazol-5-yl, [1,2,4]-oxa-diazol-3-yl, benzo[b] thiophen-3-yl, oxazol-4-yl, furan-3-yl, 4-methyl-thiophen-2-yl,thiazol-5-yl, tetrazol-1-yl, [1, 2,4] triazol-1-yl,2-methyl-thiazol-5-yl, 1-methyl-pyrazol-4-yl, 2-thiolyl-imidazol-1-yl,pyridin-2-yl, or 2,5-dimethyl-pyrrol-1-yl).

In embodiments of the present disclosure, where any of R⁷ or R^(d) areC₃₋₁₂-heterocyclyl or a group that includes a heterocyclyl moiety, suchheterocyclyl or heterocyclyl moiety is piperidinyl, piperazinyl,tetrahydrofuranyl, tetrahydrothiopyranyl, or1,1-dioxotetrahydrothio-pyranyl. More preferably, such heterocyclyl orheterocyclyl moiety is piperidin-4-yl, 1-methyl-piperidine-4-yl,1-methanesulfonyl-piperidin-4-yl, tetrahydropyran-4-yl,tetra-hydrothiopyran-4-yl, or 1,1-dioxotrahydrothiopyran-4-yl.

Where any of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁹, R¹⁰, R^(c), R^(d), R^(f),R^(g) or R^(h) is C₁₋₁₂-alkyl or contains an alkyl moiety, such alkyl ispreferably lower alkyl, i.e. C₁₋₆-alkyl, and more preferably C₁₋₄-alkyl.

In one embodiment of Formula 1, the compound is selected from the groupconsisting of Compounds 1-47 as exemplified in Examples 1-49.

The present disclosure also provides methods for treating a disease orcondition by using a P2X3 receptor antagonist, a P2X2/3 receptorantagonist, or both, the method comprising administering to a subject inneed thereof an effective amount of a compound of any of Formulae 1 to5. The disease may be genitourinary disease or urinary tract disease. Inother instances the disease may be a disease is associated with pain.The urinary tract disease may be: reduced bladder capacity; frequentmicturition; urge incontinence; stress incontinence; bladderhyperreactivity; benign prostatic hypertrophy; prostatitis; detrusorhyperreflexia; urinary frequency; nocturia; urinary urgency; overactivebladder; pelvic hypersensitivity; urethritis; prostatitits; pelvic painsyndrome; prostatodynia; cystitis; or idiophatic bladderhypersensitivity.

The disease associated with pain may be: inflammatory pain; surgicalpain; visceral pain; dental pain; premenstrual pain; central pain; paindue to burns; migraine or cluster headaches; nerve injury; neuritis;neuralgias; neuropathy; poisoning; ischemic injury; interstitialcystitis; cancer pain; viral, parasitic or bacterial infection;post-traumatic injury; pain associated with irritable bowel syndrome andinflammatory bowel disease.

In certain aspects, the present disclosure also provides methods fortreating cough or urge to cough associated with a respiratory disease,hypertension, heart failure, dyspnea, sleep apnea, fatigue, exerciseintolerance, by altering carotid body tonicity or activity in a subject,and the like. In additional instances the disorders or disease statesmay include hepatocellular carcinoma, tinnitus, migraine, itch,diabetes, endometriosis and dysmenorrhea, peripheral artery occlusivedisease (PAOD), chronic obstructive pulmonary disease (COPD), atopicdermatitis and other forms of eczema or dermatitis, bursitis,tendonitis, fibromyalgia, gout, joint replacement, lichen sclerosus,psoriasis and psoriatic arthritis, cold sores, kidney stones, gallstones, smell disorders, taste disorders including dysgeusia or burningmouth syndrome, gastro esophageal reflux disease (GERD), binge-eatingdisorders and obesity, or pain from sickle cell anemia and ischemia.

In some embodiments of the method for treating a disease mediated by aP2X3 receptor antagonist, a P2X2/3 receptor antagonist, or both,comprises administering to a subject in need thereof an effective amountof a compound of any one of Formulae 1 to 5 which shows selectivity forP2X3 vs P2X2/3. For example when the disease to be treated is medicatedby at least the P2X3 receptor, the compound may show greater selectivityfor P2X3 than P2X2/3.

In this way the present disclosure may provide a treatment which hasreduced side effects, for example reduced taste effects.

EXPERIMENTAL

The following examples are intended to be illustrative only and notlimiting in any way. Abbreviations used are those conventional in theart or the following.

ACN acetonitrile

° C. degree Celsius

DCM dichloromethane

DMF N,N-dimethylformamide

DMSO dimethylsulfoxide

EtOAc ethyl acetate

EtOH ethanol

g gram

h hour(s)

HPLC high pressure liquid chromatography

kg kilogram

L liter

LC liquid chromatography

LCMS liquid chromatography and mass spectrometry

MeOH methanol

MS mass spectrometry

MTBE methyl tert-butyl ether

min minutes

mL milliliter(s)

m/z mass to charge ratio

nm nanometer

nM nanomolar

N normal

RT or rt room temperature

sat. saturated

TFA trifluoroacetic acid

THF tetrahydrofuran

General Synthetic Schemes

Compounds of the present disclosure can be made by a variety of methodsdepicted in the illustrative synthetic reaction schemes shown anddescribed herein.

The starting materials and reagents used in preparing these compoundsgenerally are either available from commercial suppliers, such asAldrich Chemical Co., or are prepared by methods known to those skilledin the art following procedures set forth in references such as Fieserand Fieser's Reagents for Organic Synthesis; Wiley & Sons: New York,1991, Volumes 1-15; Rodd's Chemistry of Carbon Compounds, ElsevierScience Publishers, 1989, Volumes 1-5 and Supplementals; and OrganicReactions, Wiley & Sons: New York, 1991, Volumes 1-40. The followingsynthetic reaction schemes are merely illustrative of some methods bywhich the compounds of the present disclosure can be synthesized, andvarious modifications to these synthetic reaction schemes can be madeand will be suggested to one skilled in the art having referred to thedisclosure contained in this Application.

The starting materials and the intermediates of the synthetic reactionschemes can be isolated and purified if desired using conventionaltechniques, including but not limited to, filtration, distillation,crystallization, chromatography, and the like. Such materials can becharacterized using conventional means, including physical constants andspectral data.

Unless specified to the contrary, the reactions described hereinpreferably are conducted under an inert atmosphere at atmosphericpressure at a reaction temperature range of from about −78° C. to about150° C., more preferably from about 0° C. to about 125° C., and mostpreferably and conveniently at about room (or ambient) temperature (RT),e.g., about 20° C.

Scheme A illustrates one synthetic procedure usable to prepare specificcompounds of Formula (1):

Generally speaking, Scheme A contemplates: (a) reaction of an optionallysubstituted aniline with ROCS₂K; (b) reaction of the resulting thioesterwith a bromo-pyrimidine oxide; and (c) aminating the resultingpolycyclic compound.

Scheme B illustrates another synthetic procedure usable to preparespecific compounds of Formula (1):

Generally speaking, Scheme B contemplates: (a) reaction of an optionallysubstituted thiophenol with BrCH₂CN and Cs₂CO₃; (b) amine addition tothe resulting thioether; (c) enamine formation from the resulting amine;and (d) cyclization of the resulting compound to produce a compound ofFormula 1.

In Scheme B further additional steps may be used to manipulate thesubstitution on the phenyl ring. For example, when R⁴ is methyl oralkynyl, these compounds may be provided via the corresponding compoundwherein R⁴ is iodo e.g. by cross-coupling chemistry to exchange the iodogroup for a methyl or alkynyl group.

Scheme C illustrates yet another synthetic procedure usable to preparespecific compounds of Formula (1):

Generally speaking, Scheme C contemplates: (a) halogenation of anoptionally substituted pyridine; (b) boronating the resultinghalogenated pyridine; (c) converting the boronate to an hydroxypyridine; (d) reaction of the hydroxy pyridine with BrCH₂CN and Cs₂CO₃;(e) amine addition to the resulting nitrile ether; (f) enamine formationfrom the resulting amine; and (g) cyclization of the resulting compoundto produce a compound of Formula 1.

Scheme D illustrates still another synthetic procedure usable to preparespecific compounds of Formula (1):

Generally speaking, Scheme D contemplates: (a) halogenation of adimethoxypyridine; (b) introduction of R¹ into the halogenateddimethoxypyridine; (c) converting the resulting compound into an hydroxypyridine; (d) reaction of the hydroxy pyridine with BrCH₂CN and Cs₂CO₃;(e) amine addition to the resulting cyano ether; (f) enamine formationfrom the resulting amine; and (g) cyclization of the resulting compoundto produce a compound of Formula 1.

Scheme D is especially applicable to compounds wherein R⁴═OCH₃. Thefirst two steps are a variation on the general scheme set forth above.

The compounds of the present disclosure are usable for the treatment ofa wide range of genitourinary diseases, conditions and disorders,including urinary tract disease states associated with bladder outletobstruction and urinary incontinence conditions such as reduced bladdercapacity, frequency of micturition, urge incontinence, stressincontinence, bladder hyperreactivity, benign prostatic hypertrophy(BPH), prostatitis, detrusor hyperreflexia, urinary frequency, nocturia,urinary urgency, overactive bladder, pelvic hypersensitivity,urethritis, prostatitits, pelvic pain syndrome, prostatodynia, cystitis,and idiophatic bladder hypersensitivity, and other symptoms related tooveractive bladder.

The compounds of the present disclosure are also useful for thetreatment of cough or urge to cough associated with a respiratorydisease, hypertension, heart failure, dyspnea, sleep apnea, alteringcarotid body tonicity or activity in a subject.

The compounds of the present disclosure are also expected to findutility as analgesics in the treatment of diseases and conditionsassociated with pain from a wide variety of causes, including, but notlimited to, inflammatory pain, surgical pain, visceral pain, dentalpain, premenstrual pain, central pain, pain due to burns, migraine orcluster headaches, nerve injury, neuritis, neuralgias, poisoning,ischemic injury, interstitial cystitis, cancer pain, viral, parasitic orbacterial infection, post-traumatic injuries (including fractures andsports injuries), and pain associated with functional bowel disorderssuch as irritable bowel syndrome.

The present disclosure includes pharmaceutical compositions comprisingat least one compound of the present disclosure, or an individualisomer, racemic or non-racemic mixture of isomers or a pharmaceuticallyacceptable salt or solvate thereof, together with at least onepharmaceutically acceptable carrier, and optionally other therapeuticand/or prophylactic ingredients.

In general, the compounds of the present disclosure will be administeredin a therapeutically effective amount by any of the accepted modes ofadministration for agents that serve similar utilities. Suitable dosageranges are typically 1-500 mg daily, preferably 1-100 mg daily, and mostpreferably 1-30 mg daily, depending upon numerous factors such as theseverity of the disease to be treated, the age and relative health ofthe subject, the potency of the compound used, the route and form ofadministration, the indication towards which the administration isdirected, and the preferences and experience of the medical practitionerinvolved. One of ordinary skill in the art of treating such diseaseswill be able, without undue experimentation and in reliance uponpersonal knowledge and the disclosure of this Application, to ascertaina therapeutically effective amount of the compounds of the presentdisclosure for a given disease.

Compounds of the present disclosure may be administered aspharmaceutical formulations including those suitable for oral (includingbuccal and sub-lingual), rectal, nasal, topical, pulmonary, vaginal, orparenteral (including intramuscular, intraarterial, intrathecal,subcutaneous and intravenous) administration or in a form suitable foradministration by in-halation or insufflation. The preferred manner ofadministration is generally oral using a convenient daily dosage regimenwhich can be adjusted according to the degree of affliction.

A compound or compounds of the present disclosure, together with one ormore conventional adjuvants, carriers, or diluents, may be placed intothe form of pharmaceutical compositions and unit dosages. Thepharmaceutical compositions and unit dosage forms may be comprised ofconventional ingredients in conventional proportions, with or withoutadditional active compounds or principles, and the unit dosage forms maycontain any suitable effective amount of the active ingredientcommensurate with the intended daily dosage range to be employed. Thepharmaceutical compositions may be employed as solids, such as tabletsor filled capsules, semisolids, powders, sustained release formulations,or liquids such as solutions, suspensions, emulsions, elixirs, or filledcapsules for oral use; or in the form of suppositories for rectal orvaginal administration; or in the form of sterile injectable solutionsfor parenteral use. Formulations containing about one (1) milligram ofactive ingredient or, more broadly, about 0.01 to about one hundred(100) milligrams, per tablet, are accordingly suitable representativeunit dosage forms.

The compounds of the present disclosure may be formulated in a widevariety of oral administration dosage forms. The pharmaceuticalcompositions and dosage forms may comprise a compound or compounds ofthe present disclosure or pharmaceutically acceptable salts thereof asthe active component. The pharmaceutically acceptable carriers may beeither solid or liquid. Solid form preparations include powders,tablets, pills, capsules, cachets, suppositories, and dispersiblegranules. A solid carrier may be one or more substances which may alsoact as diluents, flavouring agents, solubilizers, lubricants, suspendingagents, binders, preservatives, tablet disintegrating agents, or anencapsulating material. In powders, the carrier generally is a finelydivided solid which is a mixture with the finely divided activecomponent. In tablets, the active component generally is mixed with thecarrier having the necessary binding capacity in suitable proportionsand compacted in the shape and size desired. The powders and tabletspreferably contain from about one (1) to about seventy (70) percent ofthe active compound. Suitable carriers include but are not limited tomagnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin,dextrin, starch, gelatine, tragacanth, methylcellulose, sodiumcarboxymethylcellulose, a low melting wax, cocoa butter, and the like.The term “preparation” is intended to include the formulation of theactive compound with encapsulating material as carrier, providing acapsule in which the active component, with or without carriers, issurrounded by a carrier, which is in association with it. Similarly,cachets and lozenges are included. Tablets, powders, capsules, pills,cachets, and lozenges may be as solid forms suitable for oraladministration.

Other forms suitable for oral administration include liquid formpreparations including emulsions, syrups, elixirs, aqueous solutions,aqueous suspensions, or solid form preparations which are intended to beconverted shortly before use to liquid form preparations. Emulsions maybe prepared in solutions, e.g., in aqueous propylene glycol solutions ormay contain emulsifying agents, e.g., such as lecithin, sorbitanmonooleate, or acacia. Aqueous solutions can be prepared by dissolvingthe active component in water and adding suitable colorants, flavours,stabilizers, and thickening agents. Aqueous suspensions can be preparedby dispersing the finely divided active component in water with viscousmaterial, such as natural or synthetic gums, resins, methylcellulose,sodium carboxymethylcellulose, and other well-known suspending agents.Solid form preparations include solutions, suspensions, and emulsions,and may contain, in addition to the active component, colorants,flavours, stabilizers, buffers, artificial and natural sweeteners,dispersants, thickeners and solubilizing agents.

The compounds of the present disclosure may be formulated for parenteraladministration (e.g., by injection, e.g. bolus injection or continuousinfusion) and may be presented in unit dose form in ampoules, pre-filledsyringes, small volume infusion or in multi-dose containers with anadded preservative. The compositions may take such forms as suspensions,solutions, or emulsions in oily or aqueous vehicles, e.g. solutions inaqueous polyethylene glycol.

Examples of oily or non-aqueous carriers, diluents, solvents or vehiclesinclude propylene glycol, polyethylene glycol, vegetable oils (e.g.,olive oil), and injectable organic esters (e.g., ethyl oleate), and maycontain formulatory agents such as preserving, wetting, emulsifying orsuspending, stabilizing and/or dispersing agents. Alternatively, theactive ingredient may be in powder form, obtained by aseptic isolationof sterile solid or by lyophilization from solution for constitutionbefore use with a suitable vehicle, e.g., sterile, pyrogen-free water.

The compounds of the present disclosure may be formulated for topicaladministration to the epidermis as ointments, creams or lotions, or as atransdermal patch. Ointments and creams may, e.g., be formulated with anaqueous or oily base with the addition of suitable thickening and/orgelling agents. Lotions may be formulated with an aqueous or oily baseand will in general also containing one or more emulsifying agents,stabilizing agents, dispersing agents, suspending agents, thickeningagents, or colouring agents. Formulations suitable for topicaladministration in the mouth include lozenges comprising active agents ina flavoured base, usually sucrose and acacia or tragacanth; pastillescomprising the active ingredient in an inert base such as gelatine andglycerine or sucrose and acacia; and mouth-washes comprising the activeingredient in a suitable liquid carrier.

The compounds of the present disclosure may be formulated foradministration as suppositories. A low melting wax, such as a mixture offatty acid glycerides or cocoa butter is first melted and the activecomponent is dispersed homogeneously, e.g., by stirring. The moltenhomogeneous mixture is then poured into convenient sized molds, allowedto cool, and to solidify.

The compounds of the present disclosure may be formulated for vaginaladministration. Pessaries, tampons, creams, gels, pastes, foams orsprays containing in addition to the active ingredient such carriers asare known in the art to be appropriate.

The subject compounds may be formulated for nasal administration. Thesolutions or sus-pensions are applied directly to the nasal cavity byconventional means, e.g., with a dropper, pipette or spray. Theformulations may be provided in a single or multidose form. In thelatter case of a dropper or pipette, this may be achieved by the patientadministering an appropriate, predetermined volume of the solution orsuspension. In the case of a spray, this may be achieved e.g. by meansof a metering atomizing spray pump.

The compounds of the present disclosure may be formulated for aerosoladministration, particularly to the respiratory tract and includingintranasal administration. The compound will generally have a smallparticle size e.g. of the order of five (5) microns or less. Such aparticle size may be obtained by means known in the art, e.g. bymicronization. The active ingredient is provided in a pressurized packwith a suitable propellant such as a chlorofluoro-carbon (CFC), e.g.,dichlorodifluoromethane, trichlorofluoromethane, ordichlorotetra-fluoroethane, or carbon dioxide or other suitable gas. Theaerosol may conveniently also contain a surfactant such as lecithin. Thedose of drug may be controlled by a metered valve. Alternatively theactive ingredients may be provided in a form of a dry powder, e.g. apowder mix of the compound in a suitable powder base such as lactose,starch, starch derivatives such as hydroxypropylmethyl cellulose andpolyvinylpyrrolidine (PVP). The powder carrier will form a gel in thenasal cavity. The powder composition may be presented in unit dose forme.g. in capsules or cartridges of e.g., gelatine or blister packs fromwhich the powder may be administered by means of an inhaler.

When desired, formulations can be prepared with enteric coatings adaptedfor sustained or controlled release administration of the activeingredient. For example, the compounds of the present disclosure can beformulated in transdermal or subcutaneous drug delivery devices. Thesedelivery systems are advantageous when sustained release of the compoundis necessary and when patient compliance with a treatment regimen iscrucial. Compounds in transdermal delivery systems are frequentlyattached to a skin-adhesive solid support. The compound of interest canalso be combined with a penetration enhancer, e.g., Azone(1-dodecylazacycloheptan-2-one). Sustained release delivery systems areinserted sub-cutaneously into the subdermal layer by surgery orinjection. The subdermal implants encapsulate the compound in a lipidsoluble membrane, e.g., silicone rubber, or a biodegradable polymer,e.g., polylactic acid.

The pharmaceutical preparations are preferably in unit dosage forms. Insuch form, the preparation is subdivided into unit doses containingappropriate quantities of the active component. The unit dosage form canbe a packaged preparation, the package containing discrete quantities ofpreparation, such as packeted tablets, capsules, and powders in vials orampoules. Also, the unit dosage form can be a capsule, tablet, cachet,or lozenge itself, or it can be the appropriate number of any of thesein packaged form.

Other suitable pharmaceutical carriers and their formulations aredescribed in Remington: The Science and Practice of Pharmacy, 1995,edited by Martin, Mack Publishing Company, 19th edition, Easton, Pa.Representative pharmaceutical formulations containing a compound of thepresent disclosure are described herein.

EXAMPLES

Representative compounds disclosed herein are shown in Table 1. Detailedexperimental steps and conditions for making these compounds areprovided below.

TABLE 1 Compound MW Found # Structure [M + H]⁺ 1

321.2 2

369.0 3

370.0 4

417.0 5

315.0 6

329.1 7

305.0 8

368.9 9

325.0 10

316.1 11

359.1 12

335.1 13

306.0 14

276.1 15

401.9 16

354.1 17

301.1 18

344.2 19

300.1 20

355.0 21

403.0 22

355.1 23

292.0 24

369.9 25

370.0 26

317.0 27

371.1 28

330.0 29

316.1 30

304.1 31

392.1 32

309.1 33

310.1 34

360.0 35

343.2 36

353.1 37

352.0 38

325.9 39

308.1 40

342.1 41

322.0 42

338.0 43

353.0 44

305.2 45

320.1 46

345.0 47

376.1

Example 1: Synthesis of Compound 1

Compound 1 was made by the synthetic method outlined in Scheme E:

General Procedure for Preparation of Compound i-22: To a solution ofcompound i-21 (2.0 g, 7.6 mmol, 1.0 eq) and potassiumdifluoro(isopropenyl)borane fluoride (4.5 g, 30 mmol, 4.0 eq) in toluenewas added K₂CO₃ (3.16 g, 22 mmol, 3.0 eq) and Pd(dppf)Cl₂ (558 mg, 763μmol, 0.1 eq) at 25° C. under N₂. The mixture was heated to 100° C. andstirred for 12 h. The reaction mixture was directly concentrated underreduced pressure to give a residue. The residue was further purified bycolumn chromatography eluted with petroleum ether: ethyl acetate to givecompound i-22 (1.6 g, 6.4 mmol, 90% TLC purity) as a solid, which wasused directly in the next step.General Procedure for Preparation of Compound i-23:

A mixture of compound i-22 (1.6 g, 7.1 mmol, 1.0 eq) in MeOH washydrogenated under H₂ (50 psi) with catalyst Pd/C (100 mg) at 25° C. for12 h. The mixture was filtered through celite, washed with methanol (200mL). The filtrate was added concentrated HCl (1.0 mL), and thenconcentrated to give compound i-23 (1.4 g crude) as a solid, which wasused directly in the next step. ¹H NMR: (400 MHz MeOD-d₄) δ 7.00 (s,1H), 6.92 (s, J=4.0 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 3.08-3.02 (m,1H), 1.31 (d, J=6.4 Hz, 6H.

General Procedure for Preparation of Compound i-24:

To a solution of compound i-23 (1.3 g, 6.6 mmol, 1.0 eq) in MeOH (6.5mL) and aq.HCl (1.0 M, 13 mL, 2.0 eq) was added dropwise a solution ofNaNO₂ (716 mg, 10 mmol, 564 μL, 1.5 eq) in H₂O (13 mL) at 0° C., thenthe mixture was stirred for 0.5 h. After this time, the mixture wasadded to solution of ethoxycarbothioylsulfanylpotassium (2.1 g, 13 mmol,2.0 eq) in H₂O (32 mL) at 65° C. Then mixture was stirred for 0.5 h at65° C. The mixture was poured into water (150 mL). EtOAc (150 mL) wasadded and the organic layer was separated. The aqueous layer wasextracted with EtOAc (150 mL). The extractions were combined, dried overanhydrous Na₂SO₄, and filtered. The filtrate was concentrated to givecrude product, which was further purified by silica gel column to givecompound i-24 (800 mg) as an oil.

¹H NMR: (400 MHz CDCl₃) δ 6.95 (s, 1H), 6.86 (s, 1H), 4.61 (q, J=7.2 Hz,2H), 3.94 (s, 3H), 3.86 (s, 3H), 3.41-3.83 (m, 1H), 1.35 (t, J=7.2 Hz,3H), 1.20 (d, J=6.8 Hz, 6H).

General Procedure for Preparation of Compound i-25:

To a solution of compound i-24 (700 mg, 2.3 mmol, 1.0 eq) in EtOH (8.0mL) was added aq.NaOH (3 M, 8.5 mL, 11 eq) at 25° C. Then the mixturewas heated to 65° C. and stirred for 2 h. The mixture was cooled to RTand 1,4-dithioerythritol (CAS: 6892-68-8, 20 mg) was added. The mixturewas adjusted to pH=5 with 10% aq. HCl, then extracted with EtOAc (100mL×2). The organic layer was dried over anhydrous Na₂SO₄, filtered. Thefiltrate was concentrated to give compound i-25 (500 mg, crude) as anoil, which was directly used without further purification.

General Procedure for Preparation of Compound i-26:

To a solution of compound i-25 (400 mg, 1.8 mmol, 1.0 eq) in DMF (5.0mL) was added 2-amino-5-bromo-1H-pyrimidin-6-one (357 mg, 1.8 mmol, 1.0eq) and K₂CO₃ (779 mg, 5.6 mmol, 3.0 eq) at 25° C. Then the mixture washeated to 80° C. in a sealed tube and stirred for 1 h under microwave.The mixture was filtered. The filter cake was washed with DMF (1 mL).The DMF solution was collected and combined and purified by prep-HPLC togive i-26 (220 mg) as a solid. ¹H NMR: (400 MHz DMSO-d₆) δ 11.16 (br.s,1H), 7.66 (s, 1H), 6.84-6.77 (m, 4H), 3.76 (s, 3H), 3.64 (s, 3H),3.53-3.33 (m, 1H), 1.18 (d, J=6.8 Hz, 6H). LCMS: [M+H]321.1.

General Procedure for Preparation of Compound i-27:

To a solution of DMF (143 mg, 1.9 mmol, 151 μL, 4.8 eq) was addeddropwise SOCl₂ (246 mg, 2.0 mmol, 150 μL, 5.1 eq) with cooling bath at0° C. The resulting mixture was added to a solution of i-26 (130 mg, 404μmol, 1.0 eq) in DMF (3.0 mL) at 0° C. The mixture was stirred for 0.5 hat 0° C. The reaction was concentrated to give compound i-27 (160 mg,crude) as an oil, which was directly used without further purification.LCMS: [M+H]395.2.

General Procedure for Preparation of Compound i-28:

To a solution of compound i-27 (160 mg, 405 μmol, 1.0 eq) in THF (4.0mL) was added 2,4-DMBNH₂ (2,4-Dimethoxybenzylamine, 3.4 g, 20 mmol, 50eq) at 25° C. The resulting mixture was stirred for 12 h at 25° C. Themixture was diluted with brine (50 mL), and then extracted with EtOAc(100 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered,and the filtrate was concentrated to give crude product, which wasfurther purified by prep-HPLC to give compound i-28 (120 mg, 85% LCMSpurity) as an oil, which was used directly in the next step. LCMS: [M+H]471.2.

General Procedure for Preparation of Compound 1:

To a solution of compound i-28 (120 mg, 255 μmol, 1.0 eq) in DCM (4.0mL) was added TFA (6.1 g, 54 mmol, 4.0 mL, 211 eq) at 25° C., themixture was stirred for 12 h at 25° C. The mixture was concentrated togive crude product, which was purified by prep-HPLC to give Compound 1(15 mg, 100% LCMS purity) as a solid. ¹H NMR: (400 MHz MeOD-d₄) 7.78 (s,1H), 6.95 (s, 1H), 6.88 (s, 1H), 3.86 (s, 3H), 3.78 (s, 3H), 3.61-3.53(m, 1H), 1.26 (d, J=6.8 Hz, 6H). LCMS: [M+H]⁺ 321.2.

Example 2: Synthesis of Compound 2

Compound 2 was made by the synthetic method outlined in Scheme F:

General Procedure for Preparation of Compound i-29:

To a solution of 2-bromo-4-fluoro-1-nitro-benzene (60.0 g, 273 mmol,1.00 eq) in the mixture of dichloromethane (400 mL) and methanol (440mL) was added 1 M NaOH aqueous solution (1.00 L). Then a catalyticamount of TBAB (tetrabutylammonium bromide, 360 mg, 1.26 mmol) wasadded. The reaction was stirred at 40° C. for 16 h. The reaction mixturewas partitioned between DCM and water. Then the aqueous layer wasextracted with dichloromethane (3×300 mL). The combined organic layerswere dried over Na₂SO₄, filtered and concentrated under reducedpressure. The crude product was purified by column chromatography onsilica gel to give compound i-29 (43.1 g, 186 mmol) as a solid. ¹H NMR:(400 MHz, Chloroform-d) 8.00 (d, J=9.3 Hz, 1H), 7.23 (d, J=2.6 Hz, 1H),6.93 (dd, J=2.6, 9.3 Hz, 1H), 3.90 (s, 3H).

General Procedure for Preparation of Compound i-30:

Two parallel reactions were set up as follows and subsequently combinedfor extraction and purification.

To a solution of i-29 (40.0 g, 172 mmol, 1.00 eq) and potassiumdifluoro(isopropenyl)borane fluoride (51.0 g, 344 mmol, 2.00 eq) intoluene (200 mL) was added Pd(dppf)Cl₂ (12.6 g, 17.2 mmol, 0.10 eq) andK₂CO₃ (71.5 g, 517 mmol, 3.00 eq). The reaction mixture was stirred at100° C. for 12 h under N₂ atmosphere.

The two reaction mixtures were combined and were partitioned betweenethyl acetate (200 mL) and water (200 mL). The aqueous layer wasextracted with ethyl acetate (3×200 mL). Then the combined organiclayers were dried over Na₂SO₄, filtered and concentrated under reducedpressure. The residue was purified by column chromatography on silicagel to give compound i-30 (45.0 g, 233 mmol) as an oil. ¹H NMR: (400MHz, Chloroform-d) 8.01 (d, J=8.8 Hz, 1H), 6.86 (dd, J=2.9, 9.0 Hz, 1H),6.76 (d, J=2.6 Hz, 1H), 5.17-5.14 (m, 1H), 4.93 (s, 1H), 3.90 (s, 3H),2.08 (s, 3H).

General Procedure for Preparation of Compound i-31:

To a solution of i-30 (45.0 g, 233 mmol, 1.00 eq) in methanol (800 mL)was added Pd/C (4.18 g, 1.97 mmol, 5% w.t.). The mixture was stirred at25° C. under H₂ (50 psi) for 12 h. The reaction mixture was filteredthrough celite and washed with methanol (300 mL). To the filtrate wasadded 12M HCl (40.0 mL). Then the mixture was concentrated to givecompound i-31 (53.7 g, crude, HCl) as a solid which was used for thenext step directly.

¹H NMR: (400 MHz, DMSO-d₆) 10.16 (br. s., 3H), 7.38-7.32 (m, 1H), 6.91(d, J=2.6 Hz, 1H), 6.86-6.80 (m, 1H), 3.73 (s, 3H), 3.08 (td, J=6.7,13.6 Hz, 1H), 1.16 (d, J=7.1 Hz, 6H).

General Procedure for Preparation of Compound i-32:

Two parallel reactions were set up as follows and subsequently combinedfor extraction and purification.

To a solution of i-31 (19.4 g, 95.9 mmol, 1.00 eq) in methanol (70.0 mL)and HCl (1M, 193 mL, 56.4 eq) was added dropwise a solution of NaNO₂(7.94 g, 115 mmol, 6.25 mL, 1.20 eq) in H₂O (80.0 mL) at 0° C. Themixture was stirred at 0° C. for 0.5 h. Then the mixture was addeddropwise to a solution of EtOCS₂K (30.7 g, 192 mmol, 2.00 eq) in H₂O(500 mL) at 25° C. The mixture was stirred at 25° C. for 0.5 h. The tworeaction mixtures were combined and partitioned between ethyl acetate(500 mL) and water (500 mL). The aqueous layer was extracted with ethylacetate (3×300 mL). The combined organic layers were dried over Na₂SO₄,filtered and concentrated under reduced pressure. The residue waspurified by column chromatography on silica gel to give compound i-32(22.0 g, 81.4 mmol) as an oil which was used for the next step directly.¹H NMR: (400 MHz, Chloroform-d) 7.43-7.38 (m, 1H), 6.93 (d, J=2.6 Hz,1H), 6.78 (dd, J=2.6, 8.4 Hz, 1H), 4.61 (q, J=7.1 Hz, 2H), 3.86 (s, 3H),3.38 (td, J=6.8, 13.7 Hz, 1H), 1.34 (t, J=7.1 Hz, 3H), 1.21 (d, J=7.1Hz, 6H).

General Procedure for Preparation of Compound i-33:

To a solution of i-32 (22.0 g, 81.4 mmol, 1.00 eq) in EtOH (200.00 mL)was added NaOH (3M, 298 mL, 11.0 eq). Then the mixture was stirred at65° C. for 2 h. 1,4-dithioerythritol (200 mg) was added. The mixture wasadjusted to pH=5 with 3M HCl (290 mL). Then the mixture was partitionedbetween ethyl acetate (300 mL) and water (300 mL). The aqueous layer wasextracted with ethyl acetate (3×300 mL). The combined organic layerswere dried over Na₂SO₄, filtered and concentrated under reduced pressureto give compound i-33 (13.3 g, crude) as an oil which was used for thenext step directly. ¹H NMR: (400 MHz, DMSO-d₆) 7.27 (d, J=8.4 Hz, 1H),6.78 (d, J=2.2 Hz, 1H), 6.70-6.65 (m, 1H), 4.80 (s, 1H), 3.69 (s, 3H),3.11 (td, J=6.9, 13.5 Hz, 1H), 1.15 (d, J=6.6 Hz, 6H).

General Procedure for Preparation of Compound i-34:

To a solution of i-33 (13.3 g, 72.9 mmol, 1.00 eq) in CH₃CN (100 mL) wasadded BrCH₂CN (13.1 g, 109 mmol, 1.50 eq) and Cs₂CO₃ (35.6 g, 109 mmol,1.50 eq). The mixture was stirred at 80° C. for 12 h. The reactionmixture was partitioned between ethyl acetate (100 mL) and water (100mL). The aqueous layer was extracted with ethyl acetate (3×80 mL).

The combined organic layers were dried over Na₂SO₄, filtered andconcentrated under reduced pressure. The residue was purified by columnchromatography on silica gel to give compound i-34 (10.6 g, 47.9 mmol)as an oil. ¹H NMR: (400 MHz, DMSO-d₆) 7.54 (d, J=8.8 Hz, 1H), 6.91 (d,J=3.1 Hz, 1H), 6.86 (dd, J=2.9, 8.6 Hz, 1H), 3.96 (s, 2H), 3.78 (s, 3H),3.50 (td, J=7.0, 13.8 Hz, 1H), 1.19 (d, J=6.6 Hz, 6H).

General Procedure for Preparation of Compound i-35:

To a solution of i-34 (10.6 g, 47.9 mmol, 1.00 eq) in DMF (80.0 mL) wasadded 1-tert-butoxy-N,N,N′,N′-tetramethyl-methanediamine (16.7 g, 95.8mmol, 2.00 eq). Then the mixture was stirred at 110° C. for 1 h. Thereaction mixture was used directly in the next step.

General Procedure for Preparation of Compound i-36:

To a solution of i-35 (15.4 g, 47.9 mmol, 1.00 eq) in DMF (150 mL) wasadded aniline hydrochloride (31.0 g, 240 mmol, 30.4 mL, 5.00 eq). Themixture was stirred at 120° C. for 12 h. The reaction mixture waspartitioned between toluene (100 mL) and water (100 mL). Then theaqueous layer was extracted with toluene (3×80 mL). The combined organiclayers were dried over Na₂SO₄, filtered and concentrated under reducedpressure to give compound i-36 (32.3 g, crude) as an oil which was usedin the next step directly. ¹H NMR: (400 MHz, Chloroform-d) 7.34 (dt,J=3.5, 7.1 Hz, 5H), 7.15 (d, J=7.9 Hz, 3H), 6.98 (d, J=7.9 Hz, 2H), 6.71(s, 1H), 3.80 (s, 3H), 3.49 (d, J=6.6 Hz, 1H), 1.29 (d, J=7.1 Hz, 6H).

General Procedure for Preparation of Compound i-37:

To a solution of i-36 (32.3 g, 100 mmol, 1.00 eq) in DMSO (300 mL) wasadded CH₃ONa (16.1 g, 299 mmol, 3.00 eq) and guanidine carbonate (26.9g, 149 mmol, 1.50 eq). The mixture was stirred at 110° C. for 12 h. Thereaction mixture was partitioned between ethyl acetate (200 mL) andwater (200 mL). Then the aqueous layer was extracted with ethyl acetate(3×100 mL). The combined organic layer was dried over Na₂SO₄, filteredand concentrated under reduced pressure. The residue was purified bycolumn chromatography on silica gel and prep-HPLC to give Compound i-37(4.00 g, 13.8 mmol) as a solid which was used for the next stepdirectly. ¹H NMR: (400 MHz, DMSO-d₆) 7.82 (s, 1H), 6.79 (d, J=2.6 Hz,1H), 6.73 (s, 1H), 6.69-6.66 (m, 1H), 6.31 (br. s., 2H), 3.66 (s, 3H),3.40-3.35 (m, 1H), 1.17 (d, J=6.6 Hz, 6H). LCMS: [M+H]⁺ 291.1

General Procedure for Preparation of Compound 2:

To a mixture of i-37 (200 mg, 689 μmol, 1.00 eq) and methylsulfonylmethanesulfonate (480 mg, 2.76 mmol, 4.00 eq) was added CF₃SO₃H (310.mg, 2.07 mmol, 3.00 eq). Then the mixture was stirred at 80° C. for 12h. The mixture was adjusted to pH=8 with sat. NaHCO₃ (10 mL). Themixture was partitioned between ethyl acetate (30 mL) and water (30 mL).Then the aqueous layer was extracted with ethyl acetate (3×30 mL). Thecombined organic layers were dried over Na₂SO₄, filtered andconcentrated under reduced pressure. The residue was purified byprep-HPLC to give Compound 2 (46.0 mg, 125 μmol) as a solid. ¹H NMR:(400 MHz, DMSO-d₆) 7.84 (s, 1H), 7.19 (s, 1H), 7.12 (s, 1H), 6.36 (br.s., 2H), 3.91 (s, 3H), 3.46-3.39 (m, 1H), 3.13 (s, 3H), 1.26 (d, J=6.6Hz, 6H). LCMS: [M+H]+ 369.0.

Example 3: Synthesis of Compound 3

Compound 3 was made by the synthetic method outlined in Scheme G:

Compound i-37 was prepared as outlined above in Example 2.

General Procedure for Preparation of Compound i-38:

A mixture of i-37 (200 mg, 689 μmol, 1.00 eq) and sulfurochloridic acid(802 mg, 6.89 mmol, 458 μL, 10.0 eq) was stirred at 20° C. for 2.5 h.Then SOCl₂ (164 mg, 1.38 mmol, 99.9 μL, 2.00 eq) was added. The mixturewas stirred at 20° C. for 1 h. The mixture was used for the next stepdirectly without work up and purification.

General Procedure for Preparation of Compound 3:

Compound i-38 was added to a cooled solution of NH₃ (10 mol/L, 1.38 mL,20.0 eq) in THF (1.38 mL) slowly at 0° C. The reaction mixture wasstirred at 20° C. for 12 h. The mixture was filtered and washed withCH₃OH (30 mL). The filtrate was concentrated and the residue waspurified by prep-HPLC to give Compound 3 (37.0 mg, 100 μmol) as a solid.¹H NMR: (400 MHz, DMSO-d₆) 7.87 (s, 1H), 7.22 (s, 1H), 7.06 (s, 1H),6.96 (s, 2H), 6.41 (br. s., 2H), 3.89 (s, 3H), 3.45 (td, J=6.7, 13.6 Hz,1H), 2.07 (s, 2H), 1.27 (d, J=7.1 Hz, 6H).

LCMS: [M+H]⁺ 370.0.

Example 4: Synthesis of Compound 4

Compound 4 was made by the synthetic method outlined in Scheme H

Compound i-37 was prepared as outlined above in Example 2.

General Procedure for Preparation of Compound 4:

To a solution of i-37 (1.50 g, 5.17 mmol, 1.00 eq) in HOAc (15.00 mL)was added ICl (1.01 g, 6.20 mmol, 316 μL, 1.20 eq) and H₂O (93.1 mg,5.17 mmol, 1.80 mL, 1.00 eq). The mixture was stirred at 25° C. for 12h. Then ICl (1.01 g, 6.20 mmol, 316 μL, 1.20 eq) was added and themixture was stirred at 40° C. for 12 h. Another portion of ICl (1.01 g,6.20 mmol, 316 μL, 1.20 eq) was added. The mixture was stirred at 40° C.for another 12 h. The mixture was adjusted to pH=7 with sat. NaHCO₃ (40mL). Then the mixture was partitioned between ethyl acetate (50 mL) andwater (50 mL). The aqueous layer was extracted with ethyl acetate (3×30mL). The combined organic layers were dried over Na₂SO₄, filtered andconcentrated. The residue was purified by column chromatography onsilica gel to give Compound 4 (1.00 g, 2.40 mmol). 100 mg of the solidwas further purified by SFC separation to give 25 mg Compound 4 as asolid. ¹H NMR: (400 MHz, DMSO-d₆) 7.89 (s, 1H), 7.13 (s, 1H), 6.88 (s,1H), 6.53 (br. s., 2H), 3.81 (s, 3H), 3.44-3.36 (m, 1H), 1.24 (d, J=6.6Hz, 6H).

LCMS: [M+H]⁺ 417.0.

Example 5: Synthesis of Compound 5

Compound 5 was made by the synthetic method outlined in Scheme I:

Compound 4 was prepared as outlined above in Example 4.

General Procedure for Preparation of Compound i-39:

To a solution of Compound 4 (300 mg, 721 μmol, 1.00 eq) in THF (3.00 mL)was added Pd(PPh₃)₂Cl₂ (202 mg, 288 μmol, 0.400 eq) and CuI (27.4 mg,144 μmol, 0.200 eq) under N₂. Then ethynyl(trimethyl)silane (177 mg,1.80 mmol, 2.50 eq) and diisopropylethylamine (745 mg, 5.77 mmol, 8.00eq) was added. The mixture was heated to 50° C. for 12 h under N₂.

The reaction mixture was poured into aq. NH₄Cl (15% w.t., 3 mL) andextracted with ethyl acetate (4×6 mL). The combined organic layers wereconcentrated under reduced pressure to give an oil. The residue waspurified by prep-TLC to give i-39 (110 mg, 284 μmol) as a solid.

¹H NMR: (400 MHz, Methanol-d₄) 7.92-7.90 (m, 1H), 6.91-6.87 (m, 2H),3.85 (s, 3H), 3.56-3.49 (m, 1H), 1.31-1.26 (m, 6H), 0.19 (s, 9H).

General Procedure for Preparation of Compound 5:

To a mixture of i-39 (95.0 mg, 246 μmol, 1.00 eq) in THF (2.00 mL) wasadded CsF (373 mg, 2.46 mmol, 90.6 μL, 10.0 eq) in one portion. Themixture was stirred at 50° C. for 2 h under N₂. The mixture was pouredinto H₂O (5 mL). The aqueous phase was extracted with ethyl acetate(4×10 mL). The combined organic phase was washed with brine (10 mL),dried over anhydrous Na₂SO₄, filtered and concentrated in vacuum to givea solid. The residue was purified by prep-HPLC to give Compound 5 (15.0mg, 47.7 μmol) as a solid.

¹H NMR: (400 MHz, DMSO-d₆) 7.87 (s, 1H), 6.93 (s, 1H), 6.75 (s, 1H),6.43 (br. s., 2H), 4.13 (s, 1H), 3.81 (s, 3H), 3.41 (td, J=6.8, 13.7 Hz,1H), 1.24 (d, J=6.6 Hz, 6H).

LCMS: [M+H]⁺ 315.0.

Example 6: Synthesis of Compound 6

Compound 6 was made by the synthetic method outlined in Scheme J

Starting material Compound 4 was prepared as outlined above in Example4.

General Procedure for Preparation of Compound 6:

To a mixture of Compound 4 (200 mg, 480 μmol, 1.00 eq) in THF (4.00 mL)was added trimethyl(prop-2-ynyl)silane (135 mg, 1.20 mmol, 179 μL, 2.50eq), Pd(PPh₃)₂Cl₂ (169 mg, 240 μmol, 0.5 eq) and tetrabutyl ammoniumfluoride (1 mol/L, 1.44 mL, 3.00 eq). The mixture was de-gassed and thenheated to 50° C. for 12 h under N₂. The residue was poured into H₂O (5mL). The aqueous phase was extracted with ethyl acetate (3×8 mL). Thecombined organic phase was washed with brine (10 mL), dried overanhydrous Na₂SO₄, filtered and concentrated in vacuum to give a lightyellow solid. The solid was purified by prep-HPLC to give Compound 6(16.0 mg, 48.7 μmol) as a solid. ¹H NMR: (400 MHz, DMSO-d₆) 7.86 (s,1H), 6.88 (s, 1H), 6.66 (s, 1H), 6.42 (br. s., 2H), 3.78 (s, 3H),3.43-3.36 (m, 1H), 1.99 (s, 3H), 1.24 (d, J=7.1 Hz, 6H). LCMS: [M+H]⁺329.1.

Example 7: Synthesis of Compound 7

Compound 7 was made by the synthetic method outlined in Scheme K.

Compound 4 was prepared as outlined above in Example 4.

General Procedure for Preparation of Compound 7:

To a solution of Compound 4 (200 mg, 480 μmol, 1.00 eq) in dioxane (14.0mL)/H₂O (2.00 mL) was added methylboronic acid (152 mg, 2.55 mmol, 5.30eq), K₂CO₃ (265 mg, 1.92 mmol, 4.00 eq) and Pd(PPh₃)₄ (55.5 mg, 48.0μmol, 0.100 eq). The mixture was de-gassed and then heated to 100° C.for 12 h under N₂. The mixture was cooled to RT and then poured intowater (10 mL). The aqueous phase was extracted with ethyl acetate (4×20mL). The combined organic phase was dried over anhydrous Na₂SO₄,filtered and concentrated in vacuum to give crude product Compound 7 aslight yellow solid. The residue was purified by prep-HPLC and furtherpurified by SFC separation to give Compound 7 (26.0 mg, 85.4 μmol) as asolid. ¹H NMR: (400 MHz, DMSO-d₆) 7.85 (s, 1H), 6.81 (s, 1H), 6.68 (s,1H), 6.34 (br. s., 2H), 3.76 (s, 3H), 3.46 (quin, J=6.7 Hz, 1H), 2.00(s, 3H), 1.21 (d, J=6.8 Hz, 6H). LCMS: [M+H]⁺ 305.0.

Example 8: Synthesis of Compound 8

Compound 8 was made by the synthetic method outlined in Scheme L:

Starting material compound i-37 was prepared as outlined above inExample 2.

General Procedure for Preparation of Compound 8:

To a solution of i-37 (200 mg, 689 μmol, 1.00 eq) in aqueous HBr (697mg, 40% w.t., 5.00 eq) was added aqueous H₂O₂ (156 mg, 1.38 mmol, 30%w.t., 2.00 eq). Then the mixture was stirred at 25° C. for 12 h. Anotherportion of aqueous HBr (111 mg, 1.38 mmol, 74.8 μL, 2.00 eq) and aqueousH₂O₂ (46.9 mg, 1.38 mmol, 39.7 μL, 2.00 eq) was added. Then the mixturewas stirred at 25° C. for 12 h. H₂O (5 mL) and sat. NaHSO₄ (5 mL) wereadded and the mixture was partitioned between ethyl acetate (10 mL) andwater (10 mL). Then the aqueous layer was extracted with ethyl acetate(3×10 mL). The combined organic layers were dried over Na₂SO₄, filteredand concentrated under reduced pressure. The residue was purified byprep-HPLC to give Compound 8 (18.0 mg, 48.7 μmol) as a solid. ¹H NMR:(400 MHz, Methanol-d₄) 7.90 (s, 1H), 6.99 (s, 1H), 6.92 (s, 1H), 3.84(s, 3H), 3.51-3.46 (m, 1H), 1.28 (d, J=6.6 Hz, 6H). LCMS: [M+H]⁺ 368.9.

Example 9: Synthesis of Compound 9

Compound 9 was made by the synthetic method outlined in Scheme M:

Compound i-31 was prepared according to the procedure outlined inExample 2.

General Procedure for Preparation of Compound 40:

A solution of i-31 (3.00 g, 14.8 mmol, 1.00 eq) and TosCi (3.69 g, 19.3mmol, 1.30 eq) in pyridine (30 mL) was stirred at 80° C. for 5 h. Thereaction mixture was partitioned between ethyl acetate (30 mL) and water(30 mL) and the aqueous layer was extracted with ethyl acetate (3×30mL). The combined organic layer was washed with 0.5 M HCl (3×50 mL),dried over Na₂SO₄, filtered and concentrated under reduced pressure togive i-40 (4.06 g, 12.7 mmol) as a solid which was used in the next stepdirectly. ¹H NMR: (400 MHz, Chloroform-d) 7.59-7.54 (m, 2H), 7.23 (d,J=7.9 Hz, 2H), 7.10 (d, J=8.4 Hz, 1H), 6.71 (d, J=3.1 Hz, 1H), 6.68-6.63(m, 1H), 6.12 (s, 1H), 3.79 (s, 3H), 2.88-2.77 (m, 1H), 2.40 (s, 3H),0.96 (d, J=6.6 Hz, 6H).

General Procedure for Preparation of Compound i-41:

To a solution of i-40 (3.56 g, 11.15 mmol, 1.00 eq) in CH₃CN (30.0 mL)was added TFA (1.75 g, 15.4 mmol, 1.38 eq) and NCS (1.49 g, 11.1 mmol)at 0° C. Then the mixture was stirred at 80° C. for 1 h. The reactionmixture was partitioned between ethyl acetate (50 mL) and water (50 mL).Then the aqueous layer was extracted with ethyl acetate (3×50 mL). Thecombined organic layer was dried over Na₂SO₄, filtered and concentratedunder reduced pressure to give a crude product. The crude product waspurified by column chromatography on silica gel to give i-41 (3.59 g,10.1 mmol) as a solid which was used in the next step. ¹H NMR: (400 MHz,chloroform-d) 7.58-7.54 (m, 2H), 7.24-7.21 (m, 2H), 7.13 (s, 1H), 6.68(s, 1H), 3.85 (s, 3H), 2.87 (quin, J=6.8 Hz, 1H), 2.39 (s, 3H), 0.95 (d,J=6.6 Hz, 6H).

General Procedure for Preparation of Compound i-42:

To a mixture of i-41 (2.70 g, 7.63 mmol, 1.00 eq) and phenol (1.53 g,16.25 mmol, 1.43 mL, 2.13 eq) was added hydrogen bromide in HOAc (22.5g, 97.4 mmol, 15.1 mL, 35% w.t., 12.8 eq). The mixture was stirred for12 h at 40° C. The reaction mixture was adjusted to pH=9 byprogressively adding aq. NaOH (6 mol/L, 50 mL). Then H₂O (40 mL) wasadded. The mixture was extracted with methyl tert-butyl ether (4×100mL). The combined organic phases were dried over anhydrous Na₂SO₄,filtered and concentrated in vacuum. The residue was purified byprep-HPLC to give i-42 (1.20 g, 6.01 mmol) as an oil.

¹H NMR: (400 MHz, Chloroform-d) 6.75 (s, 1H), 6.72 (s, 1H), 3.84 (s,3H), 3.44 (br. s., 2H), 2.93-2.84 (m, 1H), 1.25 (d, J=7.1 Hz, 6H).

General Procedure for Preparation of Compound i-43:

To a solution of i-42 (600 mg, 3.00 mmol, 1.00 eq) in CH₃OH (25.0 mL)and HCl (1 mol/L, 9.00 mL, 3.00 eq.) was added drop-wise a solution ofNaNO₂ (311 mg, 4.51 mmol, 245 μL, 1.50 eq) in H₂O (6.00 mL) within 0.5 hat 0° C. Then the mixture was added to a solution of potassiumethylxanthate (962 mg, 6.00 mmol, 2.00 eq) in H₂O (14.00 mL) at 65° C.Then the mixture was stirred for 0.5 h at 65° C. Ethyl acetate (20 mL)was added. The organic layer was separated. The aqueous layer wasextracted with ethyl acetate (3×30 mL). The extractions were combined,dried over anhydrous Na₂SO₄ and filtered. The filtrate was concentratedto give i-43 (700 mg, 2.30 mmol) as an oil which was used in the nextstep directly. ¹H NMR: (400 MHz, DMSO-d₆) 7.45 (s, 1H), 6.96 (s, 1H),3.99-3.83 (m, 5H), 3.38-3.36 (m, 1H), 1.35-1.19 (m, 9H).

General Procedure for Preparation of Compound i-44:

To a solution of i-43 (700 mg, 2.30 mmol, 1.00 eq) in EtOH (8.40 mL) wasadded NaOH (3 mol/L, 8.43 mL, 11.0 eq) at 10° C. Then mixture was heatedto 65° C. and stirred for 2 h. The mixture was cooled to RT.1,4-Dithioerythritol (70 mg, 0.45 mmol) was added. The mixture wasadjusted to pH=5 with aq. HCl (1 mol/L, 25 mL). The mixture wasextracted with ethyl acetate (3×60 mL). The extractions were combined,dried over anhydrous Na₂SO₄ and filtered. The filtrate was concentratedto give i-44 (630 mg, crude) as an oil which was used in the next stepdirectly. ¹H NMR: (400 MHz, Chloroform-d) 7.36-7.34 (m, 1H), 6.81 (s,1H), 3.90 (s, 3H), 3.54-3.41 (m, 1H), 1.25 (d, J=7.1 Hz, 6H).

General Procedure for Preparation of Compound i-45:

To a mixture of i-44 (630 mg, 2.91 mmol, 1.00 eq) in acetonitrile (6.30mL) was added Cs₂CO₃ (1.42 g, 4.37 mmol, 1.50 eq) and2-bromoacetonitrile (349 mg, 2.91 mmol, 194 μL, 1.00 eq) in one portion.The mixture was stirred at 80° C. for 12 h. H₂O (50 mL) was added andthe mixture was extracted with ethyl acetate (3×50 mL). The combinedorganic phase was washed with brine (50 mL), dried over anhydrousNa₂SO₄, filtered and concentrated in vacuum to give brownish dark oil.The residue was purified by silica gel chromatography to give i-45 (210mg, 821 μmol) as an oil. ¹H NMR: (400 MHz, Chloroform-d) 7.62 (s, 1H),6.89 (s, 1H), 3.95 (s, 3H), 3.67 (td, J=6.7, 13.9 Hz, 1H), 3.46 (s, 2H),1.27 (d, J=7.1 Hz, 6H).

General Procedure for Preparation of Compound i-46:

To a mixture of i-45 (210 mg, 821 μmol, 1.00 eq) inN,N-dimethylformamide (2.10 mL) was added1-tert-butoxy-N,N,N′,N′-tetramethyl-methanediamine (286 mg, 1.64 mmol,340 μL, 2.00 eq). The mixture was stirred at 110° C. for 1.5 h. Themixture was used in the next step directly without work up andpurification.

General Procedure for Preparation of Compound i-47:

To a mixture of i-46 (255 mg, 820 μmol, 1.00 eq) inN,N-dimethylformamide (2.10 mL) was added aniline (532 mg, 4.10 mmol,521 μL, 5.00 eq, HCl) at 120° C. The mixture was stirred at 120° C. for5 h. H₂O (30 mL) was added and the mixture was extracted with ethylacetate (3×30 mL). The combined organic phase was dried over anhydrousNa₂SO₄, filtered and concentrated in vacuum to give i-47 (650 mg, crude)as an oil which was used in the next step directly. ¹H NMR: (400 MHz,Chloroform-d) 7.55 (d, J=7.9 Hz, 5H), 7.00 (s, 1H), 6.99 (m, 1H), 6.86(s, 1H), 3.95 (br. s., 1H), 3.91 (s, 3H), 3.53-3.45 (m, 1H), 1.28 (d,J=7.1 Hz, 5H).

General Procedure for Preparation of Compound 9:

To a solution of i-47 (785 mg, 2.19 mmol, 1.00 eq) in dimethylsulfoxide(2.30 mL) was added guanidine carbonate (11.6 g, 64.3 mmol, 1.20 eq) andsodium methoxide (473 mg, 2.63 mmol, 2.50 eq). Then the mixture washeated to 110° C. and stirred for 12 h. H₂O (50 mL) was added and themixture was extracted with ethyl acetate (3×70 mL). The combined organicphase was dried over anhydrous Na₂SO₄, filtered and concentrated to givelight yellow solid. The solid was purified by prep-HPLC to give Compound9 (40.0 mg, 123 μmol) as a solid. ¹H NMR: (400 MHz, DMSO-d₆) 7.88 (s,1H), 7.01 (s, 1H), 6.73 (s, 1H), 6.40 (br. s., 2H), 3.84 (s, 3H),3.44-3.37 (m, 1H), 1.25 (d, J=7.1 Hz, 6H). LCMS: [M+H]⁺ 325.0.

Example 10: Synthesis of Compound 10

Compound 10 was made by the synthetic method outlined in Scheme N:

Compound 4 was prepared as outlined above in Example 4.

General Procedure for Preparation of Compound 10:

To a solution of Compound 4 (500 mg, 1.20 mmol, 1.00 eq) in DMF (5.00mL) was added CuCN (215 mg, 2.40 mmol, 2.00 eq). Then the mixture wasstirred at 120° C. for 2 h.

The mixture was cooled to RT, concentrated under reduced pressure anddirectly purified by prep-HPLC and SFC separation to give Compound 10(29.0 mg, 91.9 μmol) as a solid. ¹H NMR: (400 MHz, DMSO-d₆) 7.95 (br.s., 1H), 7.12 (s, 1H), 7.05 (s, 1H), 6.65 (br. s., 2H), 3.92 (s, 3H),3.49-3.43 (m, 1H), 1.26 (d, J=6.6 Hz, 6H). LCMS: [M+H]⁺ 316.1.

Example 11: Synthesis of Compound 11

Compound 11 was made by the synthetic method outlined in Scheme O:

Compound 10 was prepared as outlined above in Example 10.

General Procedure for Preparation of Compound 11: To a solution ofCompound 10 (200 mg, 634 μmol, 1.00 eq) in xylene (2.00 mL) was addedazidotributyltin (3.37 g, 10.1 mmol, 16.0 eq) at 120° C. The mixture wasstirred at 120° C. for 12 h. The mixture was cooled to RT and KF (737mg, 12.7 mmol, 297 μL, 20.00 eq) was added. Then the mixture wasconcentrated under reduced pressure to give a residue which was purifiedby prep-HPLC to give Compound 11 (35.0 mg, 97.6 μmol) as a solid.

¹H NMR: (400 MHz, DMSO-d₆) 7.90 (br. s., 1H), 7.53 (br. s., 1H), 7.11(br. s., 1H), 6.42 (br. s., 2H), 3.95 (br. s., 3H), 3.46 (d, J=6.1 Hz,1H), 1.30 (d, J=5.9 Hz, 6H).

LCMS: [M+H]⁺ 359.1 (M+1)+.

Example 12: Synthesis of Compound 12

Compound 12 was made by the synthetic method outlined in Scheme P:

Compound 10 was prepared as outlined above in Example 10.

General Procedure for Preparation of Compound 12:

To a solution of Compound 10 (100 mg, 317.07 μmol, 1.00 eq) in EtOH (1.0mL) was added NaOH (317 mg, 7.93 mmol, 25.00 eq) in H₂O (1.0 mL). Thenthe mixture was stirred at 80° C. for 12 h. The mixture was adjusted topH=7 with aqueous HCl (1 M) and the mixture was purified by prep-HPLC togive Compound 12 (15.0 mg, 44.8 μmol) as a solid.

¹H NMR: (400 MHz, DMSO-d₆) 7.86 (br. s., 1H), 7.01 (br. s., 1H), 6.92(br. s., 1H), 6.37 (br. s., 2H), 3.76 (br. s., 3H), 3.43 (br. s., 1H),1.24 (d, J=6.6 Hz, 6H). LCMS: [M+H]⁺ 335.1.

Example 13: Synthesis of Comparative Compound 1

Comparative compound 1 was made by the synthetic method shown in SchemeQ:

Compound 1 was prepared as outlined above in Example 1.

General Procedure for Preparation of Comparative Compound 1:

Batch 1:

To a solution of Compound 1 (20.0 mg, 62.4 μmol, 1.00 eq) indichloromethane (1.00 mL) was added a solution of m-CPBA (13.5 mg, 62.4μmol, 80.0% purity, 1.00 eq) in dichloromethane (1.00 mL) at 0° C. Thereaction mixture was stirred at 25° C. for 0.5 h.

Batch 2:

To a solution of Compound 1 (100 mg, 312 μmol, 1.00 eq) indichloromethane (5.00 mL) was added a solution of m-CPBA (67.3 mg, 312μmol, 80.0% purity, 1.00 eq) in dichloromethane (1.00 mL) at 0° C. Thereaction mixture was stirred at 0° C. for 0.5 h.

The above two mixtures from Batch 1 and Batch 2 were combined, washedwith sat. Na₂SO₃ (10 mL) and sat. Na₂CO₃ (2×10 mL). The combined organiclayers were washed with brine (20 mL), dried over anhydrous Na₂SO₄,filtered and concentrated in vacuum. The residue was purified byprep-TLC to give Comparative compound 1 (60.0 mg, 178 μmol) as a solid.¹H NMR: (400 MHz, Methanol-d₄) 7.81 (s, 1H), 7.52 (s, 1H), 6.99 (s, 1H),3.89 (d, J=7.06 Hz, 6H), 3.04-3.13 (m, 1H), 1.28 (d, J=6.62 Hz, 3H),0.95 (d, J=6.62 Hz, 3H).

LCMS: [M+H]⁺ 337.0.

Example 14: Synthesis of Comparative Compound 2

Comparative compound 2 was made by the synthetic method shown in SchemeR:

Starting material Compound 1 was prepared as outlined above in Example1.

General Procedure for Preparation of Comparative Compound 2:

To a solution of Compound 1 (400 mg, 1.25 mmol, 1.00 eq) indichloromethane (5.00 mL) was added m-CPBA (539 mg, 2.50 mmol, 80.0%purity, 2.00 eq) at 0° C. The reaction mixture was stirred at 20° C. for12 h. Dichloromethane (10 mL) was added. The mixture was washed withsat. Na₂SO₃ (10 mL), sat. Na₂CO₃ (2×10 mL) and brine (10 mL) insequence. Then the organic layer was dried over anhydrous Na₂SO₄,filtered and concentrated in vacuum. The residue was purified byprep-HPLC to give Comparative compound 2 (27.0 mg, 76.6 μmol) wasobtained as a solid. ¹H NMR: (400 MHz, Methanol-d₄) 8.23 (s, 1H), 7.63(s, 1H), 7.01 (s, 1H), 3.90 (s, 6H), 3.65 (dt, J=13.56, 6.67 Hz, 1H),1.11 (d, J=6.62 Hz, 6H).

LCMS: [M+H]⁺ 353.1.

Example 15: Synthesis of Compound 13

Compound 13 was made by the synthetic method outlined in Scheme S:

General Procedure for Preparation of Compound i-49:

To the solution of compound i-48 (5.00 g, 35.9 mmol, 1.00 eq), NaOAc(8.84 g, 107 mmol, 3.00 eq) in HOAc (65.0 mL) was added Br₂ (20.1 g, 125mmol, 6.48 mL, 3.50 eq), while maintaining the inner temperature below25° C. The mixture was stirred at 25° C. for 20 h. The mixture waspoured into ice water and neutralized to pH=7 with 25% aq. NaOHsolution. The aqueous phase was extracted with CH₂Cl₂ (3×100 mL). Theorganic phases were combined and washed with brine (100 mL), dried overanhydrous Na₂SO₄, filtered and concentrated to give compound i-49 (9.20g, 30.9 mmol) as a solid, which was used in the next step withoutpurification. ¹H NMR (400 MHz, Chloroform-d) δ=7.22 (s, 1H), 4.01 (s,3H), 3.87 (s, 3H).

General Procedure for Preparation of Compound i-50:

The mixture of compound i-49 (9.00 g, 30.3 mmol, 1.00 eq),isopropenylboronic acid pinacol ester (5.09 g, 30.3 mmol, 1.00 eq),K₂CO₃ (8.38 g, 60.6 mmol, 2.00 eq) and Pd(PPh₃)₄ (4.20 g, 3.64 mmol,0.12 eq) in 1,4-dioxane (100 mL) and H₂O (25.0 mL) was stirred at 100°C. under N₂ atmosphere for 6 h. The mixture was filtered and washed withethyl acetate (20 mL). To the filtrate was added ethyl acetate (50 mL)and brine (30 mL). The aqueous phase was separated and extracted withethyl acetate (3×100 mL). The organic phases were combined and driedover anhydrous Na₂SO₄, filtered and concentrated. The residue waspurified via column chromatography on silica gel to give compound i-50(4.00 g, 15.5 mmol) as a liquid. 1H NMR (400 MHz, Chloroform-d) δ=7.20(s, 1H), 5.39 (s, 1H), 5.33 (s, 1H), 3.99 (s, 3H), 3.88 (s, 3H), 2.14(s, 3H).

General Procedure for Preparation of Compound i-51:

To the solution of compound i-50 (3.00 g, 11.6 mmol, 1.00 eq) in THF(80.0 mL) was added n-BuLi (2.5 M, 9.30 mL, 2.00 eq) at −60° C. under N₂atmosphere. The mixture was stirred at −60° C. for 1 h. Then B(OMe)₃(3.62 g, 34.9 mmol, 3.00 eq) was added. The mixture was allowed to warmto 20° C. and stirred for 13 h. The reaction mixture was quenched withH₂O (20 mL) at 0° C. and then was adjusted to pH=4 with 1 N HCl (30 mL).Two phases were separated and the aqueous phase was extracted with ethylacetate (3×100 mL). The organic phases were combined, dried overanhydrous Na₂SO₄, filtered and concentrated. The residue was purifiedvia column chromatography on silica gel to give compound i-51 (1.10 g,4.93 mmol) as a liquid, which was used in the next step withoutpurification.

¹H NMR (400 MHz, Chloroform-d) δ=7.45 (s, 1H), 5.37 (br. s., 1H), 5.15(br. s., 1H), 4.02 (br. s., 3H), 3.91 (s, 3H), 3.73 (s, 2H), 2.22 (br.s., 3H).

General Procedure for Preparation of Compound i-52:

A mixture of compound i-51 (1.10 g, 4.93 mmol, 1.00 eq) and Pd/C (524.87mg, 4.93 mmol, 5% w.t., 1.00 eq) in MeOH (50.00 mL) was stirred at 20°C. under H₂ balloon for 15 h. The mixture was filtered through a pad ofcelite and the filter cake was washed with MeOH (150 mL). The combinedfiltrates were concentrated to give compound i-52 (800 mg, 3.55 mmol) asa liquid, which was used in the next step without purification.

¹H NMR (400 MHz, Chloroform-d) δ=7.75 (s, 1H), 4.22-4.15 (m, 1H), 4.11(s, 3H), 3.95 (s, 3H), 3.78-3.73 (m, 2H), 1.35 (d, J=6.7 Hz, 6H).

General Procedure for Preparation of Compound i-53:

To the solution of compound i-52 (290 mg, 1.29 mmol, 1.00 eq) in CH₃CN(9.00 mL) was added H₂O₂ (292 mg, 2.58 mmol, 30% w.t., 2.00 eq). Themixture was stirred at 20° C. for 0.5 h. To the mixture was addedsaturated aqueous Na₂SO₃ (5 mL) at 0° C. Then the mixture was stirred at20° C. for 5 min. To the mixture was added ethyl acetate (20 mL) and H₂O(5 mL).

The aqueous phase was separated and extracted with ethyl acetate (3×20mL). The organic phases were combined, dried over anhydrous Na₂SO₄ andconcentrated to give compound i-53 (240 mg, 1.22 mmol) as a liquid whichwas used in the next step without purification.

¹H NMR (400 MHz, Chloroform-d) δ=6.68 (s, 1H), 4.27 (br. s., 1H), 3.98(s, 3H), 3.83 (s, 3H), 3.12 (td, J=6.8, 13.7 Hz, 1H), 1.25 (d, J=6.7 Hz,6H).

General Procedure for Preparation of Compound i-54:

To compound i-53 (120 mg, 608 umol, 1.00 eq) in CH₃CN (3.00 mL) wasadded Cs₂CO₃ (297 mg, 912 umol, 1.50 eq) and BrCH₂CN (109.47 mg, 912.65umol, 1.50 eq). The mixture was stirred at 80° C. for 15 h. To thereaction mixture was added ethyl acetate (10 mL) and water (4 mL). Theaqueous phase was separated and extracted with ethyl acetate (3×10 mL).

The organic phases were combined, dried over anhydrous Na₂SO₄, filteredand concentrated to give compound i-54 (135 mg, 571 umol) as a solidwhich was used in the next step without purification. ¹H NMR (400 MHz,DMSO-d₆) δ=7.28 (s, 1H), 5.16 (s, 2H), 3.84 (s, 3H), 3.78 (s, 3H),3.22-3.25 (m, 1H), 1.15 (d, J=7.0 Hz, 6H).

General Procedure for Preparation of Compound i-55:

The mixture of compound i-54 (200 mg, 846 umol, 1.00 eq) and1-tert-butoxy-N,N,N′,N′-tetramethyl-methanediamine (295 mg, 1.69 mmol,2.00 eq) in DMF (2.00 mL) was stirred at 110° C. for 3 h. The reactionmixture was used in the next step directly.

General Procedure for Preparation of Compound i-56:

To the solution of compound i-55 (284 mg, 846 umol, 1.00 eq) in DMF(2.00 mL) was added PhNH₂ (219 mg, 1.69 mmol, 2.00 eq, HCl). The mixturewas stirred at 120° C. for 3 h. LCMS showed the starting material wasconsumed completely. To the mixture was added toluene (30 mL) and H₂O (6mL). The two phases were separated and the aqueous phase was extractedwith toluene (3×15 mL). The organic phases were combined, dried overanhydrous Na₂SO₄, filtered and concentrated to give compound i-56 (280mg, 825 umol) as a liquid which was used in the next step withoutpurification. ¹H NMR (400 MHz, Chloroform-d) δ=7.37-7.34 (m, 2H), 7.16(d, J=5.7 Hz, 2H), 6.95 (d, J=7.9 Hz, 1H), 6.80 (s, 1H), 6.70 (d, J=7.5Hz, 1H), 4.69 (s, 1H), 4.02 (s, 3H), 3.85 (s, 3H), 3.37-3.25 (m, 1H),1.28 (d, J=7.1 Hz, 6H).

General Procedure for Preparation of Compound 13:

A mixture of compound i-56 (140 mg, 412 umol, 1.00 eq), guanidinecarbonate (111 mg, 618 umol, 1.50 eq) and NaOMe (66.8 mg, 1.24 mmol,3.00 eq) in DMSO (1.50 mL) was stirred at 110° C. for 1 h. Oneadditional vial was set up as described above. The two reaction mixtureswere combined and filtered. The filtrate was purified via prep-HPLC togive Compound 13 (46.00 mg, 148 umol) as a solid. ¹H NMR (400 MHz,DMSO-d₆) δ=7.18 (s, 1H), 6.81 (s, 1H), 6.44 (br. s., 2H), 5.72 (s, 2H),3.86 (s, 3H), 3.68 (s, 3H), 3.24 (td, J=6.7, 13.6 Hz, 1H), 1.16 (d,J=6.6 Hz, 6H). LCMS: 98.2% purity, m/z=306.0 (M+1)⁺

Example 16: Synthesis of Compound 14

Compound 14 was made by the synthetic method outlined in Scheme T:

General Procedure for Preparation of Compound i-58:

To the solution of compound i-57 (10.0 g, 69.6 mmol, 1.00 eq) in THF(200 mL) and NMP (20.0 mL) was added Fe(acac)₃ (1.23 g, 3.48 mmol, 0.05eq). Then i-PrMgCl (2 M, 41.79 mL, 1.20 eq) was added dropwise at −30°C. within 30 min. The mixture was stirred at 0° C. for 1 h. The reactionmixture was quenched with saturated aqueous NH₄Cl (80 mL) at 0° C.

Then the two phases were separated and the aqueous phase was extractedwith methyl t-butyl ether (80 mL). The combined organic phases werewashed with water (4×50 mL). Then the organic phase was dried overanhydrous Na₂SO₄, filtered and concentrated to give compound i-58 (7.10g, 46.9 mmol) as a liquid which was used for the next step withoutpurification.

¹H NMR (400 MHz, Chloroform-d) δ=7.48 (t, J=7.7 Hz, 1H), 6.72 (d, J=7.1Hz, 1H), 6.54 (d, J=7.9 Hz, 1H), 3.93 (s, 3H), 2.95 (td, J=6.8, 13.7 Hz,1H), 1.28 (d, J=7.1 Hz, 6H).

General Procedure for Preparation of Compound i-59:

To the solution of compound i-58 (8.50 g, 56.2 mmol, 1.00 eq) in THF(85.0 mL) was added 1,3-dibromo-5,5-dimethyl-imidazolidine-2,4-dione(16.1 g, 56.2 mmol, 1.00 eq). The mixture was stirred at 20° C. for 3 h.To the mixture was added water (50 mL) and ethyl acetate (30 mL). Thetwo phases were separated and the aqueous phase was extracted with ethylacetate (3×40 mL). The combined organic phases were dried over anhydrousNa₂SO₄, filtered and concentrated. The residue was purified via columnchromatography on silica gel to give compound i-59 (7.10 g, 30.8 mmol)as a liquid. ¹H NMR (400 MHz, Chloroform-d) δ=7.58 (d, J=8.8 Hz, 1H),6.42 (d, J=8.4 Hz, 1H), 3.89 (s, 3H), 3.42 (td, J=6.8, 13.3 Hz, 1H),1.23 (d, J=7.1 Hz, 6H).

General Procedure for Preparation of Compound i-60:

The mixture of compound i-59 (7.10 g, 30.8 mmol, 1.00 eq), BPD(Bis(pinacolato)diboron, 11.7 g, 46.3 mmol, 1.50 eq), Pd(dppf)Cl₂ (1.13g, 1.54 mmol, 0.05 eq) and KOAc (6.06 g, 61.7 mmol, 2.00 eq) in DMF(71.0 mL) was stirred at 130° C. under N₂ atmosphere for 0.5 h. To themixture was added water (30 mL) and ethyl acetate (30 mL). The twophases were separated and the aqueous phase was extracted with ethylacetate (2×30 mL).

The combined organic phases were dried over anhydrous Na₂SO₄, filteredand concentrated. The residue was purified via column chromatography onsilica gel to give compound i-60 (4.30 g, 15.5 mmol) as a liquid. ¹H NMR(400 MHz, Chloroform-d) δ=7.90 (d, J=8.2 Hz, 1H), 6.50 (d, J=8.2 Hz,1H), 3.95 (s, 3H), 3.74 (td, J=6.7, 13.3 Hz, 1H), 1.37-1.31 (m, 12H),1.24 (d, J=6.7 Hz, 6H).

General Procedure for Preparation of Compound i-61:

To a solution of compound i-60 (4.60 g, 16.6 mmol, 1.00 eq) in MeOH(8.00 mL) was added HCl (12 M, 46.1 mL, 33.3 eq). The mixture wasstirred at 65° C. for 2 h. The mixture was cooled to RT, and wasadjusted to pH=5 with 10 N NaOH (60 mL). To the mixture was added ethylacetate (100 mL). The aqueous phase was separated and extracted withethyl acetate (3×50 mL). The organic phases were combined and dried overanhydrous Na₂SO₄. Then filtered and concentrated to give i-61 (3.20 g,16.4 mmol) as a liquid which was used for the next step withoutpurification. ¹H NMR (400 MHz, Chloroform-d) δ=8.29 (d, J=8.4 Hz, 1H),6.68-6.63 (m, 1H), 4.13 (td, J=6.6, 13.2 Hz, 1H), 4.03 (s, 3H), 1.37 (d,J=7.1 Hz, 6H).

General Procedure for Preparation of Compound i-62:

To a solution of compound i-61 (3.20 g, 16.4 mmol, 1.00 eq) in CH₃CN(50.0 mL) was added hydrogen peroxide (3.72 g, 32.8 mmol, 30% w.t., 2.00eq). The mixture was stirred at 20° C. for 0.5 h. To the mixture wasadded saturated Na₂SO₃ solution (50 mL) at 0° C. Then the mixture wasstirred at 20° C. for 10 min. To the mixture was added ethyl acetate(100 mL) and H₂O (10 mL). The aqueous phase was separated and extractedwith ethyl acetate (3×50 mL).

The organic phases were combined, washed with brine (50 mL) and driedover anhydrous Na₂SO₄. Then the solution was filtered and concentratedto give i-62 (2.50 g, 14.95 mmol) as a liquid which was used for thenext step without purification. ¹H NMR (400 MHz, Chloroform-d) δ=7.05(d, J=8.8 Hz, 1H), 6.45 (d, J=8.8 Hz, 1H), 4.45 (br. s., 1H), 3.89 (s,3H), 3.31-3.20 (m, 1H), 1.27 (d, J=6.6 Hz, 6H).

General Procedure for Preparation of Compound i-63:

To compound i-62 (2.50 g, 14.95 mmol, 1.00 eq) in CH₃CN (30.00 mL) wasadded Cs₂CO₃ (7.31 g, 22.43 mmol, 1.50 eq) and BrCH₂CN (2.69 g, 22.4mmol, 1.50 eq). The mixture was stirred at 80° C. for 13 h. To thereaction mixture was added ethyl acetate (60 mL) and water (30 mL). Theaqueous phase was separated and extracted with ethyl acetate (3×50 mL).The organic phases were combined and washed with brine (50 mL). Then thesolution was dried over anhydrous Na₂SO₄, filtered and concentrated togive i-63 (2.90 g, 14.1 mmol) as a solid which was used for the nextstep without purification. ¹H NMR (400 MHz, DMSO-d₆) δ=7.56 (d, J=8.8Hz, 1H), 6.67 (d, J=8.8 Hz, 1H), 5.14 (s, 2H), 3.82 (s, 3H), 3.36-3.27(m, 1H), 1.17 (d, J=7.1 Hz, 6H).

General Procedure for Preparation of Compound i-64:

A mixture of compound i-63 (2.90 g, 14.1 mmol, 1.00 eq) and1-tert-butoxy-N,N,N′,N′-tetramethyl-methanediamine (4.90 g, 28.1 mmol,5.83 mL, 2.00 eq) in DMF (30.0 mL) was stirred at 110° C. for 2 h. Thereaction mixture was used in the next step directly.

General Procedure for Preparation of Compound i-65:

To the solution of compound i-64 (4.31 g, 14.07 mmol, 1.00 eq) in DMF(30.00 mL) was added PhNH₂ (4.56 g, 35.2 mmol, 4.47 mL, 2.50 eq, HCl).The mixture was stirred at 120° C. for 3 h. To the mixture was addedtoluene (80 mL) and H₂O (30 mL). The two phases were separated and theaqueous was extracted with toluene (3 30 mL). The organic phases werecombined, washed with brine (30 mL). Then the solution was dried overanhydrous Na₂SO₄, filtered and concentrated to give compound i-65 (5.00g, crude) as a liquid which contained PhNH₂ and DMF. The crude productwas used for the next step without purification.

¹H NMR (400 MHz, Chloroform-d) δ=7.33 (t, J=7.3 Hz, 3H), 7.18-7.13 (m,3H), 6.94 (d, J=7.9 Hz, 2H), 6.76 (t, J=7.3 Hz, 2H), 6.69 (d, J=7.9 Hz,2H), 6.54 (d, J=8.8 Hz, 1H), 3.93 (s, 3H), 3.46-3.38 (m, 1H), 1.30 (d,J=7.1 Hz, 6H).

General Procedure for Preparation of Compound 14:

A mixture of compound i-65 (2.50 g, 8.08 mmol, 1.00 eq), guanidinecarbonate (2.18 g, 12.1 mmol, 1.50 eq) and NaOMe (1.31 g, 24.2 mmol,3.00 eq) in DMSO (25.00 mL) was stirred at 110° C. for 1 h. Oneadditional reaction was set up with the same amounts and conditions, andthe two reaction mixtures were combined at the end of the heatingperiod. To the mixture was added ethyl acetate (100 mL) and water (40mL). The two phases were separated and the aqueous phase was extractedwith ethyl acetate (2×50 mL). The organic phases were combined andwashed with brine (30 mL), dried over anhydrous Na₂SO₄, filtered andconcentrated. The residue was purified via prep-HPLC to give Compound 14(1.20 g, 4.36 mmol) as a solid. ¹H NMR (400 MHz, DMSO-d₆) δ=7.26 (s,1H), 7.08 (d, J=8.8 Hz, 1H), 6.58 (d, J=8.8 Hz, 1H), 6.44 (br. s., 2H),5.80 (s, 2H), 3.82 (s, 3H), 3.43-3.35 (m, 1H), 1.21 (d, J=6.6 Hz, 6H).LCMS: 99.7% purity, m/z=276.1 (M+1)⁺

Example 17: Synthesis of Compound 15

Compound 15 was made by the synthetic method outlined in Scheme U:

Starting material Compound 14 was prepared as outlined above in Example16.

General Procedure for Preparation of Compound 15

To a solution of Compound 14 (250 mg, 908 umol, 1.00 eq) in HOAc (2.5mL) was added a solution of ICl (295 mg, 1.82 mmol, 2.00 eq) in HOAc(2.5 mL). Then H₂O (4.00 mL) was added. The mixture was stirred at 90°C. for 2 h. Then a second portion of ICl (442 mg, 2.72 mmol, 3.00 eq)was added. The mixture was stirred at 90° C. for 4 h. The reactionmixture was adjusted to pH=8 with 1 N NaOH (2 mL) and saturated NaHCO₃(3 mL). The mixture was extracted with ethyl acetate (3×15 mL). Thecombined organic phases were washed with saturated Na₂CO₃ (10 mL) andbrine (10 mL), dried over anhydrous Na₂SO₄, filtered and concentrated.The residue was purified via prep-TLC (CH₂Cl₂:CH₃OH=20:1) to giveCompound 15 (40.0 mg, 99.7 umol) as a solid. ¹H NMR (400 MHz, DMSO-d₆)δ=7.38 (s, 1H), 7.33 (s, 1H), 6.47 (br. s., 2H), 5.89 (s, 2H), 3.86 (s,3H), 3.40-3.34 (m, 1H), 1.22 (d, J=6.6 Hz, 6H). LCMS: 97.4% purity,m/z=401.9 (M+1)⁺

Example 18: Synthesis of Compound 16

Compound 16 was made by the synthetic method outlined in Scheme V:

Compound 15 was prepared as outlined above in Example 17.

To a solution of Compound 15 (400 mg, 997 umol, 1.00 eq), CH₃SO₂Na (254mg, 2.49 mmol, 2.50 eq) and copper (I) trifluoromethanesulfonate-benzenecomplex (75.28 mg, 150 umol, 0.15 eq) in DMSO (8.00 mL) was added DMEDA(26.4 mg, 299 umol, 32.2 uL, 0.30 eq).

The mixture was stirred at 120° C. under N₂ atmosphere for 4 h. To themixture was added ethyl acetate (20 mL) and H₂O (10 mL). The two phaseswere separated and the aqueous phase was extracted with ethyl acetate(3×15 mL). The combined organic phases were washed with brine (10 mL),dried over anhydrous Na₂SO₄, filtered and concentrated. The residue waspurified via prep-HPLC to give Compound 16 (280 mg) as a solid.

¹H NMR (400 MHz, DMSO-d₆) δ=7.51 (br. s., 1H), 7.28 (s, 1H), 6.53 (br.s., 2H), 5.98 (br. s., 2H), 4.02 (s, 3H), 3.59-3.48 (m, 1H), 3.25 (s,3H), 1.27 (d, J=6.6 Hz, 6H).

LCMS: 99.8% purity, m/z=354.1 (M+1)⁺

Example 19: Synthesis of Compound 17

Compound 17 was made by the synthetic method outlined in Scheme W:

Compound 15 was prepared as outlined above in Example 17.

A solution of Compound 15 (100 mg, 249 umol, 1.00 eq), CuCN (51.3 mg,573 umol, 2.30 eq), Pd(PPh₃)₄ (57.6 mg, 49.8 umol, 0.20 eq), I₂ (25.3mg, 99.7 umol, 0.40 eq) in DMF (2.00 mL) was stirred at 100° C. under N₂atmosphere for 12 h. To the reaction mixture was added ethyl acetate (10mL), saturated NH₄Cl (3 mL) and NH₃.H₂O (0.5 mL). The two phases wereseparated and the aqueous phase was extracted with ethyl acetate (3×5mL). The combined organic phases were dried over anhydrous Na₂SO₄,filtered and concentrated. The residue was purified via prep TLC andthen purified via prep-HPLC to give Compound 17 (15.0 mg, 48.9 umol) asa solid. ¹H NMR (400 MHz, DMSO-d₆) S=7.50 (s, 1H), 7.44 (s, 1H), 6.46(br. s., 2H), 5.90 (s, 2H), 3.97 (s, 3H), 3.46 (quin, J=6.7 Hz, 1H),1.24 (d, J=6.6 Hz, 6H).

LCMS: 97.9% purity, m/z=301.1 (M+1)⁺

Example 20: Synthesis of Compound 18

Compound 18 was made by the synthetic method outlined in Scheme X:

Starting material Compound 15 was prepared as outlined above in Example17.

A solution of Compound 15 (100 mg, 249 umol, 1.00 eq),1,10-phenanthrolinetrifluoromethyl copper (624 mg, 1.99 mmol, 8.00 eq)and CuI (94.9 mg, 498 umol, 2.00 eq) in DMF (2.00 mL) was stirred at 80°C. under N₂ atmosphere for 6 h. The mixture was filtered and ethylacetate (10 mL) and H₂O (4 mL) were added to the filtrate. The twophases were separated and the aqueous phase was extracted with ethylacetate (3×10 mL). The combined organic phases were dried over anhydrousNa₂SO₄, filtered and concentrated. The residue was purified viaprep-HPLC to give Compound 18 (13.0 mg, 37.3 umol) as a solid. ¹H NMR(400 MHz, DMSO-d₆) δ=7.46 (s, 1H), 7.16 (s, 1H), 6.51 (br. s., 2H), 5.93(br. s., 2H), 3.96 (s, 3H), 3.54-3.42 (m, 1H), 1.26 (d, J=6.6 Hz, 6H).LCMS: 98.5% purity, m/z=344.2 (M+1)⁺

Example 21: Synthesis of Compound 19

Compound 19 was made by the synthetic method outlined in Scheme Y:

Compound 15 was prepared as outlined above in Example 17.

General Procedure for Preparation of Compound i-66:

To a solution of Compound 15 (100 mg, 249 umol, 1.00 eq), Pd(PPh₃)₂Cl₂(35.0 mg, 49.8 umol, 0.20 eq) and CuI (4.75 mg, 24.9 umol, 0.10 eq) inTHF (2.00 mL) was added ethynyl (trimethyl)silane (49.0 mg, 498 umol,2.00 eq) and DIPEA (258 mg, 2.00 mmol, 8.00 eq). The mixture was stirredat 50° C. for 12 h. To the mixture was added ethyl acetate (4 mL) andsaturated NH₄Cl (2 mL). The two phases were separated and the aqueousphase was extracted with ethyl acetate (3×3 mL). The combined organicphases were washed with brine (2 mL), dried with anhydrous Na₂SO₄,filtered and concentrated. The residue was purified via prep-TLC to givecompound i-66 (80.0 mg, 215 umol) as a solid. ¹H NMR (400 MHz,METHANOL-d₄) δ=7.24 (s, 1H), 7.12 (s, 1H), 3.96 (s, 3H), 3.43-3.36 (m,1H), 1.26 (d, J=6.7 Hz, 6H), 0.21 (s, 9H).

General Procedure for Preparation of Compound 19:

To the solution of i-66 (75.0 mg, 201 umol, 1.00 eq) in THF (1.60 mL)was added CsF (153 mg, 1.01 mmol, 5.00 eq). The mixture was stirred at50° C. for 5 h. Another portion of CsF (153 mg, 1.01 mmol, 5.00 eq) wasadded in. The mixture was stirred at 50° C. for 13 h. To the mixture wasadded ethyl acetate (10 mL) and saturated NH₄Cl (5 mL). The two phaseswere separated and the aqueous phase was extracted with ethyl acetate(4×10 mL). The combined organic phase was washed with brine (10 mL),dried over anhydrous Na₂SO₄, filtered and concentrated. The residue waspurified via prep-HPLC to give Compound 19 (26.0 mg, 84.9 umol) as asolid. ¹H NMR (400 MHz, DMSO-d₆) δ=7.38 (s, 1H), 7.02 (s, 1H), 6.46 (br.s., 2H), 5.88 (s, 2H), 4.33 (s, 1H), 3.89 (s, 3H), 3.40 (quin, J=6.8 Hz,1H), 1.22 (d, J=7.1 Hz, 6H).

LCMS: 97.7% purity, m/z=300.1 (M+1)⁺

Example 22: Synthesis of Compound 20

Compound 20 was made by the synthetic method outlined in Scheme Z:

Compound 15 was prepared as outlined above in Example 17.

General Procedure for Preparation of Compound i-67:

To the mixture of Compound 15 (1.00 g, 2.49 mmol, 1.00 eq), CuI (213 mg,1.12 mmol, 0.45 eq), 1,10-phenanthroline (202 mg, 1.12 mmol, 0.45 eq)and Cs₂CO₃ (1.22 g, 3.74 mmol, 1.50 eq) was added toluene (20.0 mL) andphenylmethanethiol (3.09 g, 24.9 mmol, 2.92 mL, 10.0 eq). The mixturewas stirred at 80° C. under N₂ atmosphere for 12 h. To the mixture wasadded water (10 mL) and ethyl acetate (20 mL). The two phases wereseparated and the aqueous phase was extracted with ethyl acetate (3×20mL). The organic phases were combined, dried over anhydrous Na₂SO₄,filtered and concentrated. To the residue was added petroleum (20 mL)and ethyl actetate (3 mL). The mixture was stirred at 15° C. for 30 min.During this time a pink solid precipitated. The solid was filtered andfurther purified via prep-HPLC to give compound i-67 (520 mg, 1.31 mmol)as a solid. ¹H NMR (400 MHz, DMSO-d₆) δ=7.30-7.16 (m, 6H), 7.01 (s, 1H),6.40 (br. s., 2H), 5.85 (s, 2H).

General Procedure for Preparation of Compound i-68:

To the solution of i-67 (300 mg, 755 umol, 1.00 eq) in HOAc (4.20 mL)and H₂O (1.40 mL) was added 1,3-dichloro-5,5-dimethylhydantoin (297 mg,1.51 mmol, 2.00 eq) at 0-5° C. The mixture was stirred at 0-5° C. for 1h, and then stirred at 20° C. for 3 h. The reaction mixture was used inthe next step directly without purification.

General Procedure for Preparation of Compound 20:

To a solution of NH₃ (1.03 g, 60.4 mmol, 80.0 eq) in THF (6.00 mL) wasadded dropwise the solution of i-68 (282 mg, 755 umol, 1.00 eq) in HOAc(4.20 mL) and H₂O (1.40 mL) at 0° C. The mixture was stirred at 20° C.for 12 h. To the mixture was added ethyl acetate (15 mL) and water (6mL). The two phases were separated and the aqueous phase was extractedwith ethyl acetate (2×10 mL). The organic phases were combined andconcentrated. The residue was purified via prep-HPLC to give Compound 20(92.0 mg, 259 umol, 99.7% purity) as a solid. ¹H NMR (400 MHz, DMSO-d₆)δ=7.45 (s, 1H), 7.27 (s, 3H), 6.52 (br. s., 2H), 5.94 (s, 2H), 3.97 (s,3H), 3.51 (td, J=6.6, 13.5 Hz, 1H), 1.26 (d, J=6.6 Hz, 6H.

LCMS: 99.7% purity, m/z=355.0 (M+1).

Example 23: Synthesis of Compound 21

Compound 21 was made by the synthetic method outlined in Scheme AA:

Compound i-29 was prepared as outlined above in Example 2.

General Procedure for Preparation of Compound i-70:

A mixture of i-29 (50 g, 215 mmol), potassium vinyl trifluoroborate(34.6 g, 259 mmol) and K₂CO₃ (59.6 g, 431 mmol) was stirred intetrahydrofuran (400 mL) and water (100 mL) under N₂ for 20 min. Theresulting reaction mixture was degassed three times with N₂ before beingcharged with Pd(dppf)Cl₂ (1.57 g, 2.10 mmol). The resulting reactionmixture was degassed again with N₂ and the mixture was stirred at 70° C.for 15 h. Two additional vials were set up as described above. All threereaction mixtures were combined and were partitioned between ethylacetate (1.5 L) and water (1.5 L). The aqueous layer was extracted withethyl acetate (3×1.0 L). The combined organic layers were dried overNa₂SO₄, filtered and concentrated under reduced pressure. The residuewas purified by column chromatography on silica gel to give i-69 (90.0g, 502 mmol) as an oil. ¹H NMR (400 MHz, Chloroform-d) δ=8.09-8.01 (m,1H), 7.31-7.24 (m, 1H), 7.01 (d, J=2.6 Hz, 1H), 6.87 (dd, J=2.6, 9.0 Hz,1H), 5.68 (d, J=17.4 Hz, 1H), 5.47 (d, J=11.0 Hz, 1H), 3.91 (s, 3H).

General Procedure for Preparation of Compound i-70:

A mixture of i-69 (90.0 g, 502 mmol, 1.00 eq) and Pd/C (9.01 g) in MeOH(900 mL) was stirred under H₂ (50 psi) at 25° C. for 12 h. The reactionmixture was filtered through celite and washed with MeOH (300 mL). Tothe filtrate was added 12 M HCl (90.0 mL). Then the mixture wasconcentrated to give i-70 (92.0 g, 490 mmol) as a solid which was usedin the next step directly. ¹H NMR (400 MHz, DMSO-d₆) δ=10.18 (br. s.,3H), 7.39 (d, J=8.3 Hz, 1H), 6.91-6.83 (m, 2H), 3.76 (s, 3H), 2.67 (q,J=7.5 Hz, 2H), 1.19 (t, J=7.5 Hz, 3H).

General Procedure for Preparation of Compound i-71:

To a solution of i-70 (50.0 g, 266 mmol, 1.00 eq) in MeOH (300 mL) andHCl (1 M, 501 mL, 1.88 eq) was added dropwise a solution of NaNO2 (27.6g, 400 mmol, 1.50 eq) in H2O (100 mL) at 0° C. The mixture was stirredat 0° C. for 1 h. Then the mixture was added dropwise to a solution ofEtOCS₂K (85.4 g, 533 mmol, 2.00 eq) in H₂O (700 mL). The mixture wasstirred at 25° C. for 2 h. The mixture was partitioned between ethylacetate (300 mL) and water (100 mL). The aqueous layer was extractedwith ethyl acetate (3×200 mL). The combined organic layers were driedover Na₂SO₄, filtered and concentrated under reduced pressure to give aresidue. The residue was purified by column chromatography on silica gelto give i-71 (40.0 g, 156 mmol) as an oil which was used in the nextstep directly. ¹H NMR (400 MHz, DMSO-d₆) δ=7.39 (d, J=8.8 Hz, 1H), 6.97(br. s., 1H), 6.89-6.84 (m, 1H), 4.57 (q, J=6.9 Hz, 2H), 3.80 (s, 3H),2.65 (q, J=7.5 Hz, 2H), 1.35 (t, J=7.1 Hz, 3H), 1.12 (t, J=7.5 Hz, 3H).

General Procedure for Preparation of Compound i-72:

To a solution of i-71 (40.0 g, 156 mmol, 1.00 eq) in EtOH (280 mL) wasadded aqueous NaOH (3 M, 572 mL, 11.0 eq). Then the mixture was stirredat 65° C. for 1 h. TLC showed the reaction was completed. 1,4-Dithioerythritol (100 mg) was added in and the mixture was adjusted topH=5 with aqueous HCl (3 M, 140 mL). Then the mixture was partitionedbetween ethyl acetate (100 mL) and water (100 mL). The aqueous layer wasextracted with ethyl acetate (3×100 mL). The combined organic layerswere dried over Na₂SO₄, filtered and concentrated under reduced pressureto give i-72 (18.0 g, 107 mmol) as an oil which was used in the nextstep directly. ¹H NMR (400 MHz, DMSO-d₆) δ=7.31-7.25 (m, 1H), 6.78 (d,J=2.2 Hz, 1H), 6.69 (dd, J=2.4, 8.6 Hz, 1H), 4.85 (s, 1H), 3.73-3.67 (m,3H), 2.63-2.56 (m, 2H), 1.14 (t, J=7.5 Hz, 3H).

General Procedure for Preparation of Compound i-73:

To a solution of i-72 (18.0 g, 107 mmol, 1.00 eq) in CH₃CN (120 mL) wasadded Cs₂CO₃ (52.3 g, 160 mmol, 1.50 eq) and 2-bromoacetonitrile (19.3g, 160 mmol, 1.50 eq). Then the mixture was stirred at 80° C. for 12 h.The reaction mixture was partitioned between ethyl acetate (100 mL) andwater (100 mL). The aqueous layer was extracted with ethyl acetate (3×80mL). The combined organic layers were dried over Na₂SO₄, filtered andconcentrated under reduced pressure. The residue was purified by columnchromatography on silica gel to give i-73 (7.40 g, 35.7 mmol) as an oil.¹H NMR (400 MHz, DMSO-d₆) δ=7.51 (d, J=8.4 Hz, 1H), 6.91 (d, J=2.2 Hz,1H), 6.86 (dd, J=2.4, 8.6 Hz, 1H), 3.98 (s, 2H), 3.77 (s, 3H), 2.77 (q,J=7.5 Hz, 2H), 1.16 (t, J=7.5 Hz, 3H).

General Procedure for Preparation of Compound i-75:

To a solution of i-73 (2.70 g, 13.0 mmol, 1.00 eq) in DMF (27.0 mL) wasadded 1-tert-butoxy-N,N,N′,N′-tetramethyl-methanediamine (4.54 g, 26.1mmol, 5.41 mL, 2.00 eq). The mixture was stirred at 110° C. for 1 h. Thereaction mixture was cooled to RT, and used in the next step directlywithout characterization.

To the crude reaction mixture was added aniline hydrochloride (8.43 g,65.1 mmol, 5.00 eq). The mixture was stirred at 120° C. for 12 h andthen cooled to RT. The reaction mixture was partitioned between toluene(50 mL) and water (50 mL). The aqueous layer was extracted with toluene(3×40 mL). The combined organic layers were dried over Na₂SO₄, filteredand concentrated under reduced pressure to give i-75 9.00 g, crude) as aan oil which was used in the next step directly. ¹H NMR (400 MHz,Chloroform-d) δ=7.38-7.32 (m, 7H), 6.99 (s, 1H), 6.71 (s, 1H), 3.80 (s,3H), 2.87-2.81 (m, 2H), 1.32-1.26 (m, 3H).

General Procedure for Preparation of Compound i-76:

To a solution of i-75 (9.00 g, 29.0 mmol, 1.00 eq) in DMSO (90.0 mL) wasadded guanidine carbonate (7.84 g, 43.5 mmol, 1.50 eq) and CH₃ONa (4.70g, 87.0 mmol, 3.00 eq).

The mixture was stirred at 110° C. for 12 h and then cooled to RT. Thereaction mixture was partitioned between ethyl acetate (100 mL) andwater (100 mL). The aqueous layer was extracted with ethyl acetate (3×80mL). The combined organic layers were dried over Na₂SO₄, filtered andconcentrated under reduced pressure. The residue was purified byprep-HPLC to give i-76 (676 mg, 2.45 mmol) as a solid. ¹H NMR (400 MHz,DMSO-d₆) δ=7.85 (s, 1H), 6.79 (s, 1H), 6.77-6.69 (m, 2H), 6.34 (br. s.,2H), 3.69 (s, 3H), 2.77-2.70 (m, 2H), 1.20 (t, J=7.5 Hz, 3H) LCMS:[M+H]⁺ 277.0

General Procedure for Preparation of Compound 21:

First batch: To a solution of i-76 (25.0 mg, 90.5 umol, 1.00 eq) in HOAc(0.1 mL) was added a solution of ICl (29.4 mg, 181 umol, 2.00 eq) inHOAc (0.1 mL). Then H₂O (25.0 uL) was added. The mixture was stirred at20° C. for 14 h. Another portion of ICl (29.4 mg, 181 umol, 2.00 eq) wasadded. Then the mixture was stirred at 40° C. for 2 h, and then cooledto RT. The reaction mixture was adjust to pH=8 with 4 M NaOH andsaturated Na₂CO₃.

The mixture was extracted with ethyl acetate (2×5 mL), the combinedorganic phases were washed with saturated Na₂CO₃ (5 mL), dried overanhydrous Na₂SO₄, filtered and concentrated.

Second batch: To a solution of i-76 (300 mg, 1.09 mmol, 1.00 eq) in HOAc(3 mL) was added a solution of ICl (354 mg, 2.18 mmol, 2.00 eq) in HOAc(3 mL). Then H₂O (500 uL) was added in. The mixture was stirred at 40°C. for 2 h. Another portion of ICl (177 mg, 1.09 mmol, 1.00 eq) wasadded. Then the mixture was stirred at 40° C. for 12 h. The reactionmixture was adjust to pH=8 with 4 M NaOH and saturated Na₂CO₃. Themixture was extracted with ethyl acetate (2×10 mL). Then the combinedorganic phases were washed with saturated Na₂CO₃ (5 mL), dried overanhydrous Na₂SO₄, filtered and concentrated.

The above two residues from the first batch and the second batch werecombined. This was purified via prep-HPLC to give Compound 21 (200 mg,472 umol) as a solid.

¹H NMR (400 MHz, DMSO-d₆) δ=7.88 (s, 1H), 7.08 (s, 1H), 6.88 (s, 1H),6.46 (s, 2H), 3.79 (s, 3H), 2.74 (q, J=7.5 Hz, 2H), 1.21 (t, J=7.5 Hz,3H) LCMS: [M+H]⁺ 403.0

Example 24: Synthesis of Compound 22

Compound 22 was made by the synthetic method outlined in Scheme AB:

Compound i-76 was prepared as outlined above in Example 23.

General Procedure for Preparation of Compound 22:

First batch: To a mixture of i-76 (25.0 mg, 90.5 umol, 1.00 eq) andmethylsulfonyl methanesulfonate (63.0 mg, 361 umol, 4.00 eq) was addedtrifluoromethanesulfonic acid (40.7 mg, 271 umol, 3.00 eq). The mixturewas heated at 80° C. for 12 h and cooled to RT. To the mixture was addedethyl acetate (2 mL) and H₂O (0.5 mL). Then the mixture was adjusted topH=8 with 4 M NaOH and saturated Na₂CO₃. The two phases were separatedand the aqueous phase was extracted with ethyl acetate (2×10 mL). Theorganic phases were combined, dried over anhydrous Na₂SO₄ andconcentrated.

Second batch: To a mixture of i-76 (300 mg, 1.09 mmol, 1.00 eq) andmethylsulfonyl methanesulfonate (756 mg, 4.34 mmol, 4.00 eq) was addedtrifluoromethanesulfonic acid (489 mg, 3.26 mmol, 3.00 eq). The mixturewas heated at 80° C. for 12 h and cooled to RT. To the mixture was addedethyl acetate (10 mL) and H₂O (5 mL). Then the mixture was adjusted topH=8 with 4 M NaOH and saturated Na₂CO₃. The two phases were separatedand the aqueous phase was extracted with ethyl acetate (2×10 mL). Theorganic phases were combined, dried over anhydrous Na₂SO₄ andconcentrated.

The above two residues from the two batches were combined. The mixturewas purified via prep-HPLC to give Compound 22 (68.0 mg, 188 umol) as asolid. ¹H NMR (400 MHz, DMSO-d₆) δ=7.88 (s, 1H), 7.20 (s, 1H), 7.17 (s,1H), 6.42 (br. s., 2H), 3.92 (s, 3H), 3.16 (s, 3H), 2.82 (q, J=7.5 Hz,2H), 1.26 (t, J=7.5 Hz, 3H) LCMS: [M+H]⁺ 355.1

Example 25: Synthesis of Compound 23

Compound 23 was made by the synthetic method outlined in Scheme AC:

General Procedure for Preparation of Compound i-78:

Compound i-77 (60 g, 417 mmol, 50 mL, 1.00 eq) and Fe(AcAc)₃ (7.38 g,20.9 mmol, 0.05 eq) were dissolved in THF (2 L) and NMP (200 mL). Thesuspension was cooled to −30° C. i-PrMgCl (250 mL, 1.20 eq) was addedinto above suspension while keeping the internal temperature between−30° C. to −40° C. The suspension was warmed to 0° C. and was stirredfor 1 h. Two additional reactions were set up as described above. Allthree reaction mixtures were combined. The reaction solution wasquenched with saturated aqueous NH₄Cl (500 mL) and was extracted withethyl acetate (3×500 mL). The organic layer was combined, washed withH₂O (5×250 mL), dried over Na₂SO₄ and concentrated under vacuum to givei-78 (53.0 g, 350 mmol) which was used in next step withoutpurification. ¹H NMR (400 MHz, CDCl₃-D₆) S=7.46 (t, J=7.6 Hz, 1H), 6.71(d, J=9.2 Hz, 1H), 6.52 (d, J=8.0 Hz, 1H), 3.92 (s, 3H), 2.95 (m, 1H),1.27 (d, J=7.2 Hz, 6H).

General Procedure for Preparation of Compound i-79:

To the solution of compound i-78 (120 g, 794 mmol, 1.00 eq) in THF (1.2L) was added 1,3-dibromo-5,5-dimethyl-imidazolidine-2,4-dione (205 g,794 mmol, 1.00 eq) at 0° C. in portions during 0.5 h. The mixture wasstirred at 20° C. for 3 h. To the mixture was added ice water (500 mL)and ethyl acetate (300 mL). The two phases were separated and theaqueous phase was extracted with ethyl acetate (3×400 mL). The combinedorganic phase was dried over anhydrous Na₂SO₄, filtered andconcentrated. The residue was purified via column chromatography onsilica gel to give i-79 (96 g, 417 mmol) as an oil. ¹H NMR (400 MHz,CDCl₃-D₆) δ=7.61 (d, J=8.60 Hz, 1H), 6.45 (d, J=8.60 Hz, 1H), 3.39-3.49(m, 1H), 3.92 (s, 3H), 1.25 (d, J=6.84 Hz, 6H).

General Procedure for Preparation of Compound i-81:

A mixture of compound i-79 (50.0 g, 217 mmol, 1.00 eq), Na₂S₂O₃ (85.9 g,543 mmol, 2.50 eq) and Cs₂CO₃ (142 g, 434 mmol, 2.00 eq) in t-BuOH (250mL) and toluene (250 mL) was degassed three times back filling with N₂each time before being charged with Pd₂(dba)₃ (3.98 g, 4.35 mmol, 0.02eq). The resulting reaction mixture was degassed twice back filling withN₂ each time and then warmed to 80° C. for 15 h. The reaction mixturewas cooled to 20° C. Three additional vials were set up as describedabove. All the four reaction mixtures were combined. The reactionmixture was concentrated to dryness to give a residue which was crushedin MTBE (500 mL). The mixture was filtered and the filter cake waswashed with MTBE (200 mL) to give crude compound i-80.

The combined dried filter cake was added into HCl (4 M, 200 mL) at 0°C., and Zn dust (20 g) was added into the mixture. Gas evolutionoccurred, and the mixture was stirred for 1 h. The reaction mixtureswere poured into ice-water (w/w=1/1) (2 L) and stirred for 20 min. Theaqueous phase was extracted with ethyl acetate (3×2 L). The combinedorganic phase was washed with brine (2×500 mL), dried with anhydrousNa₂SO₄, filtered and concentrated in vacuum to give i-81 (160 g, crude)as an oil. ¹H NMR (400 MHz, CDCl₃-D₆) δ=7.48 (d, J=8.4 Hz, 1H),6.45-6.48 (d, J=8.4 Hz, 1H), 3.91 (s, 1H), 3.37-3.49 (m, 1H), 1.25 (d,J=6.84 Hz, 6H).

General Procedure for Preparation of Compound i-82:

To compound i-81 (80 g, 436.51 mmol, 1.00 eq) in CH₃CN (1.6 L) was addedCs₂CO₃ (213 g, 655 mmol, 1.50 eq) and BrCH₂CN (87.7 g, 53.8 mmol, 1.50eq). The mixture was stirred at 80° C. for 15 h. One additional vial wasset up as described above. The two reaction mixtures were combined. Thereaction mixture was filtered and the filtrate was concentrated to givea residue which was purified by silica column chromatography on silicato give i-82 (81 g, 364 mmol, 41% yield) as an oil which was used forthe next step without next purification. ¹H NMR (400 MHz, CDCl₃-D₆)δ=7.77 (d, J=8.38 Hz, 1H), 6.58 (d, J=8.38 Hz, 1H), 3.87-4.00 (m, 3H),3.64-3.80 (m, 1H), 3.30-3.46 (m, 2H), 1.26 (d, J=6.62 Hz, 6H).

General Procedure for Preparation of Compound i-83:

Crude i-82 (20.0 g, 90.0 mmol, 1.00 eq) and1-tert-butoxy-N,N,N′,N′-tetramethyl-methane diamine (31.2 g, 179 mmol,37.3 mL, 2.00 eq) were dissolved in DMF (200 mL). The solution washeated to 110° C. for 4 h and cooled to RT to give a solution of crudei-83. The solution was used for next step without purification.

General Procedure for Preparation of Compound i-84:

The solution of crude i-83 (29 g, 90.0 mmol, 1.00 eq) and anilinehydrochloride (23.3 g, 180 mmol, 2.00 eq) were dissolved in DMF (200mL). The reaction solution was heated to 120° C. for 2 h. Anilinehydrochloride (23.3 g, 180 mmol, 2.00 eq) was added into the abovesolution. The solution was heated at 120° C. for 16 and cooled to RT. Tothe mixture was added ethyl acetate (200 mL) and water (100 mL). The twophases were separated and the aqueous phase was extracted with ethylacetate (3×100 mL). The organic phases were combined and washed withbrine (200 mL), dried over anhydrous Na₂SO₄, filtered and concentratedto give i-84 (29.3 g, crude) which was used directly in next stepwithout characterization.

General Procedure for Preparation of Compound 23:

Crude i-84 (29.3 g, 90.0 mmol, 1.00 eq, crude) and guanidine carbonate(24.3 g, 135 mmol, 1.50 eq) were dissolved in DMSO (200 mL). To thereaction solution was added into NaOMe (14.6 g, 269 mmol, 3.00 eq). Thesolution was heated to 110° C. for 16 h and cooled to RT. Two additionalreactions were set up as described above. All the three reactionmixtures were combined. To the mixture was added ethyl acetate (500 mL)and water (200 mL). The two phases were separated and the aqueous phasewas extracted with ethyl acetate (3×150 mL). The organic phases werecombined and washed with brine (200 mL), dried over anhydrous Na₂SO₄,filtered and concentrated. The residue was purified by columnchromatography on silica gel to give crude product. The crude productwas washed with MTBE (100 mL) to give Compound 23 (3.3 g, 37.8 mmol) asa solid. ¹H NMR (400 MHz, CDCl₃-D₆) δ=7.87 (s, 1H), 7.14 (d, J=8.4 Hz,1H), 6.56 (d, J=7.6 Hz, 1H), 6.47-6.43 (br. m., 4H), 3.80 (s, 3H), 3.47(m, 1H), 1.20 (d, J=6.4 Hz, 6H) LCMS: [M+H]⁺ 292.0

Example 26: Synthesis of Compound 24

Compound 24 was made by the synthetic method outlined in Scheme AD:

General Procedure for Preparation of Compound i-85:

Compound 23 (6.50 g, 22.3 mmol, 1.00 eq) was dissolved in Ac₂O (42 mL,20.0 eq). The solution was heated to 100° C. for 2 h, cooled to RT, andthe solvent was removed. The residue was added into saturated aqueousNa₂CO₃. The aqueous layer was extracted with ethyl acetate (3×10 mL).The combined organic layer was combined, dried over Na₂SO₄ andconcentrated. The residue was purified by silica column to give i-85(5.00 g).

¹H NMR (400 MHz, CDCl₃-D₆) δ=9.22 (br s, 1H), 8.72 (s, 1H), 8.42 (s,1H), 7.22 (d, J=8.6 Hz, 1H), 6.46 (d, J=8.6 Hz, 1H), 3.89 (s, 3H), 3.57(m, J=6.7 Hz, 1H), 2.46 (d, J=6.2 Hz, 6H), 1.23-1.19 (m, 6H).

General Procedure for Preparation of Compound i-86:

Compound i-85 (4.80 g, 12.8 mmol, 1.00 eq) and NBS (3.41 g, 19.1 mmol,1.50 eq.) were dissolved in CH₃CN (40 mL). The suspension was heated to80° C. for 1.5 h and cooled to RT. The solvent was removed. The residuewas added into saturated Na₂CO₃. The aqueous layer was extracted withethyl acetate (3×20 mL). The combined organic layers were dried overNa₂SO₄ and concentrated. The residue was purified by prep-HPLC to givei-85 (2.00 g, 4.40 mmol). ¹H NMR (400 MHz, CDCl₃-D₆) δ=8.52 (d, J=14.8Hz, 2H), 8.42 (s, 1H), 7.37 (s, 1H), 3.98 (s, 3H), 3.53 (m, 1H), 2.53(s, 3H), 2.46 (s, 3H), 1.24 (J=6.4 Hz, 6H).

General Procedure for Preparation of Compound 24:

Compound i-86 (600 mg, 1.32 mmol, 1.00 eq) and KOH (296 mg, 5.28 mmol,4.00 eq) were dissolved in MeOH (5 mL) and H₂O (5 mL). The solution washeated to 50° C. for 2 h. The solvent was removed. H₂O (10 mL) was addedinto the solution. The aqueous layer was extracted with ethyl acetate(3×20 mL). The combined organic layers were dried over Na₂SO₄ andconcentrated. The residue was purified by silica column chromatographyon silica gel (petroleum ether: ethyl acetate=10:1 to 1:1) to giveCompound 24 (300 mg, crude) as a solid. 100 mg of Compound 24 waspurified by Prep-HPLC to give 26 mg of Compound 24.

¹H NMR (400 MHz, CDCl₃-D₆) δ=8.10 (s, 1H), 7.27 (s, 1H), 5.23 (s, 2H),4.95 (s, 2H), 3.98 (s, 3H), 3.46 (m, 1H), 1.27 (d, J=6.4 Hz, 6H) LCMS:[M+H]⁺ 369.9

Example 27: Synthesis of Compound 25

Compound 25 was made by the synthetic method outlined in Scheme AE:

General Procedure for Preparation of Compound 25:

A solution of Compound 24 (60.0 mg, 162 umol, 1.00 eq, prepared asdescribed in Example 26), CH₃SO₂Na (41.4 mg, 405 umol, 2.50 eq), CuI(6.17 mg, 32.4 umol, 0.20 eq) and 1,2-diaminocyclohexane (7.40 mg, 64.8umol, 0.40 eq) in DMSO (1.20 mL) was stirred at 120° C. under N₂atmosphere for 4 h. Two additional vials were set up as described above.All the three reaction mixtures were combined and purified via prep-HPLCto give Compound 25 (55.0 mg, 149 umol) as a solid. ¹H NMR (400 MHz,DMSO-d₆) δ=7.92 (s, 1H), 7.48 (s, 1H), 6.62 (br s, 1H), 6.45 (br s, 2H),4.02 (s, 3H), 3.52-3.42 (m, 1H), 3.22 (s, 3H), 1.27 (br d, J=6.4 Hz, 6H)LCMS: [M+H]⁺ 370.0

Example 28: Synthesis of Compound 26

Compound 26 was made by the synthetic method outlined in Scheme AF:

General Procedure for Preparation of Compound 26:

A mixture of i-86 (180 mg, 396 umol, 1.00 eq, prepared as described inexample 26) and Zn(CN)₂ (93 mg, 792 umol, 2.00 eq) in DMF (4.00 mL) wasprotected by Argon. Then Pd(PPh₃)₄ (183 mg, 158 umol, 0.40 eq) was addedin one portion. The resulted orange mixture was heated at 118° C. for 17h to give a suspension. The reaction mixture was allowed to cool toambient temperature gradually and stayed till all solid deposited. Theclear solution was collected by a dropper and purified by prep-HPLC togive Compound 26 (30.0 mg) as a powder.

¹H NMR (400 MHz, DMSO-d₆) δ=7.93 (s, 1H), 7.50 (s, 1H), 6.62 (brs, 2H),6.47 (s, 2H), 3.97 (s, 3H), 3.50 (m, 1H), 1.23 (d, J=6.8 Hz, 6H) LCMS:[M+H]⁺ 317.0

Example 29: Synthesis of Compound 27

Compound 27 was made by the synthetic method outlined in Scheme AG:

General Procedure for Preparation of Compound i-87:

Compound i-86 (300 mg, 660 umol, 1.00 eq, prepared as described inexample 26), phenylmethanethiol (205 mg, 1.65 mmol, 2.50 eq), Pd₂(dba)₃(242 mg, 264 umol, 0.40 eq), Xantphos (153 mg, 264 umol, 0.40 eq) andDIEA (171 mg, 1.32 mmol, 2.00 eq) were dissolved in 1,4-dioxane (8 mL).The suspension was heated to 100° C. for 16 h under N₂. The solvent wasremoved. The residue was added into water (30 mL). The aqueous layer wasextracted with ethyl acetate (3×15 mL). The combined organic layers weredried over Na₂SO₄ and concentrate.

The residue was purified by column to give i-87 (300 mg, crude) whichwas used in next step without purification. ¹H NMR (400 MHz, CDCl₃-D₆)δ=8.25 (s, 1H), 7.21-7.16 (m, 5H), 7.02 (s, 1H), 4.01 (s, 3H), 3.99 (s,2H), 3.52 (m, 1H), 2.50 (s, 3H), 2.48 (s, 3H), 1.23 (J=7.2 Hz, 6H).

General Procedure for Preparation of Compound i-88:

Compound i-87 (180 mg, 362 umol, 1.00 eq) was dissolved in AcOH (2.5 mL)and H₂O (1 mL). The solution was cooled to 0° C. 1,3-Dichloro-5,5-dimethyl-imidazolidine-2,4-dione (143 mg, 723 umol, 2.00eq) was added into the solution at 0° C. The suspension was warmed to RTand stirred for 2 h. A solution of NH₃ (629 mg, 36.9 mmol, 80.00 eq) inTHF (10 mL) was added drop wise to the reaction solution of at 0° C. Themixture was stirred at 20° C. for 12 h. To the mixture was added ethylacetate (15 mL) and water (6 mL). The two phases were separated and theaqueous phase was extracted with ethyl acetate (2×10 mL). The organicphases were combined and dried with anhydrous Na₂SO₄, filtered andconcentrated to give i-88 (180 mg, crude) which was used in next stepwithout purification.

General Procedure for Preparation of Compound 27:

Crude compound i-88 (180 mg, 436 umol, 1.00 eq) was dissolved in MeOH (3mL) and H₂O (1 mL). KOH (97.9 mg, 1.75 mmol, 4.00 eq) was added into thesolution. The suspension was stirred at RT for 2 h. To the mixture wasadded ethyl acetate (15 mL) and water (10 mL). The two phases wereseparated and the aqueous phase was extracted with ethyl acetate (4×10mL). The organic phases were combined and dried with anhydrous Na₂SO₄,filtered and concentrated. The residue was purified via prep-HPLC togive Compound 27 (14.7 mg, 39.7 umol) as a solid. ¹H NMR (400 MHz,DMSO-d₆) δ=7.90 (s, 1H), 7.48 (s, 1H), 7.24 (s, 2H), 6.62-6.43 (br. m.,4H), 3.96 (s, 3H), 3.48 (m, 1H), 1.25 (d, J=6.4 Hz, 6H) LCMS: [M+H]⁺371.1

Example 30: Synthesis of Compound 28

Compound 28 was made by the synthetic method outlined in Scheme AH:

General Procedure for Preparation of Compound 28:

Compound 24 (200 mg, 540 umol, 1.00 eq prepared as described in Example26), trimethyl(prop-2-ynyl)silane (485 mg, 4.32 mmol, 8.00 eq),Pd(PPh₃)₂Cl₂ (152 mg, 216 umol, 0.40 eq) and TBAF (1 M, 1.62 mL, 3.00eq) were dissolved in THF (8 mL). The suspension was heated to 50° C.for 16 h under N₂. The reaction was cooled to RT. To the mixture wasadded ethyl acetate (20 mL) and saturated NH₄Cl (20 mL). The two phaseswere separated and the aqueous phase was extracted with ethyl acetate(3×15 mL). The combined organic phases were washed with brine (15 mL),dried with anhydrous Na₂SO₄, filtered and concentrated. The residue wasdissolved in DMF (5 mL) and purified by prep-HPLC. MeCN was removedunder reduced pressure and then water was removed by lyophillization togive Compound 28 (47.2 mg, 121 umol) as a solid. ¹H NMR (400 MHz,CDCl3-D₆) δ=8.10 (s, 1H), 7.12 (s, 1H), 5.28 (br. s., 2H), 5.03 (s, 2H),3.97 (s, 3H) 3.46 (m, 1H), 2.07 (s, 3H), 1.27 (d, J=6.8 Hz, 6H) LCMS:[M+H]⁺ 330.0

Example 31: Synthesis of Compound 29

Compound 29 was made by the synthetic method outlined in Scheme AH:

General Procedure for Preparation of Compound i-89:

Compound 24 (150 mg, 405 umol, 1.00 eq, prepared as described in Example26), ethynyl(trimethyl)silane (318 mg, 3.24 mmol, 8.00 eq), Pd(PPh₃)₂Cl₂(113 mg, 162 umol, 0.40 eq), CuI (15 mg, 81.0 umol, 0.20 eq) and DIPEA(419 mg, 3.24 mmol, 8.00 eq) were dissolved in THF (6 mL). Thesuspension was heated to 50° C. for 16 h. The solvent was removed invacuo. To the residue was added ethyl acetate (10 mL) and saturatedNH₄Cl (10 mL). The two phases were separated and the aqueous phase wasextracted with ethyl acetate (3×10 mL). The combined organic phases werewashed with brine (10 mL), dried with anhydrous Na₂SO₄, filtered andconcentrated. The residue was purified via silica gel column to givei-89 (150 mg, crude) which was used in next step without furtherpurification. ¹H NMR (400 MHz, CDCl3-d) δ=7.26 (s, 2H), 5.30-5.22 (m,2H), 5.03 (br s, 2H), 3.96 (s, 3H), 3.48 (td, J=6.7, 13.3 Hz, 1H), 1.25(d, J=6.6 Hz, 6H), 0.24 (s, 9H).

General Procedure for Preparation of Compound 29:

To a solution of i-89 (50 mg, 129 umol, 1.00 eq) in MeOH (3 mL) and DCM(3 mL) was added CsF (45 mg, 774 mmol, 6.00 eq). The mixture was stirredat RT for 2 h. Two additional reactions were set up as described above.All three reaction mixtures were combined.

To the mixture was added ethyl acetate (5 mL) and saturated NH₄Cl (5mL). The two phases were separated and the aqueous phase was extractedwith ethyl acetate (4×5 mL). The combined organic phases were washedwith brine (10 mL), dried over anhydrous Na₂SO₄, filtered andconcentrated. The residue was purified via prep-HPLC to give Compound 29(18.0 mg, 57.0 umol) as a solid. ¹H NMR (400 MHz, CDCl3-D₆) δ=8.10 (s,1H), 7.21 (s, 1H), 5.24 (br. s., 2H), 4.97 (br. s., 2H), 4.00 (s, 3H),3.47 (m, 1H), 3.28 (s, 1H), 1.28 (d, J=6.8 Hz, 6H) LCMS: [M+H]⁺ 316.1

Example 32: Synthesis of Compound 30

Compound 30 was made by the synthetic method outlined in Scheme AI:

General Procedure for Preparation of Compound i-91:

A solution of i-90 (5.00 g, 19.1 mmol, 1.00 eq), isopropenylboronic acidpinacol ester (3.85 g, 22.9 mmol, 1.20 eq), Pd(dppf)Cl₂ (279 mg, 0.381mmol, 0.02 eq) and NaHCO₃ (3.21 g, 38.2 mmol, 1.48 mL, 2.00 eq) in1,4-dioxane (40.0 mL) and H₂O (8.0 mL) was heated at 100° C. for 12 hunder N₂ atmosphere. To the mixture was added ethyl acetate (50 mL) andH₂O (20 mL). The two phases were separated and the aqueous phase wasextracted with ethyl acetate (2×50 mL). The combined organic phases weredried, filtered and concentrated. The residue was purified via columnchromatography on silica gel (eluting with petroleum to petroleumether:ethyl acetate=5:1) to give i-91 (3.80 g, 17.0 mmol) as an oil. ¹HNMR (400 MHz, DMSO-d₆) δ=7.55 (s, 1H), 6.90 (s, 1H), 5.16-5.08 (m, 1H),4.90-4.83 (m, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 2.02 (d, J=0.7 Hz, 3H).

General Procedure for Preparation of Compound i-92:

A solution of i-91 (3.80 g, 17.0 mmol, 1.00 eq) and Pd/C (906 mg, 8.51mmol, 0.50 eq) in MeOH (80.00 mL) was stirred at 20° C. under H₂ (50psi) for 12 h. The mixture was filtered and the solid was washed withMeOH (100 mL). Then the combined filtrates were concentrated to givei-92 (3.00 g, 15.4 mmol) as an oil which was used in the next stepwithout purification. ¹H NMR (400 MHz, DMSO-d₆) δ=6.59 (s, 1H), 6.31 (s,1H), 4.45 (s, 2H), 3.64 (s, 3H), 3.62 (s, 3H), 2.88 (td, J=6.7, 13.8 Hz,1H), 1.10 (d, J=6.6 Hz, 6H).

General Procedure for Preparation of Compound i-93:

The mixture of i-92 (1.02 g, 5.22 mmol, 3.50 eq), 5-bromopyrimidine-2,4(1H,3H)-dione (285 mg, 1.49 mmol, 1.00 eq) and hydroquinone (16.4 mg,149 umol, 0.10 eq) in ethylene glycol (6.00 mL) was stirred at 200° C.for 4 h and cooled to RT. One additional vial was set up as describedabove and heated at 200° C. for 4 h and cooled to RT. The two reactionmixtures were combined. To the mixture was added ethyl acetate (30 mL)and H₂O (10 mL).

The aqueous phase was separated and extracted with ethyl acetate (2×20mL). The organic phases were combined, dried over anhydrous Na₂SO₄,filtered and concentrated. The residue was purified via prep-HPLC togive i-93 (500 mg, 1.64 mmol) as a solid. ¹H NMR (400 MHz, DMSO-d₆)δ=11.26 (s, 1H), 10.21 (br d, J=4.4 Hz, 1H), 6.80 (s, 1H), 6.53 (s, 1H),6.38 (d, J=5.5 Hz, 1H), 5.92 (s, 1H), 3.73 (s, 3H), 3.66 (s, 3H), 3.01(quin, J=6.8 Hz, 1H), 1.13 (d, J=6.8 Hz, 6H).

General Procedure for Preparation of Compound i-94:

A mixture of i-93 (500 mg, 1.64 mmol, 1.00 eq) in PhPOCl₂ (2.76 mL, 19.7mmol, 12.00 eq) was degassed by sparging with N₂ for 3 times and thenstirred at 120° C. for 12 h under N₂ atmosphere. The reaction mixturewas poured over ice. Then ethyl acetate (30 mL) and H₂O (10 mL) wereadded in. The two phases were separated and the aqueous phase wasextracted with ethyl acetate (2×15 mL). The combined organic phases werewashed with saturated Na₂CO₃ (3×10 mL) and dried over anhydrous Na₂SO₄.Then filtered and concentrated to give i-94 (285 mg, 833 umol) as asolid which was used in the next step directly.

¹H NMR (400 MHz, CHLOROFORM-d) δ=7.76 (s, 1H), 6.86 (s, 1H), 6.66 (s,1H), 5.67 (s, 1H), 3.94 (s, 3H), 3.83 (s, 3H), 3.04 (td, J=6.7, 13.7 Hz,1H), 1.20 (d, J=7.1 Hz, 6H).

General Procedure for Preparation of Compound 30:

A solution of i-94 (285 mg, 833 umol, 1.00 eq) in NH₃/EtOH (20 N, 10 mL)in a sealed tube was placed in an autoclave. The mixture was stirred at140° C. for 48 h. The mixture was cooled to RT and concentrated. Theresidue was purified via prep- to give 50 mg of desired product whichwas further purified via prep-HPLC to give Compound 30 (14.0 mg, 46.2umol) as a solid. ¹H NMR (400 MHz, CHLOROFORM-d) δ=7.76 (s, 1H), 6.80(s, 1H), 6.09 (s, 1H), 4.91 (br s, 2H), 4.76 (s, 2H), 4.66 (s, 1H), 3.85(s, 3H), 3.72 (s, 3H), 3.04 (spt, J=6.8 Hz, 1H), 1.31 (d, J=6.6 Hz, 6H)LCMS: [M+H]⁺ 304.1

Example 33: Synthesis of Compound 31

Compound 31 was made by the synthetic method outlined in Scheme AJ:

General Procedure for Preparation of Compound i-95:

A solution of i-86 (300 mg, 660 umol, 1.00 eq, prepared as described inExample 26), CuI (6.29 mg, 33.0 umol, 0.05 eq), NaI (198 mg, 1.32 mmol,2.00 eq) and trans-N,N′-dimethyl-1,2-cyclohexanediamine (9.39 mg, 66.0umol, 0.10 eq) in 1,4-dioxane (5.00 mL) was stirred at 110° C. for 18 h,and cooled to RT. The reaction mixture was filtered and the solid waswashed with ethyl acetate (40 mL). The filtrate was concentrated and theresidue was purified via column chromatography on silica gel (elutingwith ethyl acetate) to give 360 mg of a solid which was a mixture ofdesired product, mono-Ac product and starting material. A secondreaction was run exactly as described and the crude reaction productswere combined to give 710 mg.

The solution of crude reaction mixture (710 mg) in Ac₂O (789 mg, 7.73mmol, 5.00 eq) was stirred at 100° C. for 15 min. The mixture wasadjusted to pH=7 with saturated Na₂CO₃ solution at 0° C. Then to themixture was added ethyl acetate (20 mL) and H₂O (5 mL).

The two phases were separated and the aqueous phase was extracted withethyl acetate (3×15 mL). The combined organic phases were dried overanhydrous Na₂SO₄, filtered and concentrated. The residue was purifiedvia prep-HPLC to give i-95 (220 mg, 439 umol) as a solid. ¹H NMR (400MHz, DMSO-d₆) δ=10.59 (s, 1H), 10.42 (s, 1H), 8.35 (s, 1H), 8.08 (s,1H), 3.89 (s, 3H), 3.50-3.42 (m, 1H), 2.21 (s, 3H), 2.16 (s, 3H), 1.07(d, J=6.6 Hz, 6H).

General Procedure for Preparation of Compound i-96:

A solution of i-95 (110 mg, 219 umol, 1.00 eq) and (bpy)CuSCF₃ (176 mg,549 umol, 2.50 eq) in diglyme (2.00 mL) was stirred at 130° C. for 16 hand cooled to RT. One additional vial was set up as described above. Thetwo cooled reaction mixtures were combined.

To the mixture was added ethyl acetate (20 mL) and H₂O (10 mL). The twophases were separated and the aqueous phase was extracted with ethylacetate (3×15 mL). The combined organic phases were dried over anhydrousNa₂SO₄ and then filtered and concentrated to give i-96 (180 mg, 415umol) as a solid which was used in the next step directly.

General Procedure for Preparation of Compound 31:

To the solution of i-96 (180 mg, 415 umol, 1.00 eq) in MeOH (1.60 mL)and H₂O (1.60 mL) was added KOH (93.2 mg, 1.66 mmol, 4.00 eq). Thesolution was stirred at 50° C. for 2 h and cooled to RT. To the mixturewas added ethyl acetate (10 mL) and H₂O (5 mL). The two phases wereseparated and the aqueous phase was extracted with ethyl acetate (3×10mL). The combined organic phases were dried over anhydrous Na₂SO₄,filtered and concentrated. The residue was purified via prep-TLC(CH₂Cl₂/MeOH=20/1) to give Compound 31 (90.0 mg, 230 umol) as a solid.¹H NMR (400 MHz, CHLOROFORM-d) S=8.11 (s, 1H), 7.35 (s, 1H), 5.23 (br s,2H), 4.96 (s, 2H), 4.00 (s, 3H), 3.50 (quin, J=6.7 Hz, 1H), 1.31 (d,J=6.8 Hz, 6H) LCMS: [M+H]⁺ 392.1

Example 34: Synthesis of Compound 32

Compound i-107 was made by the synthetic method outlined in Scheme AK:

General Procedure for Preparation of Compound i-106:

To a mixture of i-105 (5 g, 45.4 mmol, 1.00 eq) in DMF (100 mL) wasadded NaH (5.45 g, 136 mmol, 60% purity, 3.00 eq) in portions at 0° C.The mixture was stirred at 25° C. for 1 h. The mixture was cooled to 0°C. and paramethoxybenzyl chloride (17.8 g, 113 mmol, 2.50 eq) was addedinto the mixture at 0° C. The mixture was stirred for 13 h at 0° C. Themixture was poured into ice water (500 mL) and the mixture was extractedwith ethyl acetate (3×500 mL). The combined organic phases were washedwith brine (400 mL), dried over anhydrous Na₂SO₄, filtered andconcentrated in vacuum. The residue was purified via columnchromatography on silica gel to give i-106 (10.5 g, 30 mmol) as an oil.¹H NMR (400 MHz, Chloroform-d) δ=7.55 (d, J=8.0 Hz, 1H), 7.17 (d, J=8.0Hz, 2H), 7.07-6.99 (d, J=7.6 Hz, 2H), 6.89 (d, J=8.0 Hz, 4H), 6.08 (d,J=7.6 Hz, 1H), 4.88 (s, 2H), 4.50 (s, 2H), 3.82 (s, 6H).

General Procedure for Preparation of Compound i-107:

To a mixture of i-106 (10.5 g, 30.0 mmol, 1.00 eq) in DMF (100 mL) wasadded N-iodosuccinimide (6.74 g, 30.0 mmol, 1.00 eq) in portions. Thereaction mixture was stirred at 25° C. for 14 h. LCMS showed main peakwas the desired product. The reaction mixture was poured into ice-H₂O(500 mL). The aqueous phase was extracted with ethyl acetate (3×500 mL).

The combined organic phases were dried over anhydrous Na₂SO₄, filteredand concentrated in vacuum. The residue was purified by pre-HPLC to givei-107 (2.2 g, 4.62 mmol) as an oil which solidified gradually. ¹H NMR(400 MHz, Chloroform-d) δ=8.31 (s, 1H), 7.14 (d, J=8.8 Hz, 4H), 6.86 (d,J=9.2 Hz, 4H), 4.78 (s, 2H), 4.63 (s, 4H), 3.81 (s, 6H).

Compound 32 was made by the synthetic method outlined in Scheme AL:

General Procedure for Preparation of Compound i-98:

To the solution of i-97 (30.0 g, 164 mmol, 1.00 eq) in MeOH (300 mL) wasadded MeONa (10.9 g, 279 mmol, 1.70 eq). The mixture was stirred at 70°C. for 12 h. The mixture was concentrated. Then to the residue was addedethyl acetate (300 mL) and water (100 mL). The two phases were separatedand the aqueous phase was extracted with ethyl acetate (2×100 mL). Thecombined organic phases were dried over anhydrous Na₂SO₄, filtered andconcentrated. The residue was purified via column chromatography onsilica to give i-98 (22.7 g, 127 mmol) as a solid which was used in thenext step directly. ¹H NMR (400 MHz, CHLOROFORM-d) δ=7.57 (d, J=7.9 Hz,1H), 6.88 (d, J=7.9 Hz, 1H), 4.04 (s, 3H).

General Procedure for Preparation of Compound i-99:

To a solution of i-98 (23.0 g, 129 mmol, 1.00 eq) in 1,4-dioxane (500mL) and H₂O (200 mL) was added2-isopropenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (22.8 g, 135 mmol,1.05 eq), Cs₂CO₃ (84.2 g, 258 mmol, 2.00 eq) and Pd(PPh₃)₄ (14.9 g, 12.9mmol, 0.10 eq). The mixture was stirred at 80° C. under N₂ for 15 h. Themixture was filtered and the solid was washed with petroleum ether (100mL). The filtrate was separated and the organic phase was extracted withpetroleum ether (2×150 mL). The combined organic phases were dried overanhydrous Na₂SO₄, filtered and concentrated. The residue was purifiedvia column chromatography on silica gel to give i-99 (14.0 g, 75.8 mmol)as a liquid. ¹H NMR (400 MHz, CHLOROFORM-d) δ=7.58 (d, J=7.9 Hz, 1H),7.00 (d, J=7.9 Hz, 1H), 5.97 (dd, J=0.8, 1.9 Hz, 1H), 5.27 (quin, J=1.6Hz, 1H), 4.07-4.03 (m, 3H), 2.18-2.16 (m, 3H).

General Procedure for Preparation of Compound i-100:

To the solution of i-99 (14.0 g, 76.2 mmol, 1.00 eq) in EtOAc (500 mL)was added rhodium on Al₂O₃ (6.51 g, 63.2 mmol, 0.83 eq). The mixture wasstirred at 25° C. under H₂ balloon for 5 h. The mixture was filtered andthe solid was washed with ethyl acetate (100 mL). Then the filtrate wasconcentrated to give i-100 (13.1 g, 70.5 mmol) as a liquid.

¹H NMR (400 MHz, CHLOROFORM-d) δ=7.51 (d, J=7.7 Hz, 1H), 6.69 (d, J=7.9Hz, 1H), 4.02 (s, 2H), 4.04-4.01 (m, 1H), 2.94 (spt, J=6.8 Hz, 1H), 1.27(d, J=6.8 Hz, 6H).

General Procedure for Preparation of Compound i-101:

To the solution of i-100 (5.00 g, 26.9 mmol, 1.00 eq) in CH₃CN (50.0 mL)was added NIS (18.2 g, 80.8 mmol, 3.00 eq) and TFA (2 mL, 26.9 mmol,1.00 eq). The mixture was stirred at 25° C. for 15 h then at 80° C. for2 h. The mixture was filtered and the filtrate was adjust to pH=8 withsaturated NaHCO₃ solution. The mixture was partitioned between ethylacetate (60 mL) and water (30 mL). Then the aqueous layer was extractedwith ethyl acetate (2×30 mL). The combined organic layers were washedwith saturated Na₂SO₃ solution (2×30 mL) and dried over Na₂SO₄, filteredand concentrated. To the residue was added petroleum ether (60 mL). Themixture was stirred at 25° C. for 5 min and white solid was generated.Then the solid was filtered off and the filtrate was concentrated togive i-101 (6.70 g, 21.5 mmol) as a liquid.

¹H NMR (400 MHz, CHLOROFORM-d) δ=7.91 (s, 1H), 4.01 (s, 3H), 3.34 (spt,J=6.7 Hz, 1H), 1.22 (d, J=6.6 Hz, 6H).

General Procedure for Preparation of Compound i-102:

To the solution of i-101 (920 mg, 2.95 mmol, 1.00 eq) in 1,4-dioxane(16.0 mL) was added diphenylmethanimine (427 mg, 2.36 mmol, 0.80 eq),Cs₂CO₃ (2.41 g, 7.38 mmol, 2.50 eq), BINAP (368 mg, 590 umol, 0.20 eq)and Pd₂(dba)₃ (270 mg, 295 umol, 0.10 eq). The mixture was stirred at100° C. under N₂ for 15 h. The reaction mixture was filtered and thefilter cake was washed with ethyl acetate (50 mL). To the filtrate wasadded water (20 mL). The two phases were separated and the aqueous phasewas extracted with ethyl acetate (2×20 mL). The combined organic phaseswere dried over anhydrous Na₂SO₄, filtered and concentrated. The residuewas purified by column chromatography on silica gel to give i-102 (600mg, 1.64 mmol) as a liquid. ¹H NMR (400 MHz, CHLOROFORM-d) δ=7.80-7.75(m, 2H), 7.52-7.47 (m, 1H), 7.45-7.40 (m, 2H), 7.37-7.32 (m, 3H),7.13-7.08 (m, 2H), 6.67 (s, 1H), 3.97 (s, 3H), 3.30 (quin, J=6.8 Hz,1H), 1.19 (d, J=6.8 Hz, 6H).

General Procedure for Preparation of Compound i-103:

To a solution of i-102 (600 mg, 1.64 mmol, 1.00 eq) in THF (6.00 mL) andH₂O (1.50 mL) was added HCl (1 M, 3.28 mL, 2.00 eq). The mixture wasstirred at 25° C. for 2 h. The mixture was adjusted to pH=8 withsaturated Na₂CO₃ solution. To the mixture was added ethyl acetate (5 mL)and H₂O (3 mL). The two phases were separated and the aqueous layer wasextracted with ethyl acetate (3×10 mL). The combined organic layers werecombined, dried over Na₂SO₄ and concentrated. The residue was purifiedvia column chromatography on silica gel (eluting with petroleum ether:ethyl acetate=100:1 to 50:1) to give i-103 (300 mg, 1.50 mmol) as aliquid. ¹H NMR (400 MHz, CHLOROFORM-d) δ=7.03 (s, 1H), 3.96 (s, 3H),3.32 (brs, 2H), 2.95 (spt, J=6.7 Hz, 1H), 1.25 (d, J=6.8 Hz, 6H).

General Procedure for Preparation of Compound i-104:

To a solution of i-103 (250 mg, 1.25 mmol, 1.00 eq) in 1,4-dioxane (5.00mL) was added i-107 (357 mg, 750 umol, 0.60 eq), Cs₂CO₃ (1.02 g, 3.13mmol, 2.50 eq), Xantphos (145 mg, 250 umol, 0.20 eq) and Pd₂(dba)₃ (114mg, 125 umol, 0.10 eq). The mixture was stirred at 100° C. under N₂ for15 h. The reaction mixture was filtered and the filter cake was washedwith ethyl acetate (20 mL). To the mixture was added water (6 mL). Thenthe two phases were separated and the aqueous phase was extracted withethyl acetate (3×10 mL). The combined organic phases were dried overanhydrous Na₂SO₄, filtered and concentrated. The residue was purifiedvia prep-TLC (petroleum ether:ethyl acetate=1:1) to give i-104 (170 mg,309 umol) as a solid. ¹H NMR (400 MHz, CHLOROFORM-d) δ=7.66 (s, 1H),7.06 (d, J=8.6 Hz, 4H), 6.85 (d, J=8.6 Hz, 4H), 6.77 (s, 1H), 4.82 (s,2H), 4.67 (s, 4H), 4.49 (s, 1H), 3.94 (s, 3H), 3.80 (s, 6H), 2.52 (quin,J=6.7 Hz, 1H), 1.09 (d, J=6.6 Hz, 6H).

General Procedure for Preparation of Compound 32:

Batch 1: A solution of i-104 (50.0 mg, 91.0 umol, 1.00 eq) in TFA (0.50mL) was stirred at 80° C. under N₂ for 4 h.

Batch 2: A solution of i-104 (150 mg, 273 umol, 1.00 eq) in TFA (1.50mL) was stirred at 80° C. under N₂ for 4 h.

The above two reaction mixtures were combined. The mixture was adjust topH=8 with saturated Na₂CO₃ solution at 0° C. To the mixture was addedethyl acetate (15 mL) and water (5 mL). Then the two phases wereseparated and the aqueous phase was extracted with ethyl acetate (3×10mL). The combined organic phases were dried over anhydrous Na₂SO₄,filtered and concentrated. The residue was purified via prep-TLC to giveCompound 32 (48.0 mg, 153 umol) as a solid. ¹H NMR (400 MHz, DMSO-d₆)δ=7.48 (s, 1H), 6.54 (s, 1H), 6.35 (s, 1H), 6.07 (br s, 2H), 5.86 (s,2H), 3.84 (s, 3H), 3.29 (br d, J=6.6 Hz, 1H), 1.21 (br d, J=6.4 Hz, 6H)LCMS: [M+H]⁺ 309.1

Example 35: Synthesis of Compound 33

Compound 33 was made by the synthetic method outlined in Scheme AM:

General Procedure for Preparation of Compound i-108:

Compound 14 was prepared as described in Example 16. A mixture ofCompound 14 (2.00 g, 7.26 mmol, 1.00 eq) and Ac₂O (14.8 g, 145 mmol,20.0 eq) was stirred at 100° C. for 2 h. To the reaction mixture wasadded saturated aqueous Na₂CO₃ to adjust pH to 7. The aqueous layer wasextracted with ethyl acetate (3×10 mL). The organic layers werecombined, dried over Na₂SO₄ and concentrated. The residue was purifiedby prep-HPLC to give i-108 (1.30 g, 3.62 mmol) as a solid. ¹H NMR (400MHz, CHLOROFORM-d) δ=8.17 (br s, 1H), 7.90 (br s, 1H), 7.65 (s, 1H),7.17 (d, J=8.6 Hz, 1H), 6.60 (d, J=8.8 Hz, 1H), 3.96 (s, 3H), 3.15 (td,J=6.8, 13.7 Hz, 1H), 2.67 (s, 3H), 2.40 (s, 3H), 1.24 (d, J=6.8 Hz, 6H).

General Procedure for Preparation of Compound i-109:

To a solution of i-108 (100 mg, 278 umol, 1.00 eq) in CH₃CN (1.00 mL)was added NCS (74.3 mg, 557 umol, 2.00 eq). The mixture was stirred at80° C. for 5 h. The mixture was partitioned between ethyl acetate (5 mL)and water (10 mL). Then the aqueous layer was extracted with ethylacetate (3×8 mL). The combined organic layers were dried over Na₂SO₄,filtered and concentrated under reduced pressure. The residue waspurified by prep-TLC (petroleum ether: ethyl acetate=1:1) to give i-109(30.0 mg, 76.1 umol) as a solid. LCMS: [M+H]⁺ 352.1

General Procedure for Preparation of Compound 33:

To a solution of i-109 (100 mg, 284 umol, 1.00 eq) in MeOH (500 uL) andH₂O (500 uL) was added KOH (95.7 mg, 1.71 mmol, 6.00 eq). The mixturewas stirred at 50° C. for 2 h. The mixture was partitioned between EtOAc(3 mL) and water (5 mL). Then the aqueous layer was extracted with EtOAc(3×3 mL). The combined organic layers were dried over Na₂SO₄, filteredand concentrated under reduced pressure. The residue was purified byprep-HPLC to give Compound 33 (5.00 mg, 16.14 umol) as a solid. ¹H NMR(400 MHz, DMSO-d₆) δ=7.35 (s, 1H), 7.09 (s, 1H), 6.42 (br s, 2H), 5.83(s, 2H), 3.88 (s, 3H), 3.60 (br s, 1H), 1.18 (d, J=6.8 Hz, 6H) LCMS:[M+H]⁺ 310.1

Example 36: Synthesis of Compound 34

Compound 34 was made by the synthetic method outlined in Scheme AN:

General Procedure for Preparation of Compound i-111:

Compound i-110 (23 g, 106 mmol, 1.00 eq), Pd(dppf)Cl₂′CH₂Cl₂ (8.7 g,10.7 mmol, 0.10 eq),2-isopropenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (17.9 g, 106 mmol,1.00 eq) and Cs₂CO₃ (104 g, 319 mmol, 3.00 eq) were dissolved in H₂O (80mL) and dioxane (250 mL). The solution was heated to 100° C. for 16 h.One additional reaction was set up and identically as described aboveand heated to 100° C. for 16 h. The two reaction mixtures were cooled toRT and combined. The solvent was removed under vacuum. To the mixturewas added ice water (250 mL) and ethyl acetate (250 mL). The two phaseswere separated and the aqueous phase was extracted with ethyl acetate(3×100 mL). The combined organic phase was dried with anhydrous Na₂SO₄,filtered and concentrated. The residue was purified via columnchromatography on silica gel to give i-111 (20 g) as an oil. ¹H NMR (400MHz, CDCl₃-D₆) δ=7.96 (d, J=8.0 Hz, 1H), 7.48 (d, J=8.0 Hz, 1H), 6.06(s, 1H), 5.47 (s, 1H), 2.12 (s, 3H).

General Procedure for Preparation of Compound i-112:

Compound i-111 (4.0 g, 18 mmol, 1.00 eq) was dissolved in THF (40 mL).Rh/Al₂O₃ (1.3 g, 12.8 mmol, 0.71 eq) was added into the solution. Thereaction mixture was stirred under H₂ balloon at 25° C. for 1 h. Fouradditional reactions were set up as described above. All five reactionmixtures were combined. The mixture was filtered through a celite padand the filtrate was concentrated. The residue was purified by columnchromatography on silica gel to give i-112 (18 g, 74% yield) as an oil.LCMS: [M+H]⁺ 223.9

General Procedure for Preparation of Compound i-113: Compound i-112(18.0 g, 80.5 mmol, 1.00 eq) and NaOMe (17.4 g, 321 mmol, 4.00 eq) weredissolved in MeOH (200 mL). The suspension was heated to 80° C. for 16h. The reaction was cooled to RT. To the mixture was added ice water(200 mL) and ethyl acetate (200 mL). The two phases were separated andthe aqueous phase was extracted with ethyl acetate (3×100 mL). Thecombined organic phases were dried with anhydrous Na₂SO₄, filtered andconcentrated. The residue was purified by column chromatography onsilica gel to give i-113 (16.0 g). ¹H NMR (400 MHz, DMSO-D₆) δ=7.94 (d,J=8.0 Hz, 1H), 6.99 (d, J=7.6 Hz, 1H), 3.95 (s, 3H), 3.02-2.95 (m, 1H),1.23 (d, J=6.8 Hz, 6H).General Procedure for Preparation of Compound i-114:

Compound i-113 (4 g, 18.3 umol, 1.00 eq) and 1,3-dibromo-5,5-dimethyl-imidazolidine-2,4-dione (5.5 g, 19.2 mmol, 1.05eq) were dissolved in TFA (60 mL). The solution was stirred at 25° C.for 16 h. Saturated NaHCO₃ was added into the reaction solution at 0° C.to adjust pH=7-8. The aqueous phase was extracted with ethyl acetate(3×25 mL). The combined organic phase was washed with brine (2×25 mL),dried with anhydrous Na₂SO₄, filtered and concentrated. The residue waspurified by column chromatography on silica gel to give i-114 (3 g) asqn oil. ¹H NMR (400 MHz, CDCl₃-D₆) δ=7.89 (s, 1H), 4.03 (s, 3H),3.51-3.44 (m, 1H), 1.25 (d, J=8.8 Hz, 6H).

General Procedure for Preparation of Compound i-117:

Compound i-114 (0.75 g, 2.52 mmol, 1.00 eq), XPhos (0.12 g, 0.25 mmol,0.10 eq), Pd₂(dba)₃ (0.23 g, 0.250 mmol, 0.10 eq), Cs₂CO₃ (1.64 g, 5.04mmol, 2.00 eq) and Na₂S₂O₃.5H₂O (1.25 g, 5.04 mmol, 2.00 eq) weredissolved in t-BuOH (4 mL) and toluene (4 mL). The solution was heatedto 80° C. for 16 h and cooled to RT. One additional reaction was set upas described above, and cooled to RT after 16 h. The two reactionmixtures were combined. The reaction mixture was concentrated to drynessto give a residue which was crushed in MTBE (30 mL). The mixture wasfiltered and the filter cake was washed with MTBE (30 mL). The combineddried filter cake (2 g, crude i-115) was used in next step withoutpurification as brown solid.

Compound i-115 (2.0 g, crude) was dissolved in HCl (4 M, 13 mL, 10.3eq). The solution was cooled to 0° C. Zn (4.0 g, 60.4 mmol, 12 eq) wasadded into the solution at 0° C. The solution was warmed to 25° C. andstirred for 2 h. The mixture was filtered and the filtration was addedinto saturated NaHCO₃ to adjust pH to 7-8. The reaction solution wasextracted with DCM (3×10 mL) to give a solution of crude i-116. Theextracted solution was dried and used directly in next step.

To the extracted solution of i-116 in DCM (30 mL) was added DIEA (1.5 g,11.9 mmol, 1.50 eq) and BrCH₂CN (1.4 g, 11.9 mmol, 1.50 eq). Thesolution was heated to 50° C. for 16 h and cooled to RT. The reactionmixture was concentrated to give a residue which was purified by columnchromatography on silica gel to give i-117 (0.13 g) as anoil. ¹H NMR(400 MHz, CDCl₃-D₆) δ=8.04 (s, 1H), 4.08 (s, 3H), 3.82-3.80 (m, 1H),3.46 (s, 2H), 1.29 (d, J=6.4 Hz, 6H).

General Procedure for Preparation of Compound 34:

Compound i-117 (120 mg, 413 umol, 1.00 eq) and1-tert-butoxy-N,N,N′,N′-tetramethyl-methane diamine (144 mg, 826 umol,2.00 eq) were dissolved in DMF (3 mL). The solution was heated to 110°C. for 4 h and cooled to RT. To the mixture was added ethyl acetate (10mL) and water (10 mL). The two phases were separated and the aqueousphase was extracted with ethyl acetate (3×10 mL). The organic phaseswere combined and washed with brine (10 mL), dried over anhydrousNa₂SO₄, filtered and concentrated to give i-118 (130 mg, crude) whichwas used in next step without purification. LCMS: [M+H]⁺ 346.2 Crudei-118 (130 mg, 332 umol, 1.00 eq) and aniline (86 mg, 665 umol, 2.00 eq,HCl) were dissolved in DMF (3 mL). The solution was heated to 120° C.for 45 min and cooled to RT. To the mixture was added ethyl acetate (20mL) and water (10 mL). The two phases were separated and the aqueousphase was extracted with ethyl acetate (3×10 mL). The organic phaseswere combined and washed with brine (20 mL), dried over anhydrousNa₂SO₄, filtered and concentrated to give i-119 (130 mg, crude) whichwas used in next step without purification.

Crude i-119 (130 mg, 330 umol, 1.00 eq) and guanidine hydrochloride (126mg, 1.32 mmol, 4.00 eq) were dissolved in n-BuOH (3 mL). K₂CO₃ (182 mg,1.32 mmol, 4.00 eq) was added into the above solution. The suspensionwas heated to 110° C. for 16 h and cooled to RT. The mixture solutionwas concentrated. The residue was purified by reverse phase prep-HPLC.MeCN was removed under reduced pressure and then water was removed bylyophillization to give Compound 34 (14 mg, 118 umol) as a solid.

¹H NMR (400 MHz, CDCl₃-D₆) δ=8.11 (s, 1H), 7.33 (s, 1H), 5.24 (br. m.,2H), 4.97 (br. m., 2H), 4.02 (s, 3H), 3.58-3.52 (m, 1H), 1.30 (d, J=6.8Hz, 6H) LCMS: [M+H]⁺ 360.0

Example 37: Synthesis of Compound 35

Compound 35 was made by the synthetic method outlined in Scheme AO:

General Procedure for Preparation of Compound i-120:

To a solution of i-114 (1.00 g, 3.35 mmol, 1.00 eq, prepared asdescribed in Example 36) in dioxane (10.0 mL) was added Cs₂CO₃ (2.73 g,8.38 mmol, 2.50 eq), BINAP (209 mg, 335 umol, 0.10 eq) and Pd₂(dba)₃(307 mg, 335 umol, 0.10 eq) under N₂. Then diphenylmethanimine (911 mg,5.03 mmol, 1.50 eq) was added in. The mixture was stirred at 110° C. for22 h and cooled to RT. Water (25 mL) was added into the mixture. Theaqueous phase was extracted with ethyl acetate (4×8 mL). The combinedorganic phases were dried over anhydrous Na₂SO₄, filtered andconcentrated in vacuum to give brown oil. The residue was purified byprep-TLC to give i-120 (800 mg, 2.01 mmol) as an oil. ¹H NMR (400 MHz,Chloroform-d) δ=7.80 (d, J=7.3 Hz, 2H), 7.53-7.47 (m, 1H), 7.46-7.40 (m,2H), 7.36-7.31 (m, 3H), 7.13-7.06 (m, 2H), 6.85 (s, 1H), 3.99 (s, 3H),3.40 (spt, J=6.8 Hz, 1H), 1.22 (d, J 6.8 Hz, 6H).

General Procedure for Preparation of Compound i-121:

To a solution of i-120 (800 mg, 2.01 mmol, 1.00 eq) in THF (8.00 mL) andH₂O (1.50 mL) was added HCl (1 mol/L, 4.02 mL, 2.00 eq) slowly at 25° C.The mixture was stirred at 25° C. for 2.5 h. Water (33 mL) was addedinto the mixture. The aqueous phase was extracted with ethyl acetate(4×25 mL). The combined organic phases were washed with saturated NaHCO₃(40 mL) and dried over anhydrous Na₂SO₄, filtered and concentrated invacuum to give an oil. The residue was purified by prep-TLC to givei-121 (390 mg, 1.67 mmol) as a solid.

¹H NMR (400 MHz, DMSO-d₆) δ=7.31 (s, 1H), 4.94 (s, 2H), 3.84 (s, 3H),3.15 (td, J=6.7, 13.5 Hz, 1H), 1.16 (d, J=6.6 Hz, 6H).

General Procedure for Preparation of Compound i-122:

To a mixture of i-121 (195 mg, 832 umol, 1.00 eq) and i-107 (238 mg, 499umol, 0.60 eq, prepared as described in example 34) in dioxane (4.00 mL)was added Cs₂CO₃ (678 mg, 2.08 mmol, 2.50 eq), Xantphos (96.3 mg, 166umol, 0.20 eq) and Pd₂(dba)₃ (76.2 mg, 83.2 umol, 0.10 eq) under N₂. Themixture was stirred at 100° C. for 12 h and cooled to RT. Water (15 mL)was added. The aqueous phase was extracted with ethyl acetate (4×25 mL).The combined organic phases were dried over anhydrous Na₂SO₄, filteredand concentrated in vacuum to give a solid. The mixture was purified byprep-TLC to give i-122 (140 mg, 240 umol) as a solid.

¹H NMR (400 MHz, Chloroform-d) δ=7.65 (s, 1H), 7.04 (d, J=8.4 Hz, 4H),6.91 (s, 1H), 6.84 (d, J=8.4 Hz, 4H), 4.85 (s, 2H), 4.68 (s, 4H), 4.55(s, 1H), 3.95 (s, 3H), 3.80 (s, 6H), 2.60 (td, J=6.9, 13.4 Hz, 1H), 1.11(d, J=6.6 Hz, 6H).

General Procedure for Preparation of Compound 35:

A mixture of i-122 (140 mg, 240 umol, 1.00 eq) in TFA (1.80 mL) wasstirred at 80° C. for 3 h and cooled to RT. Ice-H₂O (5 mL) was added in.The pH was adjusted to around 8 by progressively adding saturated Na₂CO₃below 10° C. The aqueous phase was extracted with ethyl acetate (4×20mL). The combined organic phases were dried over anhydrous Na₂SO₄,filtered and concentrated in vacuum to give a solid. The residue waspurified by prep-TLC two times to give Compound 35 (51.7 mg, 151 umol)as a solid. ¹H NMR (400 MHz, Chloroform-d) δ=7.74 (s, 1H), 6.95 (s, 1H),4.90 (br s, 2H), 4.81 (br s, 2H), 4.62 (s, 1H), 3.99 (s, 3H), 3.15 (td,J=6.8, 13.3 Hz, 1H), 1.34 (d, J=6.6 Hz, 6H) LCMS: [M+H]⁺ 343.2

Example 38: Synthesis of Compound 36

Compound 36 was made by the synthetic method outlined in Scheme AP:

General Procedure for Preparation of Compound i-123:

To a mixture of i-100 (1.00 g, 5.39 mmol, 1.00 eq, prepared as describedin example 34) and methylsulfinyloxysodium (1.38 g, 13.5 mmol, 2.50 eq)in DMSO (10.0 mL) was added N,N-dimethylethylenediamine (190 mg, 2.16mmol, 0.40 eq) and copper (I) trifluoromethanesulfonate-benzene complex(543 mg, 1.08 mmol, 0.20 eq). The resulting reaction mixture was stirredat 120° C. under N₂ for 54 h. The reaction mixture was cooled to RT,filtered through a pad of celite and washed with ethyl acetate (50 mL).The filtrate was concentrated and then diluted with ethyl acetate (50mL) and water (50 mL). The two layers were separated and the aqueouslayer was extracted with ethyl acetate (2×50 mL). The combined organiclayers were washed with brine (10 mL), dried over Na₂SO₄, filtered andconcentrated under reduced pressure. The residue was purified by prepTLC to give i-123 (240 mg, 1.05 mmol) as an oil. ¹H NMR (400 MHz,Chloroform-d) δ=8.14 (d, J=7.9 Hz, 1H), 6.91 (d, J=7.7 Hz, 1H), 4.13 (s,3H), 3.22 (s, 3H), 3.03 (td, J=6.8, 13.7 Hz, 1H), 1.30 (d, J=7.1 Hz,6H).

General Procedure for Preparation of Compound i-124:

To a solution of i-123 (200 mg, 872 umol, 1.00 eq) in CH₃CN (2.00 mL)was added NIS (588 mg, 2.62 mmol, 3.00 eq) and TFA (99.4 mg, 872 umol,1.00 eq). The mixture was stirred at 80° C. for 15 h. NIS (98.1 mg, 436umol, 0.50 eq) and TFA (19.9 mg, 174 umol, 0.20 eq) was added in. Themixture was stirred at 80° C. for and additional 16 h and cooled to RT.Saturated Na₂SO₃ (20 mL) was added in. The aqueous phase was extractedwith ethyl acetate (4×20 mL). The combined organic phases were washedwith saturated NaHCO₃ (40 mL). The organic phase was dried overanhydrous Na₂SO₄, filtered and concentrated in vacuum. The residue waspurified by prep-TLC to give i-124 (270 mg, 760 umol) as a solid.

¹H NMR (400 MHz, Chloroform-d) δ=8.49 (s, 1H), 4.12 (s, 3H), 3.51-3.40(m, 1H), 3.22 (s, 3H), 1.26 (d, J=6.8 Hz, 6H).

General Procedure for Preparation of Compound i-125:

To i-124 (200 mg, 563 umol, 1.00 eq) in dioxane (1.60 mL) were addedCs₂CO₃ (458 mg, 1.41 mmol, 2.50 eq), BINAP (35.1 mg, 56.3 umol, 0.10 eq)and Pd₂(dba)₃ (51.5 mg, 56.3 umol, 0.10 eq) under N₂. Thendiphenylmethanimine (153 mg, 844 umol, 142 uL, 1.50 eq) was added in.The mixture was stirred at 110° C. for 16 h and cooled to RT. H₂O (5 mL)was added into the mixture. The aqueous phase was extracted with ethylacetate (4×5 mL). The combined organic phases were dried over anhydrousNa₂SO₄, filtered and concentrated in vacuum to give an oil. The residuewas purified by prep-TLC to afford i-125 (220 mg, 538 umol) as an oil.¹H NMR (400 MHz, Chloroform-d) δ=7.80 (d, J=7.0 Hz, 2H), 7.53-7.48 (m,1H), 7.46-7.40 (m, 2H), 7.36-7.32 (m, 3H), 7.23 (s, 1H), 7.10 (dd,J=2.9, 6.8 Hz, 2H), 4.07 (s, 3H), 3.43 (quin, J=6.8 Hz, 1H), 3.03 (s,3H), 1.24 (d, J=6.6 Hz, 6H)

General Procedure for Preparation of Compound i-126:

To a mixture of i-125 (220 mg, 538 umol, 1.00 eq) in THF (2.00 mL)/H₂O(400 uL) was added HCl (1 M, 38.5 uL, 2.00 eq) slowly at 25° C. Themixture was stirred at 25° C. for 12 h. Water (3 mL) was added into themixture. The aqueous phase was extracted with ethyl acetate (4×8 mL).The combined organic phases were washed with saturated NaHCO₃ (20 mL),dried over anhydrous Na₂SO₄, filtered and concentrated in vacuum to givean oil. The residue was purified by prep-TLC to give i-126 (100 mg, 409umol) as a solid. ¹H NMR (400 MHz, Chloroform-d) δ=7.56 (s, 1H), 4.05(s, 3H), 3.52 (br s, 2H), 3.21 (s, 3H), 3.03 (td, J=6.7, 13.5 Hz, 1H),1.28 (d, J=6.6 Hz, 6H)

General Procedure for Preparation of Compound i-127:

To a mixture of i-126 (60.0 mg, 245 umol, 1.00 eq) in dioxane (2.40 mL)was added i-107 (70.2 mg, 147 umol, 0.60 eq, prepared as described inExample 34), Cs₂CO₃ (200 mg, 614 umol, 2.50 eq), Xantphos (28.4 mg, 49.1umol, 0.20 eq) and Pd₂(dba)₃ (22.5 mg, 24.5 umol, 0.10 eq). The mixturewas stirred at 100° C. for 12 h under N₂. The reaction was cooled to RTand H₂O (5 mL) was added. The aqueous phase was extracted with ethylacetate (4×5 mL).

The combined organic phases were dried over anhydrous Na₂SO₄, filteredand concentrated in vacuum to give an oil. The mixture was purified byprep-TLC to give i-127 (38.0 mg, 64.1 umol) as a solid. ¹H NMR (400 MHz,Chloroform-d) δ=7.65 (s, 1H), 7.33 (s, 1H), 7.07 (d, J=8.8 Hz, 4H), 6.87(s, 2H), 6.85 (s, 2H), 4.78 (s, 2H), 4.66 (s, 4H), 4.57 (s, 1H), 4.03(s, 3H), 3.80 (s, 6H), 3.18 (s, 3H), 2.59-2.46 (m, 1H), 1.09 (d, J=6.6Hz, 6H)

General Procedure for Preparation of Compound 36:

First batch: A mixture of i-127 (5.00 mg, 8.44 umol, 1.00 eq) in TFA(60.0 uL) was stirred at 80° C. for 3 h. The reaction was cooled to RT.

Second and third batches, two reactions run in parallel: A mixture ofi-127 (38.0 mg, 1.00 eq) in TFA (450 uL) was stirred at 80° C. for 3 h.The reactions were cooled to RT.

The above three mixtures were combined and ice-H₂O (2 mL) was added in.The pH was adjusted to around 8 by progressively adding saturated Na₂CO₃below 10° C. The aqueous phase was extracted with ethyl acetate (4×10mL). The combined organic phases were dried over anhydrous Na₂SO₄,filtered and concentrated in vacuum. The residue was purified byprep-HPLC to give Compound 36 (16.8 mg, 36.8 umol, TFA salt) as a solid.

¹H NMR (400 MHz, DMSO-d₆) δ=11.84 (br s, 1H), 8.39 (br s, 1H), 7.76 (brs, 1H), 7.56 (br s, 1H), 7.48 (s, 1H), 7.20 (s, 1H), 6.82 (s, 1H), 3.99(s, 3H), 3.31-3.28 (m, 1H), 3.22 (s, 3H), 1.23 (d, J=6.6 Hz, 6H) LCMS:[M+H]⁺ 353.1

Example 39: Synthesis of Compound 37

Compound 37 was made by the synthetic method outlined in Scheme AQ:

General Procedure for Preparation of Compound i-129:

To a solution of i-128 (60.0 g, 273 mmol, 1.00 eq) in the mixture ofdichloromethane (400 mL) and methanol (440 mL) was added 1 M NaOHaqueous solution (1.00 L). Then a catalytic amount of TBAB (360 mg, 1.26mmol) was added. The reaction was stirred at 40° C. for 16 h and thencooled to RT. The reaction mixture was partitioned between DCM (500 mL)and water (500 mL). Then the aqueous layer was extracted withdichloromethane (3×300 mL). The combined organic layers were dried overNa₂SO₄, filtered and concentrated under reduced pressure. The crudeproduct was purified by column chromatography on silica gel to givecompound i-129 (43.1 g, 186 mmol) as a solid.

¹H NMR (400 MHz, Chloroform-d) δ=8.00 (d, J=9.3 Hz, 1H), 7.23 (d, J=2.6Hz, 1H), 6.93 (dd, J=2.6, 9.3 Hz, 1H), 3.90 (s, 3H)

General Procedure for Preparation of Compound i-130:

To a solution of i-129 (40.0 g, 172 mmol, 1.00 eq) and potassium2-propenyltrifluoroborate (51.0 g, 344 mmol, 2.00 eq) in toluene (200mL) was added Pd(dppf)Cl₂ (12.6 g, 17.2 mmol, 0.10 eq) and K₂CO₃ (71.5g, 517 mmol, 3.00 eq). The reaction mixture was stirred at 100° C. for12 h under N₂ atmosphere and cooled to RT. One additional vial was setup as described above and the reaction carried out identically. The tworeaction mixtures were combined and were partitioned between ethylacetate (200 mL) and water (200 mL). The aqueous layer was extractedwith ethyl acetate (3×200 mL). Then the combined organic layers weredried over Na₂SO₄, filtered and concentrated under reduced pressure. Theresidue was purified by column chromatography on silica gel to givecompound i-130 (45.0 g, 233 mmol) as an oil. ¹H NMR (400 MHz,Chloroform-d) δ=8.01 (d, J=8.8 Hz, 1H), 6.86 (dd, J=2.9, 9.0 Hz, 1H),6.76 (d, J=2.6 Hz, 1H), 5.17-5.14 (m, 1H), 4.93 (s, 1H), 3.90 (s, 3H),2.08 (s, 3H)

General Procedure for Preparation of Compound i-131:

To a solution of i-130 (45.0 g, 233 mmol, 1.00 eq) in methanol (800 mL)was added Pd/C (4.18 g, 1.97 mmol, 5% w.t.). The mixture was stirred at25° C. under H₂ (50 psi) for 12 h. The reaction mixture was filteredthrough celite under nitrogen and washed with methanol (300 mL). To thefiltrate was added 12M HCl (40.0 mL). Then the mixture was concentratedto give compound i-132 (53.7 g, crude, HCl) as a solid which was usedfor the next step directly.

¹H NMR (400 MHz, DMSO-d₆) δ=10.16 (br. s., 3H), 7.38-7.32 (m, 1H), 6.91(d, J=2.6 Hz, 1H), 6.86-6.80 (m, 1H), 3.73 (s, 3H), 3.08 (td, J=6.7,13.6 Hz, 1H), 1.16 (d, J=7.1 Hz, 6H)

General Procedure for Preparation of Compound i-132:

A solution of i-131 (3.00 g, 14.8 mmol, 1.00 eq) and tosyl chloride(3.69 g, 19.3 mmol, 1.30 eq) in pyridine (30 mL) was stirred at 80° C.for 5 h. The reaction mixture was partitioned between ethyl acetate (30mL) and water (30 mL) and the aqueous layer was extracted with ethylacetate (3×30 mL). The combined organic layer was washed with 0.5 M HCl(3×50 mL), dried over Na₂SO₄, filtered and concentrated under reducedpressure to give i-132 (4.06 g, 12.7 mmol) as a solid which was used inthe next step directly.

¹H NMR (400 MHz, Chloroform-d) δ=7.59-7.54 (m, 2H), 7.23 (d, J=7.9 Hz,2H), 7.10 (d, J=8.4 Hz, 1H), 6.71 (d, J=3.1 Hz, 1H), 6.68-6.63 (m, 1H),6.12 (s, 1H), 3.79 (s, 3H), 2.88-2.77 (m, 1H), 2.40 (s, 3H), 0.96 (d,J=6.6 Hz, 6H)

General Procedure for Preparation of Compound i-133:

To a solution of i-132 (10 g, 31.3 mmol, 1.00 eq) in CH₃CN (100 mL) wasadded TFA (4.93 g, 43.2 mmol, 3.2 mL, 1.38 eq) and NIS (7.04 g, 31.3mmol, 1.00 eq) at 0° C. The mixture was stirred at 80° C. for 17 h andcooled to RT. The reaction mixture was partitioned between ethyl acetate(100 mL) and water (100 mL). Then the aqueous layer was extracted withethyl acetate (2×50 mL). The combined organic layers were washed withbrine (50 mL), dried over Na₂SO₄, filtered and concentrated underreduced pressure. The crude product was purified by columnchromatography on silica gel to give i-133 (8.20 g, 18.4 mmol) as asolid which was used in the next step. ¹H NMR (400 MHz, chloroform-d)δ=7.58-7.54 (m, 2H), 7.24-7.21 (m, 2H), 7.13 (s, 1H), 6.68 (s, 1H), 3.85(s, 3H), 2.87 (m, 1H), 2.39 (s, 3H), 0.95 (d, J=6.6 Hz, 6H)

General Procedure for Preparation of Compound i-134:

The solution of i-133 (2.00 g, 4.49 mmol, 1.00 eq), sodiummethylsulfinate (1.15 g, 11.2 mmol, 2.50 eq), CuI (171 mg, 898 umol,0.20 eq), (1S,2S)-cyclohexane-1,2-diamine (205 mg, 1.80 mmol, 0.40 eq)in DMSO (20.0 mL) was stirred at 120° C. under N₂ atmosphere for 20 hand cooled to RT. Water (120 mL) was added in. The aqueous phase wasextracted with ethyl acetate (4×50 mL). The combined organic phases weredried over anhydrous Na₂SO₄, filtered and concentrated in vacuum to givean oil. The residue was purified by column chromatography on silica gelto give i-134 (1.00 g, 2.52 mmol) as a solid. ¹H NMR (400 MHz, DMSO-d₆)δ=7.52-7.50 (m, 1H), 7.39-7.34 (m, 3H), 7.24 (s, 1H), 7.08-7.03 (m, 1H),3.93 (s, 3H), 3.16-3.13 (s, 3H), 2.52 (m, 1H), 2.36 (s, 3H), 0.98 (d,J=6.8 Hz, 6H)

General Procedure for Preparation of Compound i-135:

Compound i-134 (900 mg, 2.26 mmol, 1.00 eq), PhOH (453 mg, 4.81 mmol,2.13 eq) and hydrogen bromide (28.9 mmol, 4.48 mL, 35%, 12.77 eq) wereadded to a round bottomed flask. The mixture was stirred for 12 h at 40°C. The pH was adjusted to approximately pH 9-10 by progressively addingNaOH (6 mol/L). Then H₂O (15 mL) was added in. The mixture was extractedwith ethyl acetate (4×30 mL). The combined organic phases were driedover anhydrous Na₂SO₄, filtered and concentrated under vacuum. Theresidue was purified by column chromatography on silica gel and furtherpurified by prep-HPLC. The mixture from prep-HPLC was adjusted to pH 9with saturated NaHCO₃. The aqueous phase was extracted with ethylacetate (4×200 mL). The combined organic phases were dried overanhydrous Na₂SO₄, filtered and concentrated in vacuum to give i-135 (290mg, 1.19 mmol) as a solid.

¹H NMR (400 MHz, Chloroform-d) δ=7.28 (s, 1H), 6.85 (s, 1H), 3.94 (s,3H), 3.20 (s., 3H), 2.99-2.92 (m, 1H), 1.29-1.27 (d, J=7.1 Hz, 6H)

General Procedure for Preparation of Compound i-135:

To a mixture of i-135 (50 mg, 205 umol, 1.00 eq) and i-107 (58.7 mg, 123umol, 0.60 eq, prepared as described in example 34) in dioxane (2.00 mL)was added Xantphos (23.8 mg, 41 umol, 0.20 eq) and Cs₂CO₃ (134 mg, 0.41mmol, 2.50 eq). The resulting reaction mixture was degassed with N₂three times and Pd₂(dba)₃ (18.8 mg, 20.6 umol, 0.10 eq) was added underN₂. The mixture was stirred at 100° C. for 14 h under N₂ and cooled toRT. Three additional vials were set up as described above and thereactions carried out in an identical manner. All four reaction mixtureswere combined. The reaction mixtures were poured into H₂O (5 mL). Theaqueous phase was extracted with ethyl acetate (3×5 mL). The combinedorganic layers were washed with brine (5 mL), dried over anhydrousNa₂SO₄, filtered and concentrated in vacuum. The mixture was purified byprep-TLC to give i-135 (62 mg, crude) as a solid. LCMS: [M+H]⁺ 592.4

General Procedure for Preparation of Compound 37:

A mixture of i-135 (62 mg, 105 umol, 1.00 eq) in TFA (0.5 mL) wasstirred at 80° C. for 14 h under N₂, and the reaction cooled to RT. ThepH was adjusted to approximately 8 by progressively adding saturatedaqueous Na₂CO₃ (2 mL) below 10° C. The aqueous phase was extracted withethyl acetate (2×5 mL). The combined organic layers were washed withbrine (2×5 mL), dried over anhydrous Na₂SO₄, filtered and concentratedin vacuum. The residue was purified by prep-TLC to give a crude solidwhich was purified by prep-HPLC to give Compound 37 (5.0 mg, 14 umol) asa solid. ¹H NMR (400 MHz, Methanol-d₄) δ=7.70 (s, 1H), 7.04 (s, 1H),6.94 (s, 1H), 4.93 (br s, 2H), 4.82 (br s, 2H), 4.77 (s, 1H), 3.96 (s,3H), 3.17 (s, 3H), 3.10 (m, 1H), 1.34 (d, J=6.8 Hz, 6H) LCMS: [M+H]⁺352.0

Example 40: Synthesis of Compound 38

Compound 38 was made by the synthetic method outlined in Scheme AR:

General Procedure for Preparation of Compound i-137:

To the solution of i-136 (30.0 g, 164 mmol, 1.00 eq) in MeOH (300 mL)was added MeONa (10.9 g, 279 mmol, 1.70 eq). The mixture was stirred at70° C. for 12 h and cooled to RT. The mixture was concentrated undervacuum. Then to the residue was added ethyl acetate (300 mL) and water(100 mL). The two phases were separated and the aqueous phase wasextracted with ethyl acetate (2×100 mL). The combined organic phaseswere dried over anhydrous Na₂SO₄, filtered and concentrated. The residuewas purified via column chromatography on silica gel to give i-137 (22.7g, 127 mmol) as a solid which was used for the next step directly. ¹HNMR (400 MHz, CHLOROFORM-d) δ=7.57 (d, J=7.9 Hz, 1H), 6.88 (d, J=7.9 Hz,1H), 4.04 (s, 3H)

General Procedure for Preparation of Compound i-138:

To a solution of i-137 (23.0 g, 129 mmol, 1.00 eq) in 1,4-dioxane (500mL) and H₂O (200 mL) was added2-isopropenyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (22.8 g, 135 mmol,1.05 eq), Cs₂CO₃ (84.2 g, 258 mmol, 2.00 eq) and Pd(PPh₃)₄ (14.9 g, 12.9mmol, 0.10 eq).

The mixture was stirred at 80° C. under N₂ for 15 h and cooled to RT.The mixture was filtered and the solid was washed with petroleum ether(100 mL). The filtrate was separated and the organic phase was extractedwith petroleum ether (2×150 mL). The combined organic phases were driedover anhydrous Na₂SO₄, filtered and concentrated. The residue waspurified via column chromatography on silica gel (eluting with petroleumether) to give i-138 (14.0 g, 75.8 mmol) as a liquid. ¹H NMR (400 MHz,CHLOROFORM-d) δ=7.58 (d, J=7.9 Hz, 1H), 7.00 (d, J=7.9 Hz, 1H), 5.97(dd, J=0.8, 1.9 Hz, 1H), 5.27 (quin, J=1.6 Hz, 1H), 4.07-4.03 (m, 3H),2.18-2.16 (m, 3H)

General Procedure for Preparation of Compound i-139:

To the solution of i-138 (14.0 g, 76.2 mmol, 1.00 eq) in EtOAc (500 mL)was added rhodium on Al₂O₃ (6.51 g, 63.2 mmol, 0.83 eq). The mixture wasstirred at 25° C. under H₂ balloon for 5 h. The mixture was filtered andthe solid was washed with ethyl acetate (100 mL). Then the filtrate wasconcentrated to give i-139 (13.1 g, 70.5 mmol) as a liquid.

¹H NMR (400 MHz, CHLOROFORM-d) δ=7.51 (d, J=7.7 Hz, 1H), 6.69 (d, J=7.9Hz, 1H), 4.02 (s, 2H), 4.04-4.01 (m, 1H), 2.94 (spt, J=6.8 Hz, 1H), 1.27(d, J=6.8 Hz, 6H)

General Procedure for Preparation of Compound i-140:

To the solution of i-139 (5.00 g, 26.9 mmol, 1.00 eq) in CH₃CN (50.0 mL)was added NIS (18.2 g, 80.8 mmol, 3.00 eq) and TFA (2 mL, 26.9 mmol,1.00 eq). The mixture was stirred at 25° C. for 15 h then at 80° C. for2 h and cooled to RT. The mixture was filtered and the filtrate wasadjust to pH=8 with saturated NaHCO₃ solution. The mixture waspartitioned between ethyl acetate (60 mL) and water (30 mL). Then theaqueous layer was extracted with ethyl acetate (2×30 mL). The combinedorganic layers were washed with saturated Na₂SO₃ solution (2×30 mL) anddried over Na₂SO₄, filtered and concentrated. To the residue was addedpetroleum ether (60 mL). The mixture was stirred at 25° C. for 5 min andwhite solid was generated. Then the solid was filtered off and thefiltrate was concentrated to give i-140 (6.70 g, 21.5 mmol) as a liquid.¹H NMR (400 MHz, CHLOROFORM-d) δ=7.91 (s, 1H), 4.01 (s, 3H), 3.34 (spt,J=6.7 Hz, 1H), 1.22 (d, J=6.6 Hz, 6H)

General Procedure for Preparation of Compound i-141:

Compound i-140 (1.50 g, 4.81 mmol, 1.00 eq), Pd₂(dba)₃ (440 mg, 481umol, 0.10 eq), Xantphos (278 mg, 481 umol, 0.10 eq), DIEA (1.24 g, 9.63mmol, 2.00 eq) and methyl 2-sulfanylacetate (613 mg, 5.78 mmol, 1.20 eq)were dissolved in dioxane (16 mL). The solution was heated to 80° C. for16 h and cooled to RT. One additional reaction was set up as describedabove and carried out in an identical manner. The two reaction mixtureswere combined. To the mixture was added ethyl acetate (20 mL) and water(20 mL). The two phases were separated and the aqueous phase wasextracted with ethyl acetate (3×20 mL). The organic phases were combinedand washed with brine (20 mL), dried over anhydrous Na₂SO₄, filtered andconcentrated. The residue was purified by MPLC to give i-141 (2.30 g,7.94 mmol) as an oil which was used in the next step directly. ¹H NMR(400 MHz, CDCl₃-d) δ=7.73 (s, 1H), 4.02 (s, 3H), 3.70 (s, 3H), 3.68-3.63(m, 1H), 3.47 (s, 2H), 1.23 (d, J=6.4 Hz, 6H)

General Procedure for Preparation of Compound i-142:

To a solution of NH₃ (10 M, 9 mL, 10.00 eq) in MeOH (30 mL) was addedi-141 (2.30 g, 9.01 mmol, 1.00 eq). The mixture was stirred at 25° C.for 12 h. The solvent was removed in vacuo to give i-142 (2.00 g, 7.28mmol) as a solid which was used in next step without purification. ¹HNMR (400 MHz, CDCl₃-d) δ=7.63 (s, 1H), 6.73 (br, 1H), 5.91 (br, 1H),4.01 (s, 3H), 3.61-3.56 (m, 1H), 3.46 (s, 2H), 1.23 (d, J=6.8 Hz, 6H)

General Procedure for Preparation of Compound i-143:

To a solution of i-142 (2.00 g, 7.28 mmol, 1.00 eq) and TEA (2.95 g,29.1 mmol, 4.00 eq) in CHCl₃ (30 mL) was added TFAA (3.06 g, 14.6 mmol,2.00 eq) at 0° C. The mixture was warmed to 25° C. and stirred for 1 h.To the mixture was added ice water (25 mL). The two phases wereseparated and the aqueous phase was extracted with ethyl acetate (3×10mL). The combined organic phases were dried over anhydrous Na₂SO₄,filtered and concentrated. The residue was purified via columnchromatography on silica gel to give i-143 (1.40 g, 5.45 mmol) as anoil. ¹H NMR (400 MHz, CDCl₃-d) δ=7.83 (s, 1H), 4.05 (s, 3H), 3.76-3.66(m, 1H), 3.45 (s, 2H), 1.26 (d, J=6.4 Hz, 6H)

General Procedure for Preparation of Compound i-144:

Compound i-143 (600 mg, 2.34 mmol, 1.00 eq) and 1-tert-butoxy-N, N, N′,N′-tetramethyl-methanediamine (814 mg, 4.67 mmol, 2.00 eq) weredissolved in DMF (7 mL). The solution was heated to 110° C. for 1 h andcooled to RT. To the mixture was added ethyl acetate (15 mL) and water(15 mL). The two phases were separated and the aqueous phase wasextracted with ethyl acetate (3×15 mL). The organic phases were combinedand washed with brine (15 mL), dried over anhydrous Na₂SO₄, filtered andconcentrated to give i-144 (600 mg, crude) which was used in next stepwithout purification. LCMS: [M+H]⁺ 312.2

General Procedure for Preparation of Compound i-145:

Compound i-144 (600 mg, 1.68 mmol, 1.00 eq), aniline hydrochloride (435mg, 3.36 mmol, 2.00 eq) were dissolved in DMF (8 mL). The solution washeated to 120° C. for 1 h and cooled to RT. To the mixture was addedethyl acetate (20 mL) and water (10 mL). The two phases were separatedand the aqueous phase was extracted with ethyl acetate (3×10 mL). Thecombined organic phases were washed with brine (20 mL), dried overanhydrous Na₂SO₄, filtered and concentrated to give i-145 (600 mg,crude) which was used in next step without purification.

General Procedure for Preparation of Compound 38:

Compound i-145 (600 mg, 1.67 mmol, 1.00 eq) and guanidine hydrochloride(638 mg, 6.68 mmol, 4.00 eq) were dissolved in n-BuOH (8 mL). Then K₂CO₃(923 mg, 6.68 mmol, 4.00 eq) was added. The suspension was heated to110° C. for 16 h, and then cooled to RT. To the mixture was added ethylacetate (20 mL) and water (20 mL). The two phases were separated and theaqueous phase was extracted with ethyl acetate (3×20 mL). The organicphases were combined and dried over anhydrous Na₂SO₄, filtered andconcentrated. The residue was purified by reverse phase prep-HPLC. MeCNwas removed under reduced pressure and then water was removed bylyophillization to give Compound 38 (65.1 mg, 0.20 mmol) as a solid.

¹H NMR (400 MHz, DMSO-d₆) δ=7.92 (s, 1H), 7.16 (s, 1H), 6.61 (br, 2H),6.43 (s, 2H), 3.91 (s, 3H), 3.47-3.41 (m, 1H), 1.21 (d, J=6.8 Hz, 6H)LCMS: [M+H]⁺ 325.9

Example 41: Synthesis of Compound 39

Compound 39 was made by the synthetic method outlined in Scheme AS:

General Procedure for Preparation of Compound i-147:

To a solution of i-146 (50.0 g, 227 mmol, 1.00 eq) in dichloromethane(500 mL) and methanol (500 mL) was added the solution of NaOH (36.4 g,909 mmol, 4.00 eq) in H₂O (360 mL). The reaction was stirred at 40° C.for 16 h and cooled to RT. The reaction mixture was partitioned betweendichloromethane (500 mL) and water (500 mL). Then the aqueous layer wasextracted with dichloromethane (3×300 mL). The combined organic layerswere dried over Na₂SO₄, filtered and concentrated under reducedpressure. The crude product was purified by column chromatography onsilica gel to give i-147 (50 g, 215 mmol) as a solid.

¹H NMR (400 MHz, Chloroform-d) δ=8.00 (d, J=9.3 Hz, 1H), 7.23 (d, J=2.8Hz, 1H), 6.93 (dd, J=2.7, 9.2 Hz, 1H), 3.90 (s, 3H)

General Procedure for Preparation of Compound i-148:

To a solution of i-147 (50.0 g, 215 mmol, 1.00 eq), K₂CO₃ (59.6 g, 431mmol, 2.00 eq) and isopropenylboronic acid pinacol ester (33.5 g, 226mmol, 1.05 eq) in THF (800 mL) and H₂O (200 mL) was added Pd(dppf)Cl₂(1.58 g, 2.15 mmol, 0.01 eq) under N₂. The resulting reaction mixturewas degassed four times back filling with N₂ each time and the mixturewas stirred at 70° C. for 15 h under N₂ atmosphere. The reaction mixturewas cooled to RT, filtered through a pad of celite and washed with ethylacetate (500 mL). The filtrate was concentrated and then diluted withethyl acetate (500 mL) and water (500 mL). The two layers were separatedand the aqueous layer was extracted with ethyl acetate (2×500 mL). Thecombined organic layers were washed with brine (500 mL), dried overNa₂SO₄, filtered and concentrated under reduced pressure. The residuewas dissolved with petroleum ether (250 mL).

Then the mixture was filtered and the filtrate was concentrated to givecompound i-148 (40.0 g, 207 mmol) as an oil. LCMS: [M+H]⁺ 193.7

General Procedure for Preparation of Compound i-149:

To a solution of i-148 (30.0 g, 155 mmol, 1.00 eq) in methanol (300 mL)was added Pd/C (3.0 g, 5% w.t.). The mixture was stirred at 50° C. underH₂ (50 psi) for 5 h. The reaction mixture was cooled and filteredthrough celite and washed with methanol (500 mL).

The mixture was concentrated under reduced pressure. The crude productwas purified by column chromatography on silica gel to give i-149 (25.0g, 151 mmol) as a solid which was used in the next step directly. LCMS:[M+H]⁺ 165.8

General Procedure for Preparation of Compound i-150:

A solution of i-149 (30.0 g, 182 mmol, 1.00 eq) and TosCl (45.0 g, 236mmol, 1.30 eq) in pyridine (300 mL) was stirred at 80° C. for 5 h andcooled to RT. The reaction mixture was partitioned between ethyl acetate(300 mL) and water (300 mL) and the aqueous layer was extracted withethyl acetate (2×500 mL). The combined organic layers were washed with0.5 M HCl (2×500 mL), dried over Na₂SO₄, filtered and concentrated underreduced pressure. The crude product was purified by columnchromatography on silica gel to give i-150 (50 g, 156 mmol) as an oil.¹H NMR (400 MHz, Chloroform-d) δ=7.59-7.54 (m, 2H), 7.23 (d, J=7.9 Hz,2H), 7.10 (d, J=8.4 Hz, 1H), 6.71 (d, J=3.1 Hz, 1H), 6.68-6.63 (m, 1H),6.12 (s, 1H), 3.79 (s, 3H), 2.88-2.77 (m, 1H), 2.40 (s, 3H), 0.96 (d,J=6.6 Hz, 6H)

General Procedure for Preparation of Compound i-151:

To a solution of i-150 (10.0 g, 31.3 mmol, 1.00 eq) in CH₃CN (100 mL)was added TFA (4.93 g, 43.2 mmol, 1.38 eq) and NCS (4.18 g, 31.3 mmol,1.00 eq) at 0° C. Then the mixture was stirred at 80° C. for 5 h. Thereaction mixture was cooled to RT and partitioned between ethyl acetate(200 mL) and water (200 mL). Then the aqueous layer was extracted withethyl acetate (2×100 mL). The combined organic layers were dried overNa₂SO₄, filtered and concentrated under reduced pressure. The crudeproduct was purified by column chromatography on silica gel to givei-151 (10 g, crude) as a solid. ¹H NMR (400 MHz, chloroform-d)δ=7.59-7.54 (m, 2H), 7.27-7.21 (m, 2H), 7.15 (s, 1H), 6.71 (s, 1H), 3.88(s, 3H), 2.91 (quin, J=6.8 Hz, 1H), 2.41 (s, 3H), 0.99 (d, J=6.8 Hz, 6H)

General Procedure for Preparation of Compound i-152:

To a mixture of i-151 (9.0 g, 25.4 mmol, 1.00 eq) and phenol (2.39 g,25.4 mmol, 1.0 eq) was added hydrogen bromide in HOAc (70 mL). Themixture was stirred for 15 h at 40° C. The reaction mixture was cooledto RT, and adjusted to pH 9 by progressively adding aqueous NaOH (6mol/L, 200 mL). The mixture was extracted with ethyl acetate (200 mL).The two layers were separated and the aqueous layers were extracted withethyl acetate (2×100 mL).

The combined organic phases were dried over anhydrous Na₂SO₄, filteredand concentrated in vacuum. The residue was purified by prep-HPLC togive i-152 (2.0 g, 10.0 mmol) as an oil.

¹H NMR (400 MHz, Chloroform-d) δ=6.77 (s, 1H), 6.75 (s, 1H), 3.85 (s,3H), 2.93-2.85 (m, 1H), 2.55 (br s, 2H), 1.26 (d, J=6.8 Hz, 6H)

General Procedure for Preparation of Compound i-153:

To a mixture of i-152 (40.0 mg, 200 umol, 1.00 eq) in 1,4-dioxane (2.00mL) was added i-107 (57.2 mg, 120 umol, 0.60 eq, prepared as describedin example 34), Cs₂CO₃ (163 mg, 500 umol, 2.50 eq), Xantphos (23.2 mg,40.1 umol, 0.20 eq) and Pd₂(dba)₃ (18.3 mg, 20.0 umol, 0.10 eq). Themixture was stirred at 100° C. for 12 h under N₂. One additional vialwas set up as described above and the reaction run in an identicalmanner. The two reaction mixtures were combined. The mixture wasfiltered and concentrated in vacuum to give an oil. The mixture was thenpurified by prep-HPLC to give i-153 (22.0 mg, 40.1 umol) as a solid.

¹H NMR (400 MHz, chloroform-d) δ=7.32 (s, 1H), 7.06 (d, J=8.6 Hz, 4H),6.90 (d, J=8.6 Hz, 4H), 6.77-6.71 (m, 1H), 6.52 (s, 1H), 4.85 (s, 4H),3.86 (s, 3H), 3.82 (s, 6H), 3.79 (s, 2H), 2.39-2.33 (m, 1H), 1.02 (d,J=6.8 Hz, 6H)

General Procedure for Preparation of Compound 39:

A mixture of i-153 (18.0 mg, 32.8 umol, 1.00 eq) in TFA (1.0 mL) wasstirred at 80° C. for 14 h and cooled to RT. The pH was adjusted toapproximately 8 by progressively adding saturated Na₂CO₃ (2 mL) below10° C. The aqueous phase was extracted with ethyl acetate (2×5 mL). Thecombined organic phases were dried over anhydrous Na₂SO₄, filtered andconcentrated in vacuum. The residue was purified by prep-HPLC to giveCompound 39 (4.1 mg, 13.3 umol, TFA) as a solid. ¹H NMR (400 MHz,Methanol-d₄) δ=6.99 (s, 1H), 6.97 (s, 1H), 6.80 (s, 1H), 3.86 (s, 3H),3.18-3.04 (m, 1H), 1.26 (d, J=6.8 Hz, 6H) LCMS: [M+H]⁺ 308.1

Example 42: Synthesis of Compound 40

Compound 40 was made by the synthetic method outlined in Scheme AT:

General Procedure for Preparation of Compound i-155:

To a solution of i-154 (5.0 g, 26.2 mmol, 1.00 eq) in CCl₄ (40.0 mL) wasadded NBS (4.66 g, 26.2 mmol, 1.00 eq). Then the mixture was stirred at80° C. for 4 h and cooled to RT. The reaction mixture was quenched byaddition aqueous NaOH (50 mL, 1M) at 25° C.

Then the aqueous layer was extracted with ethyl acetate (2×50 mL). Thecombined organic layers were dried over Na₂SO₄, filtered andconcentrated under reduced pressure. The crude product was purified bycolumn chromatography on silica gel (eluted from petroleum ether/ethylacetate=20/1 to petroleum ether/ethyl acetate=15/1) to give i-155 (2.8g, 10.4 mmol) as a solid. ¹H NMR (400 MHz, chloroform-d) δ=7.11 (s, 1H),7.00 (s, 1H), 3.93 (br s, 2H), 3.83 (s, 3H)

General Procedure for Preparation of Compound i-156:

To a solution of i-155 (1.5 g, 5.55 mmol, 1.00 eq), NaHCO₃ (0.93 g, 11.1mmol, 2.00 eq) and isopropenylboronic acid pinacol ester (1.12 g, 6.67mmol, 1.20 eq) in 1,4-dioxane (10 mL) and H₂O (2.5 mL) was addedPd(dppf)Cl₂ (90 mg, 0.11 mmol, 0.02 eq) under N₂ atmosphere. Thereaction mixture was stirred at 100° C. for 14 h. The reaction mixturecooled and poured into water (20 mL). The mixture was extracted withethyl acetate (3×10 mL). Then the combined organic layers were washedwith brine (10 mL), dried over Na₂SO₄, filtered and concentrated underreduced pressure. The residue was purified by column chromatography onsilica gel to give compound i-156 (0.9 g, 3.9 mmol) as an oil. ¹H NMR(400 MHz, Chloroform-d) δ=6.92 (s, 1H), 6.72 (s, 1H), 5.35 (s, 1H), 5.09(s, 1H), 3.83 (s, 3H), 2.18 (s, 2H), 1.28 (s, 3H)

General Procedure for Preparation of Compound i-157:

To a solution of i-156 (0.9 g, 3.9 mmol, 1.00 eq) in methanol (10 mL)was added Pd/C (0.3 g, 5% w.t.). The mixture was stirred at 50° C. underH₂ (50 psi) for 4 h and cooled to RT. The reaction mixture was filteredthrough celite. Then the mixture was concentrated to give crude i-157which was purified by column chromatography on silica gel to give i-157(0.4 g, 1.7 mmol) as an oil. ¹H NMR (400 MHz, Chloroform-d) δ=6.90 (s,1H), 6.83 (s, 1H), 3.86 (s, 3H), 2.95 (m, 1H), 1.28 (d, J=6.8 Hz, 6H)5=6.90 (s, 1H), 6.83 (s, 1H), 3.86 (s, 3H), 2.95 (m, 1H), 1.28 (d, J=6.8Hz, 6H)

General Procedure for Preparation of Compound i-158:

To a mixture of i-157 (80 mg, 343 umol, 1.00 eq) and i-107 (98 mg, 206umol, 0.60 eq, prepared as described in example 34) in dioxane (3.00 mL)was added Xantphos (40 mg, 69 umol, 0.20 eq) and Cs₂CO₃ (279 mg, 0.86mmol, 2.50 eq). The resulting reaction mixture was degassed with N₂three times and Pd₂(dba)₃ (76.2 mg, 83.2 umol, 0.10 eq) was added underN₂. Then the mixture was stirred at 100° C. for 14 h under N₂ and cooledto RT. Three additional vials were set up as described above and thereactions carried out in an identical manner. The four reaction mixtureswere combined. The reaction mixtures were poured into H₂O (50 mL).

The aqueous phase was extracted with ethyl acetate (3×50 mL). Thecombined organic phases were washed with brine (50 mL), dried overanhydrous Na₂SO₄, filtered and concentrated in vacuum. The mixture waspurified by prep-TLC to give i-158 (130 mg, 223 umol) as a solid.

¹H NMR (400 MHz, Chloroform-d) δ=7.64 (s, 1H), 7.05 (d, J=8.3 Hz, 4H),6.84 (d, J=8.3 Hz, 4H), 6.80 (s, 1H), 6.64 (s, 1H), 4.69 (s, 4H), 3.84(s, 3H), 3.80 (s, 6H), 2.49 (m, 1H), 1.09 (d, J 7.0 Hz, 6H)

General Procedure for Preparation of Compound 40:

A mixture of i-158 (130 mg, 223 umol, 1.00 eq) in TFA (4 mL) was stirredat 80° C. for 14 h. The reaction mixture was cooled, and concentrated toremove TFA under N₂.

The residue was diluted with ethyl acetate (10 mL). The combined organiclayers were washed with saturated NaHCO₃ (2×3 mL). The aqueous phase wasextracted with ethyl acetate (2×5 mL). The combined organic phases weredried over anhydrous Na₂SO₄, filtered and concentrated in vacuum. Theresidue was purified by prep-HPLC to give Compound 40 (9.8 mg, 21.5umol, TFA) as a solid. ¹H NMR (400 MHz, Methanol-d₄) δ=7.09 (s, 1H),6.97 (d, J=5.1 Hz, 2H), 3.89 (s, 3H), 3.25-3.10 (m, 1H), 1.28 (d, J=6.8Hz, 6H) LCMS: [M+H]⁺ 341.9

Example 43: Synthesis of Compound 41

Compound 41 was made by the synthetic method outlined in Scheme AU:

General Procedure for Preparation of Compound 41:

The solvent (dioxane) was degassed for 30 min by sparging with N₂. Asolution of DIEA (644 mg, 4.99 mmol, 1.00 eq) in dioxane (30 mL) wasadded to a mixture of Compound 15 (2.00 g, 4.99 mmol, 1.00 eq, preparedas described in example 17), Pd₂(dba)₃ (137 mg, 150 umol, 0.03 eq),Xantphos (144 mg, 250 umol, 0.05 eq) and NaSMe (367 mg, 5.24 mmol, 1.05eq) under Ar. The reaction was heated to 100° C. for 36 h under Ar. Uponcooling the reaction mixture was filtered and the filter cake was washedwith dioxane (4×20 mL). The filtrate was concentrated in vacuum to leavea residue. Then the residue was purified via column chromatography onsilica gel to give Compound 41 (1.40 g, 4.36 mmol) as a solid.

¹H NMR (400 MHz, DMSO-d₆) δ=7.23 (s, 1H), 6.95 (s, 1H), 6.47 (br s, 2H),5.78 (s, 2H), 3.89 (s, 3H), 3.32-3.25 (m, 1H), 2.30 (s, 3H), 1.19 (d,J=6.6 Hz, 6H) LCMS: [M+H]⁺ 322.0

Example 44: Synthesis of Compound 42

Compound 42 was made by the synthetic method outlined in Scheme AV:

General Procedure for Preparation of Compound 42:

A solution of oxone (762 mg, 1.24 mmol, 1.00 eq) in H₂O (10 mL) wasadded to a solution of Compound 41 (400 mg, 1.24 mmol, 1.00 eq) inmethanol (10 mL) at −10-0° C. The reaction mixture was stirred below 0°C. for 20 minutes. The reaction mixture was filtered and the filter cakewas washed with ethyl acetate (3×50 mL). Ethyl acetate (450 mL) andsaturated aqueous sodium sulfite (100 mL) were added to the filtrate.The two phases were separated.

The organic phase was washed with saturated sodium sulfite solution (100mL) and brine (2×100 mL), dried over Na₂SO₄ and concentrated in vacuumto give Compound 42 (0.43 g, crude) as yellow solid. ¹H NMR (400 MHz,DMSO-d₆) δ=7.46 (s, 1H), 7.25 (s, 1H), 6.51 (br s, 2H), 5.95 (br s, 2H),3.94 (s, 3H), 3.51 (td, J=6.6, 13.3 Hz, 1H), 2.72 (s, 3H), 1.26 (br d,J=6.7 Hz, 6H) LCMS: [M+H]⁺ 338.0

Example 45: Synthesis of Compound 43

Compound 43 was made by the synthetic method outlined in Scheme AW:

General Procedure for Preparation of Compound i-159:

A mixture of Compound 41 (500 mg, 1.56 mmol, 1.00 eq) and Ac₂O (1.63 g,16.0 mmol, 1.50 mL, 10.29 eq) was stirred at 100° C. for 1 h. Thereaction mixture was cooled to RT, and concentrated in vacuum to removeexcessive Ac₂O. Cooled saturated sodium bicarbonate solution (100 mL)was added and the mixture was extracted with dichloromethane (3×100 mL).

The combined organic layers were washed with brine (2×100 ml), driedwith anhydrous Na₂SO₄, filtered and concentrated in vacuum to leave aresidue. The residue was purified via column chromatography on silicagel to give i-159 (420 mg, 1.04 mmol) as a solid. ¹H NMR (400 MHz,CHLOROFORM-d) δ=8.18 (s, 1H), 7.91 (br s, 1H), 7.63 (s, 1H), 6.96 (s,1H), 4.04 (s, 3H), 3.03-3.14 (m, 1H), 2.67 (s, 3H), 2.39 (br s, 3H),2.36 (s, 3H), 1.21 (br d, J=6.8 Hz, 6H)

General Procedure for Preparation of Compound i-160:

A mixture of i-159 (200 mg, 493 umol, 1.00 eq), Chloramine-T (337 mg,1.48 mmol, 3.00 eq) and TBAB (318 mg, 987 umol, 2.00 eq) indichloromethane (8 mL) was stirred at 20-30° C. for 3 h. The reactionmixture was filtered and the filter cake was washed with dichloromethane(3×15 mL). The filtrate was concentrated in vacuum to leave a residue asan oil. The residue was purified by prep-TLC to give i-160 (200 mg, 348umol) as a solid.

¹H NMR (400 MHz, CHLOROFORM-d) δ=8.10 (s, 1H), 7.94 (s, 1H), 7.75 (d,J=7.8 Hz, 2H), 7.66 (s, 1H), 7.23 (d, J=7.8 Hz, 2H), 6.98 (s, 1H), 4.07(s, 3H), 3.32-3.24 (m, 1H), 2.83 (s, 3H), 2.64 (s, 3H), 2.44 (s, 3H),2.39 (s, 3H), 1.26 (d, J=5.6 Hz, 6H)

General Procedure for Preparation of Compound i-161:

H₂O₂ (355 mg, 10.4 mmol, 300 uL, 60.00 eq) was added to a solution ofi-160 (100 mg, 174 umol, 1.00 eq) and K₂CO₃ (241 mg, 1.74 mmol, 10.00eq) in methanol (2 mL) and acetonitrile (0.2 mL). The reaction mixturewas stirred for 20 h at 20-30° C. The reaction mixture was concentratedin vacuum to remove the solvents. Water (25 mL) and dichloromethane (25mL) were added. Then the two phases were separated and the aqueous phasewas extracted with dichloromethane (2×25 mL). The combined organiclayers were washed with brine (2×25 mL), dried over anhydrous Na₂SO₄,filtered and concentrated in vacuum to give i-161 (80 mg, 146 umol) asan oil which was used in the next step without further purification. ¹HNMR (400 MHz, CHLOROFORM-d) δ=9.40 (br s, 1H), 7.85 (s, 1H), 7.70 (d,J=8 Hz, 2H), 7.53 (s, 1H), 7.21 (d, J=8 Hz, 2H), 6.16 (br s, 2H), 4.04(s, 3H), 3.49 (s, 3H), 3.39 (td, J=7.0, 13.6 Hz, 1H), 2.50 (br s, 3H),2.38 (s, 3H), 1.29 (d, J=7.2 Hz, 6H)

General Procedure for Preparation of Compound 43:

Compound i-161 (50 mg, 91.1 umol, 1.00 eq) was dissolved in CHCl₃ (1.00mL). H₂SO₄ (442 mg, 4.50 mmol, 49.4 eq) was added at 0° C. The mixturewas stirred for 24 h at 25° C. H₂O (1.00 mL) was added. The reactionmixture was stirred for 5 h at 25° C. The reaction mixture was pouredinto saturated sodium bicarbonate solution (20 mL) and the pH was around8-9. The aqueous phase was extracted with dichloromethane (3×20 mL). Thecombined organic layers were washed with brine (3×20 mL), dried overNa₂SO₄, filtered and concentrated in vacuum to leave a residue. Theresidue was purified by prep-HPLC to give the Compound 43 (8 mg, 22.7umol, 25% yield) as white solid. ¹H NMR (400 MHz, METHANOL-d₄) δ=7.66(s, 1H), 7.35 (s, 1H), 4.59 (br s, 1H), 4.10 (s, 3H), 3.54 (td, J=6.8,13.5 Hz, 1H), 3.24 (s, 3H), 1.32 (dd, J=1.8, 6.7 Hz, 6H) LCMS: [M+H]⁺353.0

Example 46: Synthesis of Compound 44

Compound 44 was made by the synthetic method outlined in Scheme AX:

General Procedure for Preparation of Compound i-163:

To a solution of i-162 (5.00 g, 35.9 mmol, 1.00 eq) and NaOAc (8.84 g,108 mmol, 3.00 eq) in HOAc (65.0 mL) was added Br₂ (20.1 g, 126 mmol,6.48 mL, 3.50 eq) while maintaining the inner temperature below 25° C.The mixture was stirred at 25° C. for 20 h. The mixture was adjusted topH 7 with 25% aqueous NaOH solution. The aqueous phase was extractedwith DCM (3×100 mL). The organic phases were combined and washed withbrine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentratedto give i-163 (8.78 g, 29.6 mmol) as a solid. This product was used inthe next step directly. ¹H NMR (400 MHz, CHLOROFORM-d) δ=7.22 (s, 1H),4.01 (s, 3H), 3.87 (s, 3H)

General Procedure for Preparation of Compound i-164:

To a mixture of i-163 (8.78 g, 29.6 mmol, 1.00 eq) andisopropenylboronic acid pinacol ester (4.97 g, 29.6 mmol, 1.00 eq) in1,4-dioxane (100 mL) and H₂O (25.0 mL) was added K₂CO₃ (8.17 g, 59.1mmol, 2.00 eq) and Pd(PPh₃)₄ (4.10 g, 3.55 mmol, 0.12 eq) under N₂.

The mixture was stirred at 100° C. for 6 h. The mixture was filtered andthe solid was washed with EtOAc (100 mL). The two phases were separatedand the aqueous phase was extracted with EtOAc (3×100 mL). The combinedorganic phases were dried over anhydrous Na₂SO₄, filtered andconcentrated. The residue was purified by column chromatography onsilica gel to give i-164 (3.50 g, 13.6 mmol) as an oil. ¹H NMR (400 MHz,CHLOROFORM-d) δ=7.20 (s, 1H), 5.40 (s, 1H), 5.33 (s, 1H), 4.00 (s, 3H),3.88 (s, 3H), 2.14 (s, 3H)

General Procedure for Preparation of Compound i-165:

To a solution of i-164 (2.50 g, 9.69 mmol, 1.00 eq) in EtOAc (10.0 mL)was added rhodium/Al₂O₃ (1.40 g, 678 umol, 5% purity, 0.07 eq). Themixture was stirred at 25° C. under H₂ balloon for 15 h. The mixture wasfiltered and the solid washed with EtOAc (3×10 mL). The combined organiclayers were concentrated under reduced pressure to give i-165 (2.10 g,8.07 mmol, 83% yield) as light yellow oil which was used in the nextstep directly.

¹H NMR (400 MHz, CHLOROFORM-d) δ=7.13 (s, 1H), 4.02-3.97 (m, 3H), 3.85(s, 3H), 3.38 (spt, J=6.7 Hz, 1H), 1.22 (d, J=6.8 Hz, 6H)

General Procedure for Preparation of Compound i-166:

To a solution of i-165 (2.70 g, 10.4 mmol, 1.00 eq) in 1,4-dioxane (20.0mL) was added diphenylmethanimine (2.82 g, 15.6 mmol, 1.50 eq), Cs₂CO₃(8.45 g, 26.0 mmol, 2.50 eq), BINAP (1.29 g, 2.08 mmol, 0.20 eq) andPd₂(dba)₃ (1.14 g, 1.25 mmol, 0.12 eq) under N₂. The mixture was stirredat 100° C. for 12 h. The mixture was cooled to RT, and filtered, and thesolid washed with EtOAc (30 mL). To the filtrate was added H₂O (50 mL).The two phases were separated and the aqueous phase was extracted withEtOAc (2×30 mL). The combined organic phases were dried over anhydrousNa₂SO₄, filtered and concentrated. The residue was purified by columnchromatography on silica gel to give i-166 (1.80 g, 4.99 mmol) as asolid.

¹H NMR (400 MHz, CHLOROFORM-d) δ=7.85-7.77 (m, 2H), 7.52-7.39 (m, 3H),7.36-7.29 (m, 3H), 7.17-7.09 (m, 2H), 6.15 (s, 1H), 3.97 (s, 3H), 3.46(s, 3H), 3.32 (spt, J=6.7 Hz, 1H), 1.17 (d, J=6.8 Hz, 6H)

General Procedure for Preparation of Compound i-167:

To a solution of i-166 (1.80 g, 4.99 mmol, 1.00 eq) in THF (15.0 mL) andH₂O (3.00 mL) was added HCl (1 M, 9.98 mL, 2.00 eq). The mixture wasstirred at 25° C. for 2 h. The mixture was adjusted to pH 8 withsaturated Na₂CO₃ solution. To the mixture was added EtOAc (30 mL) andH₂O (30 mL). The two phases were separated and the aqueous layer wasextracted with EtOAc (3×30 mL). The combined organic layers werecombined, dried over Na₂SO₄ and concentrated. The residue was purifiedby column chromatography on silica gel to give i-167 (900 mg, 4.59 mmol)as an oil. ¹H NMR (400 MHz, CHLOROFORM-d) δ=6.53 (s, 1H), 3.96 (s, 3H),3.82 (s, 3H), 2.93 (td, J=6.7, 13.3 Hz, 1H), 1.24 (d, J=6.8 Hz, 6H)

General Procedure for Preparation of Compound i-168:

To a solution of i-167 (450 mg, 2.29 mmol, 1.00 eq) and i-107 (655 mg,1.38 mmol, 0.60 eq, prepared as described in Example 34) in 1,4-dioxane(5.00 mL) was added Xantphos (265 mg, 459 umol, 0.20 eq), Cs₂CO₃ (1.87g, 5.73 mmol, 2.50 eq) and Pd₂(dba)₃ (210 mg, 229.30 umol, 0.10 eq)under N₂. The mixture was stirred at 100° C. for 12 h and cooled to RT.The mixture was filtered and the solid was washed with EtOAc (15 mL). Tothe filtrate was added H₂O (20 mL). The two phases were separated andthe aqueous phase was extracted with EtOAc (3×15 mL). The combinedorganic phases were dried over anhydrous Na₂SO₄, filtered andconcentrated. The residue was purified by column chromatography onsilica gel to give i-168 (150 mg, 275 umol) as a solid. ¹H NMR (400 MHz,CHLOROFORM-d) δ=7.47 (s, 1H), 7.10 (d, J=8.6 Hz, 4H), 6.89-6.84 (m, 4H),6.29 (s, 1H), 4.80 (s, 4H), 3.95 (s, 3H), 3.81 (s, 6H), 3.68 (s, 3H),2.50-2.44 (m, 1H), 1.04 (d, J=6.6 Hz, 6H)

General Procedure for Preparation of Compound 44:

Compound 168 (150 mg, 275 umol, 1.00 eq) was added to TFA (2.00 mL) andthe mixture was stirred at 80° C. for 4 h and cooled to RT. The mixturewas adjusted to pH 8 with saturated Na₂CO₃ solution at 0° C. To themixture was added EtOAc (5 mL) and H₂O (5 mL).

Then the two phases were separated and the aqueous phase was extractedwith EtOAc (3×5 mL).

The combined organic phases were dried over anhydrous Na₂SO₄, filteredand concentrated. The mixture was purified by prep-HPLC to give Compound44 (22.0 mg, 72.3 umol) as a solid.

¹H NMR (400 MHz, METHANOL-d₄) δ=6.84 (s, 1H), 6.81 (s, 1H), 3.94 (s,3H), 3.77 (s, 3H), 3.17-3.07 (m, 1H), 1.20 (d, J=6.8 Hz, 6H) LCMS:[M+H]⁺ 305.2

Example 47: Synthesis of Compound 45

Compound 45 was made by the synthetic method outlined in Scheme AY:

General Procedure for Preparation of Compound i-170:

To a solution of compound i-176 (20 g, 98 mmol, 1.00 eq),2-isopropenyl-4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolane (17.3 g, 103mmol, 1.05 eq) and Na₂CO₃ (20.8 g, 196 mmol, 2.00 eq) in 1,4-dioxane(160 mL) and H₂O (40 mL) was added Pd(dppf)Cl₂ (1.43 g, 1.96 mmol, 0.02eq). The resulting reaction mixture was degassed twice back filling withN₂ each time and then heated to 90° C. for 15 h. The reaction mixturewas cooled to RT, filtered through a pad of celite and eluted with EtOAc(500 mL). To the filtrate was added water (200 mL). The two layers wereseparated and the aqueous layer was extracted with EtOAc (2×500 mL). Thecombined organic layers were washed with brine (200 mL), dried overanhydrous Na₂SO₄, filtered and concentrated under reduced pressure. Theresidue was purified by column chromatography on silica gel to givecompound i-170 (16 g) as a solid. ¹H NMR (400 MHz, CHLOROFORM-d) δ=7.67(s, 1H), 5.86 (d, J=1.5 Hz, 1H), 5.09-5.02 (m, 1H), 4.93-4.74 (s, 2H),4.02 (s, 3H), 1.25 (s, 3H)

General Procedure for Preparation of Compound i-171:

To a solution of i-170 (7.70 g, 46.6 mmol, 1.00 eq) in MeOH (77 mL) wasadded Pd/C (770 mg, 306 umol, 5% purity). The suspension was degassedunder vacuum and purged with H₂ several times. The mixture was stirredunder H₂ (50 psi) at 50° C. for 2 h, and cooled to RT. The reactionmixture was filtered and the filtrate was concentrated to give i-171(8.20 g, crude) as an oil. ¹H NMR (400 MHz, CHLOROFORM-d) δ=7.36 (s,1H), 4.56 (s, 2H), 3.98 (s, 3H), 2.84 (m, J=6.9 Hz, 1H), 1.24 (s, 6H)

General Procedure for Preparation of Compound i-172:

To a stirred solution of i-171 (53.0 g, 317 mmol, 1.00 eq) in DME (250mL) and toluene (100 mL) was added KI (105 g, 634 mmol, 2.00 eq) and CuI(18.1 g, 91 mmol, 0.30 eq) at 0° C. The reaction mixture was degassedfor 30 min by sparging with N₂. Then isoamylnitrite (223 g, 1.90 mol,6.00 eq) was added dropwise. The reaction mixture was heated to 60° C.for 2 h. The reaction mixture was poured into ice-water (w/w=1/1) (1 L)and stirred for 20 min.

After a separation, the aqueous phase was extracted with ethyl acetate(3×1 L). The combined organic layers were washed with saturated aqueoussodium sulfite (2×500 mL) and brine (2×500 mL), dried over anhydrousNa₂SO₄, filtered and concentrated in vacuum to give a residue. Theresidue was purified by column chromatography on silica gel to givecompound i-172 (33 g) as an oil. ¹H NMR (400 MHz, CHLOROFORM-d) δ=7.83(s, 1H), 4.01 (s, 3H), 2.93-3.02 (m, 1H), 1.29 (d, J=7.2 Hz, 6H)

General Procedure for Preparation of Compound i-173:

To a stirred solution of i-172 (5.00 g, 18 mmol, 1.00 eq) in DCM (50 mL)was added urea hydrogen peroxide (16.9 g, 180 mmol, 10 eq) and TFAA (25mL) at 0° C. The reaction mixture was heated to 40° C. for 3 h. Thereaction mixture were poured into ice-water (w/w=1/1) (100 mL). After aseparation, the aqueous phase was extracted with DCM (3×100 mL). Thecombined organic layers were washed with saturated aqueous sodiummetabisulfite (2×50 mL) and brine (2×50 mL), dried over anhydrousNa₂SO₄, filtered and concentrated in vacuum to give a residue. Theresidue was purified by column chromatography on silica gel to givecompound i-173 (3 g, crude) as an oil. ¹H NMR (400 MHz, CHLOROFORM-d)δ=7.88 (s, 1H), 4.06 (s, 3H), 3.14-3.07 (m, 1H), 1.28 (d, J=6.8 Hz, 6H)

General Procedure for Preparation of Compound i-174:

A solution of i-173 (1.25 g, 4.25 mmol, 1.00 eq) in Ac₂O (10 mL) wasstirred and heated to 110° C. for 15 h under Ar. The reaction mixturewas concentrated to dryness and then diluted with ice water (5 mL) andextracted with EtOAc (2×5 mL). The combined organic layers were washedwith brine (5 mL), dried over Na₂SO₄, filtered and concentrated underreduced pressure. The residue was purified by column chromatography onsilica gel to give i-174 (200 mg, 0.59 mmol) as an oil which was used inthe next step directly. ¹H NMR (400 MHz, CHLOROFORM-d) δ=4.03 (s, 3H),3.01-2.94 (m, 1H), 2.35 (s, 3H), 1.24 (d, J=6.8 Hz, 6H)

General Procedure for Preparation of Compound i-175:

To a stirred solution of i-174 (90 mg, 0.27 mmol, 1.00 eq) in MeOH (1mL) was added NaOH (21 mg, 0.54 mmol, 2 eq). The mixture was stirred at0° C. for 3 h. The reaction mixture was concentrated to dryness. Thenthe residue was diluted with H₂O (5 mL) and extracted with EtOAc (3×5mL). The combined organic layers were washed with brine (2×5 mL), driedover Na₂SO₄, filtered and concentrated under reduced pressure. Theresidue was purified by prep-TLC to give i-175 (40 mg, 0.14 mmol) as asolid which was used for the next step directly. ¹H NMR (400 MHz,DMSO-d₆) δ=11.36 (s, 1H), 3.81 (s, 3H), 3.14-3.07 (m, 1H), 1.17 (d,J=6.8 Hz, 6H)

General Procedure for Preparation of Compound i-176:

To a stirred solution of i-175 (200 mg, 0.68 mmol, 1.00 eq) in CH₃CN (2mL) was added Cs₂CO₃ (443 mg, 1.36 mmol, 2.00 eq) and BrCH₂CN (98 mg,0.82 mmol, 1.20 eq). The mixture was stirred at 90° C. for 15 h underAr. The reaction mixture was concentrated to dryness and diluted withH₂O (5 mL) and extracted with EtOAc (3×5 mL). The combined organiclayers were washed with brine (2×5 mL), dried over Na₂SO₄, filtered andconcentrated. The residue was purified by prep-TLC to give i-176 (80 mg,0.24 mmol, 35% yield) as an oil.

¹H NMR (400 MHz, CHLOROFORM-d) δ=5.01 (s, 2H), 3.99 (s, 3H), 3.29-3.14(m, 1H), 1.25 (d, J=6.8 Hz, 6H)

General Procedure for Preparation of Compound i-177:

To a stirred solution of i-176 (80 mg, 0.24 mmol, 1.00 eq) in DMF (2 mL)was added 1-tert-butoxy-N,N,N′,N′-tetramethyl-methane diamine (84 mg,0.48 mmol, 2.00 eq). The solution was heated to 110° C. for 2 h. Thesolution was cooled to RT, and used in the next step withoutpurification.

General Procedure for Preparation of Compounds i-178 and i-179:

To a stirred solution of i-177 (80 mg, 0.18 mmol, 1.00 eq) in DMF (1 mL)was added aniline hydrochloride (120 mg, 0.9 mmol, 5.00 eq). Thereaction mixture was heated to 120° C. for 15 h. The reaction mixturewas concentrated to dryness, and diluted with H₂O (10 mL) and extractedwith methyl t-Butyl ether (3×5 mL). The combined organic layers werewashed with brine (2×5 mL), dried over Na₂SO₄, filtered and concentratedto give a mixture of i-178 and i-179 (200 mg, crude) as solids whichwere used directly in the next step without purification.

General Procedure for Preparation of Compound 45:

To a stirred solution of i-178 and i-179 (200 mg, 69 mmol, 1.00 eq) inDMSO (1.0 mL) was added NaOMe (3.7 mg, 69 mmol, 1.0 eq) and guanidinecarbonate (16.4 mg, 138 umol, 2.00 eq). The reaction mixture wasdegassed for 3 times by sparging with N₂. The reaction mixture washeated to 110° C. for 15 h. The reaction mixture was cooled, andpurified by prep-HPLC to give Compound 45 (2 mg) as a solid. Compoundi-180 was not isolated but was detected in the crude. ¹H NMR (400 MHz,CHLOROFORM-d) δ=7.39 (s, 1H), 6.13-5.58 (m, 2H), 3.97 (s, 3H), 3.13 (s,1H), 3.02 (s, 6H), 1.23 (d, J=6.8 Hz, 6H) LCMS: [M+H]⁺ 320.1

Example 48: Synthesis of Compound 46

Compound 46 was made by the synthetic method outlined in Scheme AZ:

General Procedure for Preparation of Compound i-181:

To a solution of i-172 (10 g, 36.0 mmol, 1.00 eq, prepared as describedin example 47) in DMF (100 mL) was added CuI (6.8 g, 36.0 mmol, 1.00 eq)and methyl-2, 2-difluoro-2-2(fluorosulfonyl)-acetate (13.8 g, 71.9 mmol,2.00 eq) under N₂. The resulting reaction mixture was degassed 2 timesback filling with N₂ each time and then heated to 120° C. for 17 h. Thereaction mixture was cooled to 20° C. The reaction mixture was dilutedwith H₂O (250 mL) and extracted with EtOAc (3×100 mL). The combinedorganic layers were washed with brine (2×50 mL), dried over Na₂SO₄,filtered and concentrated under reduced pressure. The residue waspurified by column chromatography on silica gel (petroleum ether/ethylacetate=100:1 to 50:1) to give compound i-181 (10 g, 45.4 mmol) as anoil.

¹H NMR (400 MHz, CHLOROFORM-d) δ=8.08 (s, 1H), 4.08 (s, 3H), 3.17-3.03(m, 1H), 1.34 (d, J=6.8 Hz, 6H)

General Procedure for Preparation of Compound i-182:

To a stirred solution of i-181 (9.00 g, 40.9 mmol, 1.00 eq) in DCM (90mL) was added urea hydrogen peroxide (19.2 g, 204 mmol, 5 eq) and TFAA(45 mL) at 0° C. The reaction mixture was stirred at 0° C. for 5 h. Thereaction mixture was poured into ice-water (w/w=1/1) (500 mL). After asseparation, the aqueous phase was extracted with EtOAc (3×500 mL). Thecombined organic phase were washed with brine (2×100 mL), dried overanhydrous Na₂SO₄, filtered and concentrated in vacuum. The residue waspurified by column chromatography on silica gel (petroleum ether:ethylacetate=20:1) to give compound i-182 (6 g, 25.4 mmol) as an oil whichwas used in the next step without purification. LCMS: [M+H]⁺ 226.9

General Procedure for Preparation of Compound i-183:

The solution of i-182 (3.00 g, 12.7 mmol, 1.00 eq) in Ac₂O (30 mL) wasstirred and heated to 110° C. for 5 h under Ar. The reaction mixture wasconcentrated to dryness and then diluted with ice H₂O (50 mL) andextracted with EtOAc (2×50 mL). The combined organic layers were washedwith brine (50 mL), dried over Na₂SO₄, filtered and concentrated underreduced pressure. The residue was purified by silica columnchromatography on silica gel to give i-183 (1.2 g, 4.31 mmol) as an oilwhich was used in the next step directly. LCMS: [M+H]⁺ 279.0

General Procedure for Preparation of Compound i-184:

To a stirred solution of i-183 (3.00 g, 10.8 mmol, 1.00 eq) in MeOH (30mL) was added NaOH (431 mg, 10.8 mmol, 1.00 eq). The mixture was stirredat 0° C. for 5 h. The reaction mixture was concentrated to dryness,diluted with H₂O (50 mL) and extracted with EtOAc (3×50 mL). Thecombined organic layers were washed with brine (2×5 mL), dried overNa₂SO₄, filtered and concentrated under reduced pressure to give i-184(3 g, crude) as an oil which was used in the next step directly. LCMS:[M+H]⁺ 236.9

General Procedure for Preparation of Compound i-185:

To a stirred solution of i-184 (3.00 g, 12.7 mmol, 1.00 eq) in CH₃CN (30mL) was added Cs₂CO₃ (8.28 g, 25.4 mmol, 2.00 eq) and BrCH₂CN (1.83 g,15 mmol, 1.20 eq). The mixture was stirred at 90° C. for 15 h under Ar.The reaction mixture was cooled and concentrated to dryness, dilutedwith H₂O (50 mL) and extracted with EtOAc (3×50 mL). The combinedorganic layers were washed with brine (50 mL), dried over Na₂SO₄,filtered and concentrated. The residue was purified by prep-TLC to givei-185 (600 mg, 2.18 mmol) as an oil.

¹H NMR (400 MHz, CHLOROFORM-d) δ=5.04 (s, 2H), 4.06 (s, 3H), 3.48-3.24(m, 1H), 1.29 (dd, J=6.8 Hz, 6H)

General Procedure for Preparation of Compound i-186:

A stirred solution of i-185 (100 mg, 317 mmol, 1.00 eq) in DMF-DMA (1.0mL) was degassed for 3 times by sparging with N₂. The reaction mixturewas heated to 130° C. for 13 h. The reaction mixture was cooled to RTand concentrated in vacuum to give i-186 (100 mg, crude) as an oil whichwas used without purification in the next step. LCMS: [M+H]⁺ 331.0

General Procedure for Preparation of Compound i-187:

To a stirred solution of crude i-186 (100 mg, 0.30 mmol, 1.00 eq) in DMF(0.2 mL) was added aniline hydrochloride (78 mg, 0.6 mmol, 2.00 eq). Thereaction mixture was heated to 120° C. for 2 h. The reaction mixture wascooled to RT, and concentrated to dryness, and diluted with H₂O (5 mL)and extracted with methyl t-Butyl ether (3×5 mL). The combined organiclayers were washed with brine (2×5 mL), dried over Na₂SO₄, filtered andconcentrated to give i-187 (100 mg, crude) as an oil which was useddirectly without purification. LCMS: [M+H]⁺ 379.0

General Procedure for Preparation of Compound 46:

To a stirred solution of i-187 (100 mg, 0.26 mmol, 1.00 eq) in n-BuOH (1mL) was added K₂CO₃ (73 mg, 0.53 mmol, 2.00 eq) and guanidinehydrochloride (50 mg, 0.53 mmol, 2.00 eq.) at 0° C. The reaction mixturewas degassed for 3 times by sparging with N₂. The reaction mixture washeated to 100° C. for 15 h and cooled to RT. The reaction mixture wasfiltered and the filtrate was concentrated in vacuum. The residue waspurified by prep-HPLC to give Compound 46 (9.0 mg, TFA) as a solid. ¹HNMR (400 MHz, CHLOROFORM-d) δ=7.62 (s, 1H), 5.77 (br s, 2H), 4.10 (s,3H), 3.45-3.33 (m, 1H), 1.37 (d, J=6.6 Hz, 6H) LCMS: [M+H]⁺ 345.0

Example 49: Synthesis of Compound 47

Compound 47 was made by the synthetic method outlined in Scheme BA:

General Procedure for Preparation of Compound 47:

A suspension of compound 15 (1 g, 2.49 mmol, 1 equiv) and (bpy)CuSCF₃(1.2 g, 3.74 mmol, 1.5 equiv) in diglyme (10 m) was placed in a sealedtube and heated to 130° C. for 24 h. After cooling to RT,tetrahydrofuran (100 mL) was added and the reaction was filtered througha Celite pad. The filter cake was rinsed with tetrahydrofuran (100 mL)and the filtrate was concentrated under reduced pressure. The residuewas diluted with water (200 mL) and concentrated ammonium hydroxide (20mL). After stirring at RT for 20 min, the solid was filtered off anddried and dried under vacuum at 40° C. overnight. The solid was purifiedby silica gel chromatography to give partially purified Compound 47 (100mg, 80% purity by LCMS). Further purification by prep-TLC affordedCompound 47 (22 mg, >95% purity) as a solid. ¹H NMR (400 MHz, THF-d8)δ=7.45 (s, 1H), 7.43 (s, 1H), 5.91 (br s, 2H), 5.38 (br s, 2H), 4.05 (s,3H), 3.55 (m, 1H), 2.55 (s, 1H), 1.33 (d, 6H). LCMS: [M+H]⁺ 376.1

Biological Assay

1321N1 human astrocytoma and HEK293 human embryonic kidney cells werestably transfected with human P2X2 and P2X3 receptor subunits to formheteromeric P2X2/3 channels and passaged in flasks. Additionally, HEK293cells were stably transfected with human P2X3 receptor subunits to formhomomeric P2X3 channels.

Approximately 24 hours before the FlexStation calcium fluorescenceexperiment, cells were released from their flasks, centrifuged andre-suspended in nutrient medium. The cells were aliquoted intoblack-wall, clear-bottom 96 well plates at a density of 25,000 cells perwell and incubated overnight in a humidified, CO₂-enriched (5%)atmosphere at 37° C.

On the day of the experiment, cells were washed with assay buffer(calcium- and magnesium-free Hank's balanced salt solution, 20 mM HEPES,2 mM CaCl₂; AB) and loaded with 4 μM Fluo-4 (P2X2/3) or Calcium 6(Molecular Devices, according to manufacturer's instructions; P2X3)calcium-sensitive fluorescent dye in 100 μL AB.

After 1 hour of dye loading at 37° C., 1321N1-hP2X2/3 cells were washedtwo times with AB and test compound or vehicle added to each well in atotal volume of 150 μL AB. HEK-hP2X3 cells were not washed because theCalcium 6 dye kit includes an extracellular dye that quenches unabsorbedCalcium 6 dye; test compound or vehicle were added directly to the assayplates to achieve the appropriate concentration of test compound in atotal volume of 150 μL AB.

After 20 minutes incubation at RT and protected from light, the assayplates were loaded into the FlexStation microplate reader and baselinefluorescence measured with an excitation wavelength of 485 nm andemission wavelength readings centered at 525 nm (515 nm cut off).

The agonist was dispensed by the FlexStation during fluorescencemeasurement to construct agonist activation and antagonist inhibitioncurves. The final agonist concentration for inhibition was 1 μMα,β-meATP for P2X3 and 3 μM ATP for P2X2/3. Peak fluorescence wasmeasured and curves generated using a four parameter nonlinearregression equation.

The data in Table 2 were obtained using the assay referred to above:

TABLE 2 Average pIC₅₀ Selectivity Compound # P2X3 P2X2/3 P2X3/P2X2/3  17.0 <5 >100  2 6.3 <5 >18  3 6.8 <5 >67  4 6.9 5.2 48  5 7.4 5.4 97  66.1 <5 >13  7 6.5 <5 >34  8 6.7 <5 >47  9 6.8 <5 >56 10 <5 <5 NA 11 6.8<5 >58 12 5.3 <5 >2 Comparative Compound 1 <5 <5 NA Comparative Compound2 <5 <5 NA 13 7.4 6.7 5.2 14 5.9 <5 >7.1 15 7.2 6.4 6.5 16 7.2 <5 >14517 6.0 <5 >10 18 7.2 5.8 23 19 8.2 6.7 28 20 7.7 6.4 19 21 6.4 <5 >24 225.4 <5 >3 23 5.4 <5 >3 24 7.0 6.4 4 25 6.7 <5 >52 26 5.1 <5 >1 27 7.16.2 7.3 28 6.1 5.2 7.2 29 7.3 6.7 3.9 30 7.2 5.8 28 31 5.4 <5 >2.5 328.0 6.4 34 33 7.6 6.1 26 34 6.1 5.2 8.3 35 7.4 5.1 198 36 7.6 <5 >370 376.9 <5 >73 38 6.7 <5 >48 39 7.6 5.3 208 40 7.1 <5 >123 41 7.9 6.3 41 426.5 <5 >33 43 5.5 <5 >3.4 44 8.0 5.7 225 45 5.8 <5 >6.0 46 7.0 6.0 10 476.2 5.9 2.1

The potential tolerability benefits of P2X3 channel selectivity havebecome evident with experience from clinical studies using noveldrug-like antagonists. Previously reported carbon- and oxygen-linkeddiaminopyrimidine analogs display either no or only modest potencyselectivity favoring homotrimeric P2X3 over heterotrimeric P2X2/3channels.

For example the most selective carbon-linked analog displays a 16 foldselectivity ratio. Oxygen-linked examples shown in Table 1 (X═O) exhibitan average P2X3-to-P2X2/3 selectivity ratio of 10 (potencies shown aspIC₅₀s).

The data in Table 3 shows the pIC_(50s) and selectivity ofdiaminopyrimidine antagonists of the P2X3 and P2X2/3 ion channels ofpreviously disclosed oxygen-linked versus sulfur linked analogs of thepresent disclosure.

TABLE 3

X = O¹ X = S Selec- Selec- Row R P2X3 P2X2/3 tivity P2X3² P2X2/3³ tivityA OCH₃ 7.6 6.3 20 7.0 <5 >100 B I 8.0 7.1 8 6.8 5.2 48 C S(O)₂CH₃ 7.06.0 10 6.3 <5 >18 D Cl 7.6 7.0 4 6.8 <5 >50 Average selectivity: 10 >50¹Mean pIC_(50S) from Carter et al, Bioorg Med Chem Lett 2009 Mar15;19(6):1628-31. ²Mean pIC₅₀, hP2X3, HEK293 cells ³Mean pIC₅₀, hP2X2/3,1321N1 (astrocytoma) cells

One of the most selective diaminopyrimidine inhibitors previously known,the oxygen-linked analog in row A, has pIC_(50s) of 7.6 and 6.3 for theP2X3 and P2X2/3 receptors, respectively, a potency ratio of 20(pIC50=−log IC₅₀, Ratio=10̂(P2X3pIC₅₀−P2X2/3pIC₅₀). The correspondingsulfur-linked analog (Row A, X═S; compound 1) exhibits pIC_(50s) of 7.00and <5 (highest concentration tested is 10 μM) at P2X3 and P2X2/3,respectively, or a selectivity ratio that is greater than 100.

All other pairs of analogs shown in Table 3 exhibit a significantincrease in the selectivity ratio for the sulfur-linked analog relativeto the corresponding oxygen- or carbon-linked compound.

Importantly, the average selectivity for sulfur-linked compounds inTable 3 is more than 5 times greater than the average selectivity of theoxygen-linked compounds.

The trend extends beyond these four examples to all diaminopyrimidineanalogs that have published inhibition activity at the P2X3 and P2X2/3receptors for oxygen- and carbon-linked analogs the averageselectivity=4, while for the sulfur-linked analogs of the presentdisclosure, the average selectivity is 45.

While the present disclosure has been described with reference to thespecific embodiments thereof, it should be understood by those skilledin the art that various changes may be made and equivalents may besubstituted without departing from the true spirit and scope of thepresent disclosure. In addition, many modifications may be made to adapta particular situation, material, composition of matter, process,process step or steps, to the objective spirit and scope of the presentdisclosure. All such modifications are intended to be within the scopeof the claims appended hereto.

1. A compound of Formula 1:

or a pharmaceutically acceptable salt thereof, wherein: W is selectedfrom CH₂, O, S and NH; X₁ is N or CR²; X₂ is CR³; X₃ is CR⁴; X₄ is CR⁵;X₅ is N or CR⁶, provided, however, when X₁ is C—R², W is not O or —CH₂—;Y is selected from hydrogen or —NR^(d)R^(e), wherein one of R^(d) andR^(e) is hydrogen, and the other is: hydrogen; C₁₋₁₂-alkyl;C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-haloalkoxy; C₁₋₁₂-hydroxyalkyl; C₂₋₁₂-alkoxyalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;C₂₋₁₂-aminocarbonyloxyalkyl; C₁₋₁₂-hydroxycarbonylalkyl;C₂₋₁₂-hydroxylalkyloxycarbonylalkyl; C₅₋₁₂-aryl; C₆₋₁₂-arylalkyl;C₅₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl;C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; andC₄₋₁₂-heterocyclylalkyl; D is an optional oxygen; R¹ is selected fromC₁₋₁₂-alkyl; C₂₋₁₂-alkenyl; C₂₋₁₂-alkynyl; C₃₋₁₂-cycloalkyl;C₃₋₁₂-cycloalkenyl; halo; C₁₋₁₂-haloalkyl; and C₁₋₁₂-hydroxyalkyl; R²,R³, R⁴ and R⁵ are each independently selected from hydrogen;C₁₋₁₂-alkyl; C₂₋₁₂-alkenyl; C₂₋₁₂-alkynyl; amino; halo; amido;C₁₋₁₂-haloalkyl; C₁₋₁₂-alkoxy; hydroxy; C₁₋₁₂-haloalkoxy; nitro;C₁₋₁₂-hydroxyalkyl; C₂₋₁₂-alkoxyalkyl; C₁₋₁₂-hydroxyalkoxy;C₃₋₁₂-alkynylalkoxy; C₁₋₁₂-alkylsulfonyl; C₅₋₁₂-arylsulfonyl; cyano;C₆₋₁₂-aryl; C₅₋₁₂-heteroaryl; C₃₋₁₂-heterocyclyl;C₄₋₁₂-heterocyclylalkoxy; C₆₋₁₂-aryloxy; C₅₋₁₂-heteroaryloxy;C₇₋₁₂-arylalkyloxy; C₆₋₁₂-heteroaralkyloxy; optionally substitutedphenoxy; —(CH₂)_(m)—(Z)_(n)—(CO)—R^(f) and—(CH₂)_(m)—(Z)_(n)—SO₂—(NR^(g))_(n′)—R^(f), where m, n and n′ are eachindependently 0 or 1; Z is O or NR^(g); R^(f) is selected from hydrogen,C₁₋₁₂-alkyl, hydroxy, C₁₋₁₂-alkoxy, amino, C₁₋₁₂-hydroxyalkyl andC₂₋₁₂-alkoxyalkyl; each R^(g) is independently hydrogen or C₁₋₁₂-alkyl;or alternatively, R³ and R⁴ together with the atoms to which they areattached may form a five or six-membered ring that optionally includesone or two heteroatoms independently selected from O, S and N; oralternatively, R² and R³ may together form an alkylene dioxy; or R² andR³ together with the atoms to which they are attached form a five orsix-membered ring that optionally includes one or two heteroatomsindependently selected from O, S and N; R⁶ is selected from hydrogen;and C₁₋₁₂-alkyl; and R⁷ is selected from hydrogen; C₁₋₁₂-alkyl;C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-haloalkoxy; C₁₋₁₂-hydroxyalkyl; C₂₋₁₂-alkoxyalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;C₃₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl;C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; andC₁₋₁₂-heterocyclylalkyl.
 2. The compound of claim 1, or apharmaceutically acceptable salt thereof, wherein X₁ is C—R² and W is S,providing compounds of Formula 1a as follows:


3. The compound of claim 1, or a pharmaceutically acceptable saltthereof, wherein X₁ is N, providing compounds of the Formula 1b, asfollows:

4-12. (canceled)
 13. The compound of claim 1, or a pharmaceuticallyacceptable salt thereof, wherein X₅ is N, providing compounds of Formula1l, as follows:


14. The compound of claim 1, or a pharmaceutically acceptable saltthereof, wherein X₅ is CR⁶, providing compounds of Formula 1m, asfollows.

provided, however, when X₁ is CR², W is not O or —CH₂—.
 15. The compoundof claim 1, or a pharmaceutically acceptable salt thereof, wherein W isO.
 16. The compound of claim 1, or a pharmaceutically acceptable saltthereof, wherein W is S.
 17. The compound of claim 1, or apharmaceutically acceptable salt thereof, wherein W is CH₂.
 18. Thecompound of claim 1, or a pharmaceutically acceptable salt thereof,wherein W is NHR.
 19. The compound of claim 1 of Formula 2, or apharmaceutically acceptable salt thereof:

wherein: R¹ is C₁₋₁₂-alkyl; C₂₋₁₂-alkenyl; C₃₋₁₂-cycloalkyl; orC₃₋₁₂-cycloalkenyl; or halo; R³ and R⁴ each independently is: hydrogen;C₁₋₁₂-alkyl; C₂₋₁₂-alkenyl; C₂₋₁₂-alkynyl; amino; halo; amido;C₁₋₁₂-haloalkyl; C₁₋₁₂-alkoxy; hydroxy; C₁₋₁₂-haloalkoxy; nitro;C₁₋₁₂-hydroxyalkyl; C₂₋₁₂-alkoxyalkyl; C₁₋₁₂-hydroxyalkoxy;C₃₋₁₂-alkynylalkoxy; C₂₋₁₂-alkylsulfonyl; C₆₋₁₂-arylsulfonyl; cyano;C₆₋₁₂-aryl; C₅₋₁₂-heteroaryl; C₃₋₁₂-heterocyclyl;C₄₋₁₂-heterocyclylalkoxy; C₆₋₁₂-aryloxy; C₅₋₁₂-heteroaryloxy;C₇₋₁₂-arylalkyloxy; C₆₋₁₂-heteroarylalkyloxy; optionally substitutedphenoxy; —(CH₂)_(m)—(Z)_(n)—(CO)—R^(f) or—(CH₂)_(m)—(Z)_(n)—SO₂—(NR^(g))_(n′)—R^(f), where m, n and n′ are eachindependently 0 or 1; Z is O or NR^(g); R^(f) is hydrogen, C₁₋₁₂-alkyl,hydroxy, C₁₋₁₂-alkoxy, amino, C₁₋₁₂-hydroxyalkyl or C₂₋₁₂-alkoxyalkyl;each R^(g) is independently hydrogen or C₁₋₁₂-alkyl; or alternatively,R³ and R⁴ together with the atoms to which they are attached may form afive or six-membered ring that optionally includes one or twoheteroatoms independently selected from O, S and N; R⁷ is selected fromhydrogen; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl;C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy; C₁₋₁₂-hydroxyalkyl;C₂₋₁₂-alkoxyalkyl; acetyl; C₁₋₁₂-alkylsulfonyl;C₂₋₁₂-alkylsulfonylalkyl; C₂₋₁₂-aminocarbonyloxyalkyl;C₂₋₁₂-hydroxycarbonylalkyl; C₂₋₁₂-hydroxyalkyloxycarbonylalkyl;C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl; C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl;C₆₋₁₂-heteroarylalkyl; C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; andC₄₋₁₂-heterocyclylalkyl; and R^(d) is selected from hydrogen;C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-haloalkoxy; C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;C₂₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl;C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; andC₄₋₁₂-heterocyclylalkyl.
 20. A compound of Formula 3, or apharmaceutically acceptable salt thereof:

wherein: R³ and R⁴ each independently is: hydrogen; C₁₋₁₂-alkyl;C₂₋₁₂-alkenyl; C₂₋₁₂-alkynyl; amino; halo; amido; C₁₋₁₂-haloalkyl;C₁₋₁₂-alkoxy; hydroxy; C₁₋₁₂-haloalkoxy; nitro; C₁₋₁₂-hydroxyalkyl;C₂₋₁₂-alkoxyalkyl; C₁₋₁₂-hydroxyalkoxy; C₃₋₁₂-alkynylalkoxy;C₁₋₁₂-alkylsulfonyl; C₆₋₁₂-arylsulfonyl; cyano; C₆₋₁₂-aryl;C₅₋₁₂-heteroaryl; C₃₋₁₂-heterocyclyl; C₄₋₁₂-heterocyclylalkoxy;C₆₋₁₂-aryloxy; C₅₋₁₂-heteroaryloxy; C₇₋₁₂-arylalkyloxy;C₁₋₁₂-heteroaralkyloxy; optionally substituted phenoxy;—(CH₂)_(m)—(Z)_(n)—(CO)—R^(f) or—(CH₂)_(m)—(Z)_(n)—SO₂—(NR^(g))_(n′)—R^(f), where m, n and n′ are eachindependently 0 or 1; Z is O or NR^(g); R^(f) is hydrogen, C₁₋₁₂-alkyl,hydroxy, C₁₋₁₂-alkoxy, amino, C₁₋₁₂-hydroxyalkyl or C₂₋₁₂-alkoxyalkyl,and each R^(g) is independently hydrogen or C₁₋₁₂-alkyl; oralternatively, R³ and R⁴ together with the atoms to which they areattached may form a five or six-membered ring that optionally includesone or two heteroatoms independently selected from O, S and N; R⁷ isselected from: hydrogen; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl;C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy;C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; acetyl; C₁₋₁₂-alkylsulfonyl;C₂₋₁₂-alkylsulfonylalkyl; C₂₋₁₂-aminocarbonyloxyalkyl;C₂₋₁₂-hydroxycarbonylalkyl; C₂₋₁₂-hydroxyalkyloxycarbonylalkyl;C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl; C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl;C₁₋₁₂-heteroarylalkyl; C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; andC₄₋₁₂-heterocyclylalkyl; and R^(d) is selected from: hydrogen;C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-haloalkoxy; C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;C₂₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₁₋₁₂-heteroarylalkyl;C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; andC₄₋₁₂-heterocyclylalkyl.
 21. The compound of claim 1 of Formula 4, or apharmaceutically acceptable salt thereof:

wherein: R¹ is C₁₋₁₂-alkyl; C₂₋₁₂-alkenyl; C₃₋₁₂-cycloalkyl; orC₃₋₁₂-cycloalkenyl; or halo; R² is hydrogen; C₁₋₁₂-alkyl; C₂₋₁₂-alkenyl;C₂₋₁₂-alkynyl; amino; halo; amido; C₁₋₁₂-haloalkyl; C₁₋₁₂-alkoxy;hydroxy; C₁₋₁₂-haloalkoxy; nitro; C₁₋₁₂-hydroxyalkyl; C₂₋₁₂-alkoxyalkyl;C₁₋₁₂-hydroxyalkoxy; C₃₋₁₂-alkynylalkoxy; C₁₋₁₂-alkylsulfonyl;C₆₋₁₂-arylsulfonyl; cyano; C₆₋₁₂-aryl; C₅₋₁₂-heteroaryl;C₃₋₁₂-heterocyclyl; C₄₋₁₂-heterocyclylalkoxy; C₆₋₁₂-aryloxy;C₅₋₁₂-heteroaryloxy; C₇₋₁₂-arylalkyloxy; C₆₋₁₂-heteroarylalkyloxy;optionally substituted phenoxy; or —(CH₂)_(m)—(Z)_(n)—(CO)—R^(f) or—(CH₂)_(m)—(Z)_(n)—SO₂—(NR^(g))_(n′)—R^(f), where m, n and n′ are eachindependently 0 or 1; Z is O or NR^(g); R^(f) is hydrogen, C₁₋₁₂-alkyl,hydroxy, C₁₋₁₂-alkoxy, amino, C₁₋₁₂-hydroxyalkyl or C₂₋₁₂-alkoxyalkyl,and each R^(g) is independently hydrogen or C₁₋₁₂-alkyl; R⁷ is selectedfrom: hydrogen; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl;C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy; C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl;acetyl; C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;C₂₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl;C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; andC₄₋₁₂-heterocyclylalkyl; R^(d) is selected from: hydrogen; C₁₋₁₂-alkyl;C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-haloalkoxy; C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;C₂₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl;C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; andC₄₋₁₂-heterocyclylalkyl; Q is (CR⁹)_(x), one of A and E is O, S or NR¹⁰and the other is (CR⁹)_(x) or N, wherein each x is independently 1 or 2;or alternatively, Q is N, one of A and E is NR¹⁰ and the other is(CR⁹)_(x); each R⁹ is independently hydrogen, C₁₋₁₂-alkyl, halo orC₁₋₁₂-alkoxy; and R¹⁰ is hydrogen, C₁₋₁₂-alkyl, C₁₋₁₂-hydroxyalkyl,C₂₋₁₂-alkoxyalkyl, —(CH₂)_(m)—(Z)_(n)—(CO)—R^(f), or—(CH₂)_(m)—(Z)_(n)—SO₂—(NR^(g))^(n′)—R^(f).
 22. The compound of claim 1of Formula 5, or a pharmaceutically acceptable salt thereof:

wherein: R¹ is: C₁₋₁₂-alkyl; C₂₋₁₂-alkenyl; C₃₋₁₂-cycloalkyl; orC₃₋₁₂-cycloalkenyl; or halo; R⁴ is: hydrogen; C₁₋₁₂-alkyl;C₂₋₁₂-alkenyl; C₂₋₁₂-alkynyl; amino; halo; amido; C₁₋₁₂-haloalkyl;C₁₋₁₂-alkoxy; hydroxy; C₁₋₁₂-haloalkoxy; nitro; C₁₋₁₂-hydroxyalkyl;C₂₋₁₂-alkoxyalkyl; C₁₋₁₂-hydroxyalkoxy; C₃₋₁₂-alkynylalkoxy;C₁₋₁₂-alkylsulfonyl; C₆₋₁₂-arylsulfonyl; cyano; C₆₋₁₂-aryl;C₅₋₁₂-heteroaryl; C₃₋₁₂-heterocyclyl; C₄₋₁₂-heterocyclylalkoxy;C₆₋₁₂-aryloxy; C₁₋₁₂-heteroaryloxy; C₇₋₁₂-arylalkyloxy;C₆₋₁₂-heteroarylalkyloxy; optionally substituted phenoxy; or—(CH₂)_(m)—(Z)_(n)—(CO)—R^(f) or—(CH₂)_(m)—(Z)_(n)—SO₂—(NR^(g))_(n′)—R^(f), where m, n and n′ are eachindependently 0 or 1; Z is O or NR^(g); R^(f) is hydrogen, C₁₋₁₂-alkyl,hydroxy, C₁₋₁₂-alkoxy, amino, C₁₋₁₂-hydroxyalkyl or C₂₋₁₂-alkoxyalkyl;each R^(g) is independently hydrogen or alkyl; R⁷ is selected fromhydrogen; C₁₋₁₂-alkyl; C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl;C₁₋₁₂-haloalkyl; C₁₋₁₂-haloalkoxy; C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl;acetyl; C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;C₂₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl;C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; andC₄₋₁₂-heterocyclylalkyl; R^(d) is selected from: hydrogen; C₁₋₁₂-alkyl;C₃₋₁₂-cycloalkyl; C₄₋₁₂-cycloalkylalkyl; C₁₋₁₂-haloalkyl;C₁₋₁₂-haloalkoxy; C₁₋₁₂-hydroxyalky; C₂₋₁₂-alkoxyalkyl; acetyl;C₁₋₁₂-alkylsulfonyl; C₂₋₁₂-alkylsulfonylalkyl;C₂₋₁₂-aminocarbonyloxyalkyl; C₂₋₁₂-hydroxycarbonylalkyl;C₂₋₁₂-hydroxyalkyloxycarbonylalkyl; C₆₋₁₂-aryl; C₇₋₁₂-arylalkyl;C₆₋₁₂-arylsulfonyl; C₅₋₁₂-heteroaryl; C₆₋₁₂-heteroarylalkyl;C₅₋₁₂-heteroarylsulfonyl; C₃₋₁₂-heterocyclyl; andC₄₋₁₂-heterocyclylalkyl; Q is (CR⁹)_(x), one of A and E is O, S or NR¹⁰and the other is (CR⁹)_(x) or N, wherein each x is independently 1 or 2;or alternatively, Q is N, one of A and E is NR¹⁰ and the other is(CR⁹)_(x); each R⁹ is independently hydrogen, C₁₋₁₂-alkyl, halo orC₁₋₁₂-alkoxy; and R¹⁰ is hydrogen, C₁₋₁₂-alkyl, C₁₋₁₂-hydroxyalkyl,C₂₋₁₂-alkoxyalkyl, —(CH₂)_(m)—(Z)_(n)—(CO)—R^(f), or—(CH₂)_(m)—(Z)_(n)—SO₂—(NR^(g))_(n′)—R^(f).
 23. A compound of claim 1,or a pharmaceutically acceptable salt thereof, selected from:


24. A composition which comprises an inert carrier and a compound ofclaim 1, or a pharmaceutically acceptable salt thereof. 25-30.(canceled)
 31. The compound of claim 2, or a pharmaceutically acceptablesalt thereof, wherein X₅ is CH.
 32. The compound of claim 15, or apharmaceutically acceptable salt thereof, wherein X₅ is CH.
 33. Thecompound of claim 31, or a pharmaceutically acceptable salt thereof,wherein X₁ is N or CH.